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Longitudinal Cerebrospinal Fluid Biomarkers of Alzheimer Disease: Movement Toward the
Diagnosis, Prognosis and Staging of Disease
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Alzheimer’s disease (AD) is a devastating neurodegenerative disease that slowly claims the
memories and experiences that comprise the life experiences of individuals that suffer from the
disease. Despite a continually accelerating pace of research and discovery, a viable therapeutic
intervention for AD has yet to be realized. There are a multitude of factors that may contribute to
this difficulty including the challenge of separating the overall disease of Alzheimer’s from the
clinically recognizable memory loss that occurs in what is now known to be the end-stage of the
disease. Efforts to treat AD have increasingly turned toward very early disease states, before
clinical signs and symptoms become apparent, as a number of clinical trials have failed to meet
cognitive endpoints over the last 5-10 years – potentially due to the sole recruitment of
individuals already experiencing significant cognitive decline.
One important aspect of AD treatment is identification. It is now recognized that the disease
begins more than a decade before the signature symptoms of cognitive impairment become
apparent. Identifying individuals in this “preclinical” disease state has become a primary focus of
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many investigators who believe that AD must be targeted and fought well before the clinical
manifestations of memory impairment appear.
Biomarkers, indicators of normal biological or pathological processes that may be studied as a
means to give individuals a disease diagnosis, prognosis, or theragnosis – provided a treatment is
available for the disease in question – are of paramount importance in many diseases. AD has
proved a difficult target to nail down reliable, sensitive, and specific biomarkers. This is in part
due to analytical difficulties in major, core biomarkers of disease and in part due to setbacks in
clinical trials of promising therapeutic candidates.
The current work begins with an overview of biomarker modalities used in AD; however, the
primary focus is on protein biomarkers in cerebrospinal fluid (CSF). CSF provides an intimate
window to the central nervous system that, in the case of AD, has shown the ability to identify
and monitor disease progress over time in cohorts of cognitively normal and demented
individuals. In an effort to pinpoint AD before clinical signs and symptoms manifest, biomarker
research in preclinical AD has become a robust area of investigation. CSF biomarkers of amyloid
pathology, neuronal damage, and neuroinflammation are discussed in two independent cohorts:
the Adult Children Study (ACS) from Washington University in St. Louis and the Alzheimer’s
Disease Neuroimaging Initiative.
The ACS cohort is comprised of middle-aged, cognitively normal individuals recruited on a
volunteer basis from community dwelling participants with and without a family history of AD.
The ADNI cohort is comprised of older individuals also recruited on a volunteer basis from
community dwelling participants, though participants are recruited with respect to clinical status
and include cognitively normal individuals, individuals with mild cognitive impairment, and
individuals with AD, in addition to being older than the ACS cohort.

x

In both cohorts, it was found that CSF markers of amyloid plaques – one of two required
pathological hallmarks that indicate AD – changed earlier than those of tau tangles, the second
required pathological hallmark.
Currently, examining biomarkers on a group-wide basis is the best way to get an accurate picture
of biomarkers at baseline and followup lumbar punctures (LPs). As the goal is to be able to give
individual people a diagnosis and prognosis of their disease, the behavior of biomarkers is
particularly interesting because studies have found that CSF Aβ42 changes up to 15 or more
years before cognitive signs and symptoms become apparent and, hopefully, beginning treatment
in this period will be helpful not only for diagnosing for individuals with AD dementia, but also
for individuals with very early disease.
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Chapter 1: Introduction
Portions of this chapter were published in the April 2014 issue of Biological Psychiatry1.

1.1 Background
Alzheimer disease (AD) is a chronic, progressive neurodegenerative disease that slowly strips
individuals of their memories and other cognitive functions. In the United States alone, an
estimated 5.5 million people are living with AD in 2017, and an estimated 253 billion dollars
will be spent caring for individuals with AD or other dementias, with both estimates predicted to
rise substantially as the population ages2. Unlike diseases such as heart disease or stroke, deaths
from AD increased more than 89% between the year 2000 and 2014 - making development an
intervention to slow or halt the disease has a paramount focus2. As AD research moves forward,
recent proposals from some leaders in the field have trended toward defining AD on a continuum
as the disease is multifactorial, quite variable between individuals, and a large body of research
is still needed to fully define AD from onset to end of life3, though AD is currently diagnosed in
clinical stages4. These stages fit in to the proposed view of a continuum; preclinical AD is
defined by the absence of clinical signs or symptoms but evidence of pathological amyloid and
tau accumulation in the brain, mild cognitive impairment (MCI) (or prodromal AD) is defined by
the addition of mild clinical symptoms such as a consistent inability to remember appointments,
and mild, moderate, and severe dementia are marked by further dramatic cognitive impairment
ultimately resulting in complete dependence on caregivers for all daily activities. Instead of
strictly defining each stage, research has begun to indicate – particularly in preclinical disease –
that stages may not be clearly demarcated, and some lenience when making diagnostic,
prognostic, and eventually theragnostic judgments may be needed3.
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Currently, a definitive diagnosis of AD still requires postmortem identification of the
pathological hallmarks of the disease: extracellular amyloid plaques composed mainly of
aggregated amyloid-β (Aβ) peptides and neurofibrillary tangles composed mainly of
hyperphosphorylated forms of the microtubule associated protein, tau (P-tau)4. Clinical diagnosis
of AD is based on guidelines established by the National Institute of Neurological Disorders and
Stroke–Alzheimer’s Disease and Related Disorders Association (NINDS-ADRDA), although the
sensitivity and specificity of such a diagnosis is lower than desirable5. The addition of
biomarkers to the diagnostic criteria for AD may increase the sensitivity and specificity of both
the diagnostic and prognostic capabilities currently available through clinical and cognitive
assessment. One goal of studying biomarkers is to reliably identify those with AD pathological
changes (preclinical AD), as well as predict the odds that such individuals will clinically
progress and at what rate.
Intensive research has propelled the field closer to finding a disease-modifying therapy, but
setbacks in clinical trials and inherent difficulties in successfully tracking disease progress premortem continue to be major roadblocks. The most promising clinical trials to date have focused
on anti-Aβ antibodies that bind either aggregated or soluble forms of Aβ and encourage the
removal or neutralization of these species from the brain. Phase III trials of the anti-Aβ
antibodies bapineuzumab and solanezumab in mild to moderate dementia believed to be due to
AD ended in late 2012. Two bapineuzumab trials showed no effect on the primary outcomes, the
Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) or Disability
Assessment for Dementia (DAD), either in carriers of the Apolipoprotein ε4 (APOE ε4) allele or
in noncarriers, but did show encouraging changes in two disease biomarkers in the APOE ε4
carrier group compared with placebo6. Two additional trials were halted early due to these
2

negative results and did not show the same changes in disease biomarkers7. Two trials involving
solanezumab also failed to show efficacy in the primary outcome of ADAS-Cog and
Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) scale, but did
show changes in blood and cerebrospinal fluid (CSF) amyloid levels, as expected based on the
application of an anti-amyloid antibody8.
In part because clinical trials have been unsuccessful in reversing, halting, or slowing cognitive
decline, the investigation of AD biomarkers has been propelled forward. A widely held belief is
that some of this failure is due to the exclusive enrollment of individuals who already exhibit
mild or moderate dementia, stages of AD that are accompanied by robust neuronal cell death. At
even earlier stages of the disease (very mild dementia and MCI due to AD), neuron loss in
certain critical brain regions is already significant9. Thus, it is important to diagnose individuals
at the preclinical and MCI disease stages - and enroll them in clinical trials - in order to identify
and apply therapies that have the best chance of preserving normal cognitive function.
A key roadblock is the development of robust, reliable biomarkers: as in many other medical
conditions, the primary aim of biomarker development is to provide a diagnosis or prognosis to
individuals with a disease or to track disease progress or severity. These are of particular
importance because the underlying causative pathology of AD begins as many as 15-20 years
before the appearance of cognitive symptoms10, meaning the identification of disease must take
place when there are no clinically identifiable signs of impairment. In AD, biomarkers are most
widely used in research – focusing on identification of individuals with preclinical disease, in
differential diagnosis with other dementias, and perhaps most interestingly to provide a
downstream indicator of treatment efficacy in disease-modifying agents.
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As the AD community moves toward a treatment, it seems certain that biomarkers will play a
key role in the process. It is the goal of investigators to determine the most effective combination
of biomarkers to enable identification, differentiation, and treatment of the disease in question.
Cognitive measures can serve as a biomarker of disease; however, CSF biomarkers as measures
of underlying pathology and disease progression are the focus of this work, along with relevant
investigations in imaging biomarkers (magnetic resonance imaging [MRI] and positron emission
tomography [PET]). Each modality presents its own challenges for identifying and/or developing
viable markers from assay validation, intra- and inter-lab consistency in measurement to accurate
identification of when and how biomarkers change during disease, and these challenges add to
those in the overarching field of biomarker usage in the clinical diagnosis of AD such as how to
best use biomarkers in regular clinical practice.
Nevertheless, within the last five years, groundbreaking clinical trials such as the Dominantly
Inherited Alzheimer Network – Trials Unit (DIAN-TU)11, the Anti-Amyloid Treatment in
Asymptomatic Alzheimer’s Disease (A4) trial12, and others have begun enrolling preclinical
individuals, as identified by genetic testing or biomarker status, and will use various biomarkers
to track drug target engagement and/or as endpoint measures of drug efficacy. The DIAN-TU
will hopefully be particularly informative as to the temporal ordering and efficacy of several
multimodal biomarkers in a genetically defined population. The comparison of biomarkers in the
DIAN-TU population vs. sporadic, or late onset, AD could eventually allow the identification of
the optimal window for therapeutic intervention the sporadic population. A number of caveats
apply, particularly the development of an efficacious AD intervention, but one of the primary
underpinnings of this theory is that ADAD and sporadic AD are the same disease; therefore
investigations concerning biomarker trajectories of all modalities are of paramount importance.
4

1.2 Biomarker Modalities
As outlined above, this work pertains largely to CSF biomarkers of AD, with relevant imaging
biomarkers included as ancillary analyses. However, it is necessary to consider all biomarker
modalities when attempting to identify a progression of disease indicators. Section 1.2 is
dedicated to a brief literature review of current fluid (CSF, plasma, serum), imaging (MRI, PET),
and cognitive biomarkers that aid investigators in better defining the spectrum of AD from
preclinical through mild cognitive impairment and ultimate dementia. A brief summary of
biomarkers covered in Chapter 1.2 can be found in Table 1.1.

1.2.1 Core CSF Biomarkers
CSF is considered a prime source for AD biomarkers because many proteins and metabolites in
CSF directly reflect the internal milieu of the brain. A lumbar puncture (LP) is necessary for the
collection of CSF which makes it somewhat more invasive than a blood draw. However,
complications stemming from LP are not frequent13,14, and when the procedure is performed by
experienced clinicians, it is usually not painful.
Three proteins are typically considered the gold standard for AD CSF biomarkers – Aβ42, total
tau (Tau) and tau phosphorylated at threonine 181 (P-tau). Aβ and tau proteins are the most
abundant components of amyloid plaques and neurofibrillary tangles, respectively. Each of these
analytes has been extensively studied and validated in a variety of cohorts world-wide and, while
absolute concentrations of each marker may vary, similar results have been reported in multiple
studies.
Amyloid β42
Aβ42 is a 42 amino acid peptide created from the processing of the amyloid precursor protein
(APP). There are multiple lengths of Aβ peptides; the 42 amino acid form is the most abundant
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in amyloid plaques. Significantly reduced levels of CSF Aβ42 in individuals diagnosed with AD,
compared to cognitively normal, age-matched individuals, is one signature of amyloid plaques15.
Studies have shown that CSF Aβ42 levels correlate inversely with amyloid plaque load in the
brain as determined by postmortem histology16 and concomitant in vivo plaque measurement
using amyloid imaging, regardless of clinical status17–23. CSF Aβ42 is likely low in the presence
of amyloid deposition due to its sequestration in plaques24. Continued investigation on the link
between CSF and imaging Aβ levels indicates that CSF Aβ42 begins changing prior to amyloid
imaging25,26, which replicates changes seen in autosomal dominant AD (ADAD)27. Low CSF
Aβ42 is useful as a marker that predicts future clinical disease progression and rate of cognitive
decline, especially in the early clinical stages of the disease28–30. Most recently, longitudinal
studies of AD biomarkers have shown CSF Aβ42 is perhaps the most reliable indicator of
preclinical AD31–33. Aβ42 alone is not a sufficient biomarker for AD diagnosis and prognosis34,35,
nor does it mark the presence of other AD pathologies, however, more recent recommendations
do support the use of CSF Aβ42 to supplement clinical evaluation for differential diagnosis or to
aid judgment in atypical or unclear cases36,37.
Tau
Tau is a microtubule associated protein that, when quantified in the CSF, is considered to be a
biomarker of neuronal injury in AD. High levels of tau in the CSF may reflect neuronal damage,
as is suggested by increases in tau after acute neuronal injury such as stroke, traumatic brain
injuries, and Creutzfeld-Jakob disease (CJD)38,39. Phospho-tau levels correlate with total tau and
also correlate closely with neurofibrillary tangle load in AD40. Tau is normally released by
neurons in the absence of cell death. Evidence from wild type and transgenic mice expressing
mutant human Tau (P301S) suggests tau is continuously secreted from healthy neurons into the
brain interstitial fluid space41. In addition, both soluble and aggregated forms of tau have been
6

shown to be secreted by cultured cells42. CSF tau and P-tau are significantly increased in AD and
Mild Cognitive Impairment (MCI)29(p200),40,43. More recent studies indicate levels of both tau and
P-tau are also increased in preclinical AD, though likely after Aβ42 levels have already
dropped44, which mirrors changes seen in ADAD27. Similar to CSF Aβ42 versus PET Aβ42, CSF
Tau may also begin to increase prior to tangles being visualized with Tau PET imaging45. Levels
of P-tau in CSF are also associated with disease progression in AD cases46 and may aid in
differential diagnosis between AD and other dementias47. Some longitudinal studies have also
indicated that tau and P-tau change after indicators of amyloid abnormality31. Tau and P-tau are
similar to Aβ42 in diagnostic and prognostic performance but are not sufficient biomarkers on
their own.
Tau or Ptau181 to Aβ42 Ratios
The Tau/Aβ42 ratio, when analyzed, has a history of good performance in identifying individuals
with AD. The Geneva Task Force for the Roadmap of Alzheimer’s Biomarker report on the
clinical validity of CSF biomarkers in AD states that the ratio of Tau or Ptau to Aβ42 often is
superior to Aβ42 alone when predicting AD in individuals with MCI48. This was seen both in
biomarker meta-analysis reports as well as primary research reports, however, the Task Force
recommended against the use of such ratios because they may be abnormal in individuals where
CSF Tau alone increases (such as in CJD).

1.2.2 Non-Core CSF Biomarkers
Because it is likely that no single biomarker will perform satisfactorily on its own, identification
and development of additional CSF biomarkers that do not directly reflect AD pathology
(plaques and tangles), but instead reflect more general processes such as neurodegeneration and
inflammation might be very useful. Unbiased approaches such as proteomics and multi-analyte
profiling have been used to identify novel fluid biomarkers. A unique challenge presented by
7

these unbiased approaches, however, has been identifying biomarkers that have high enough
sensitivity and specificity to warrant investigation in large cohorts. Five CSF proteins have
proved useful in differentiating AD from cognitively normal individuals in large, independent
cohorts: visinin-like protein 1 (VILIP-1); Neurogranin (Ng); synaptosomal associated protein 25
(SNAP-25); chitinase-3-like protein 1 (YKL-40); and neurofilament light (NfL).
Amyloid β40 and Aβ42 to Aβ40 Ratio
Aβ40 is the most abundant isoform of Aβ in the CSF at roughly ten times the concentration of
CSF Aβ42, but relatively less reported in studies of AD biomarkers. One large meta-analysis in
2011 did not report on Aβ40 as a CSF biomarker49, while a more recent meta-analysis from 2016
reported that levels of CSF Aβ40 did not differ significantly between individuals with MCI due
to AD and MCI, but did report a “significant but minor” average effect size in distinguishing AD
from control individuals, with Aβ40 levels being slightly lower in AD50. However, unlike CSF
Aβ42 and the Tau(s), this result was not wholly consistent across all 25 papers analyzed; 7 of 25
studies showed almost no difference between AD and control individuals and one study showed
higher levels. These meta-analyses reflect an interesting attitude in the research community of
Aβ40 perhaps being less important than Aβ42 as a diagnostic or prognostic tool. A more recent
study does report lower levels of CSF Aβ40 in individuals with preclinical AD as defined by low
CSF Aβ42 levels and no cognitive impairment44. Reported in Chapter 2 of the current work, it
was found that levels of Aβ40 decreased over time in middle-aged cognitively normal
individuals, but findings were inconsistent between two assay platforms31. These inconsistencies
likely contribute heavily to the relative dis-use of CSF Aβ40 as a common biomarker for AD.
Despite CSF Aβ40 not performing as well as CSF Aβ42 as a biomarker of AD, the Aβ42 to
Aβ40 ratio has nonetheless been proposed as a useful CSF biomarker because, while CSF Aβ42
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levels may also be reduced in individuals with subcortical white matter lesions, CSF Aβ40 is
unaffected51, resulting in better performance of the Aβ42 to Aβ40 ratio than Aβ42 alone in
detecting amyloid pathology in MCI and AD. These and other studies indicate that the ratio may
be a better predictor of AD pathology by adjusting for differences in overall amyloid production
between individuals48, which becomes particularly evident when investigating CSF amyloid
compared with amyloid PET measures. In this case, when assessing both CSF and PET amyloid,
the concordance between CSF Aβ42 alone and amyloid PET is improved by substituting the CSF
Aβ42 to Aβ40 ratio51–54.
VILIP-1
VILIP-1 is a neuron-specific intracellular calcium sensor protein. Particularly expressed in
cortical and hippocampal neurons, VILIP-1 is found at high levels in the dendritic compartment
mainly associated with cell membranes55. Levels of CSF VILIP-1 have been shown to be
elevated in stroke56. Immunohistochemical and cell culture studies on VILIP-1 localization in
AD revealed an association with dystrophic neurites as well as amyloid plaques and tau
tangles57,58. Increases in CSF VILIP-1 have been observed in AD compared with cognitively
normal controls as well as individuals with MCI59,60. Elevated VILIP-1 levels also perform as a
strong predictor of future cognitive decline in individuals with MCI/very mild dementia and in
cognitively normal controls61–63. Longitudinal studies on VILIP-1 have not yet been widely
executed, though VILIP-1 and Tau correlate very well in the CSF, suggesting that VILIP-1 may
increase after amyloid changes are evident in preclinical disease31, and in ADAD may begin to
decline after incipient cognitive impairment64. VILIP-1 may also aid in the differentiation
between AD and other dementias such as Dementia with Lewy Bodies (DLB)65,66. When studied
in conjunction with CSF Aβ42, Tau and P-Tau, VILIP-1 performs similarly to the Tau(s),
indicating that it will not be a sufficient biomarker on its own.
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Ng
Neurogranin is a postsynaptic calmodulin-binding protein expressed largely in neuronal
dendrites that seems necessary for sensing calcium concentration and calmodulin activity, thus
strengthening synapses67. In AD, Ng is elevated in the CSF compared to cognitively normal
individuals and provides diagnostic and prognostic utility similar to that of the core AD CSF
biomarkers68,69. In preclinical AD, Ng is also elevated and predicts cognitive decline70,71,
indicating it may be a useful biomarker across multiple disease stages. Longitudinally, levels of
Ng in CSF increased in cognitively normal individuals at risk of developing dementia though did
not change over time in individuals with MCI or AD72. Studies assessing Ng for differential
diagnosis provided evidence that elevated Ng may aid in differentiation AD from behavioral
variant frontotemporal dementia (bvFTD), LBD, Parkinson Disease (PD), progressive
supranuclear palsy, and multiple system atrophy73,74, and major depressive disorder75. In many of
the studies cited above, other CSF proteins such as Tau were measured, with Ng correlating with
Tau and P-Tau. Further longitudinal research is necessary to determine where and how Ng best
fits in the staging, diagnosis, or prognosis of AD.
SNAP-25
SNAP-25 is a presynaptic t-SNARE protein involved in regulating neurotransmitter release
through facilitation of synaptic vesicle release at presynaptic terminals76. Much of the work on
SNAP-25 pertaining to AD has been done in postmortem tissue, where decreases in SNAP-25
protein levels are seen in AD, and other dementias, compared with control individuals77–79. Few
studies in the CSF of demented compared with cognitively normal individuals have been
reported. The first showed higher levels of SNAP-25 fragments in AD and prodromal AD
compared with cognitively normal individuals80; the second showed increased levels of SNAP25 in the CSF of individuals with advanced PD81. Much work remains to determine the temporal
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ordering of changes in SNAP-25 compared with other CSF proteins in AD, including
longitudinal cohort studies.
NfL
Neurofilament Light is the lowest weight member of the neurofilament family found in neurons.
Heavily involved in axonal structure, NfL levels in CSF have been studied in a wide variety of
neurodegenerative disorders and are considered a marker of white matter lesions82,83. In
amyotrophic lateral sclerosis (ALS)84, FTD85,CJD86, and Parkinson’s Disease Dementia (PDD)87,
as well as vascular dementia (VaD)88, CSF NfL is elevated compared with normal controls. A
particular focus has been the differential diagnosis of AD and FTD using CSF NfL, in which
consistently higher levels of NfL were seen in FTD compared to AD89–91. As with other non-core
markers, significant work remains to determine the usefulness of NfL for differential diagnosis
among neurodegenerative diseases92,93. In AD, NfL levels are increased at the MCI and dementia
stages of clinical impairment and may indicate disease progression94,95 but are not elevated in
preclinical disease44,96, suggesting a later stage of NfL involvement, though further research is
needed.
YKL-40
YKL-40 is the one of two non-neuronal associated proteins to show promise as a CSF AD
biomarker; it is an astrocytic protein upregulated in a variety of neuroinflammatory conditions97–
99

, however, despite being a chitinase, YKL-40 has no chitinase activity and its exact function

remains to be elucidated. Early reports on YKL-40 in CSF showed elevations in AD vs. control
individuals, with diagnostic and prognostic performance on par with the core CSF
biomarkers100,101, though results were not universally replicated102. More recent studies,
including longitudinal analyses, have shown that YKL-40 levels increase with advancing age
which may complicate its analysis in older cohorts31,103. However, there is evidence that YKL-40
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could be useful to differentiate between AD and other dementias such as VaD104, DLB and
PDD103, but not FTD105,106. YKL-40 needs more research, particularly longitudinally, to
determine its best application as a biomarker of neuroinflammation in AD.
TREM2
The other non-neuronal protein is soluble Triggering Receptor Expressed on Myeloid Cells 2
(sTREM2), associated primarily with microglia in the brain. Studies in DIAN and a LOAD
cohort showed increases in sTREM2 in MCI and AD compared with control individuals107,108,
but a third study showed only an association with sTREM2 and age109. Though promising,
TREM2 is in very early stages of investigation as an AD CSF biomarker.

1.2.3 Blood Biomarkers
Identification of blood biomarkers (plasma and serum) for AD has proved particularly
challenging. Possible contributing factors include low expression of target biomarker proteins in
the periphery that could make quantification of central nervous system (CNS)-derived analytes
difficult, as well as the relatively higher levels of total protein in plasma and serum compared
with CSF which could interfere with analyte detection.
Core and Novel Analytes in Blood Serum and Plasma
Findings from studies exploring blood-based biomarkers in AD have been largely inconclusive.
The core biomarker Aβ42, as well as the non-core Aβ40, alone have historically shown no utility
in differentiating AD from control individuals or assessing prognosis110,111, though differences
have been found between APOE ε4 carriers versus noncarriers110,112.However, one study did
report reductions in the plasma Aβ42/Aβ40 ratio in individuals with MCI and in those who
transitioned from cognitively normal to MCI113. Two recent studies also found a predictive
association between (1) the plasma Aβ42/Aβ40 ratio and cortical amyloid burden measure by
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PET114 and (2) the plasma Aβ42/Aβ40 an amyloid positivity defined by PET or mass
spectrometry, in this case with high accuracy and precision115.
Studies assessing plasma tau are at a similar uncertain stage due to the recent development of
Tau PET agents116,117, though one study states that plasma tau and NfL levels may aid in
identifying or ruling out neurodegeneration in rapidly progressive neurological syndromes118 and
another identified elevated plasma Ptau181 in AD and Down Syndrome (DS) compared to control
individuals119. The non-core analyte NfL has had some success in plasma120,121 and serum122 in
differentiating MCI and AD individuals from control individuals. Plasma Ng, however, was not
able to differentiate MCI or AD from control individuals123.
Much of the focus in blood-based fluid biomarkers has involved novel multi-analyte panels124–
127

. While results from these studies generally show efficacy in differentiating AD from control

individuals, in some cases even longitudinally128, there are important factors to consider: often
the cohort size or composition makes it difficult to translate results to other cohorts; these studies
are often very recent and therefore not replicated in additional cohorts; the use of general multianalyte panels may result in lower success rates in differential diagnosis between AD and other
dementias.
Overall, the state of blood biomarkers in AD has been held in its infancy for a number of years.
Largely, this status hinges upon a lack of reproducibility and an unclear path to clinical
utilization129. As these are very early stage, many manuscripts cited above use assays developed
“in-house” and are different from cohort to cohort. Lessons learned from studying CSF
biomarkers indicate that a common technique or assay would likely be beneficial to more clearly
outlining biomarker proteins in blood.
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1.2.4 Imaging Biomarkers
Imaging biomarkers capture a broad range of AD-associated processes, from brain size and
structure to the presence of protein aggregates. Imaging biomarkers can be non-invasive or
moderately invasive based on the modality used (ie, MRI vs. PET with radioactivity). One
particular advantage for imaging biomarkers is the ability to image and track special patterns
(e.g. regional atrophy, binding of PET tracers in regions with pathology). As with fluid
biomarkers, inter-lab standardization is paramount but can be quite difficult due to the use of
different makes and models of scanners, each with their own idiosyncrasies130.
MRI Biomarkers
Volumetric MRI is one of the most studied imaging biomarkers. The measurement of the size of
a brain region at a single time point and within individuals longitudinally allows for detection of
atrophy in either whole brain or targeted areas131–133. In many studies, a marked decrease in
volume is observed in AD – this is seen both in normalized whole brain volume and in specific
areas such as the hippocampus and entorhinal cortex134,135. Volumetric MRI performs as well as
the CSF gold standard biomarkers for diagnosis and prognosis, from preclinical through
advanced disease states, and has a rich history of investigation using both single timepoint and
longitudinal data136–140. What remains to solidify MRI volumetric biomarkers for clinical use is
similar to CSF biomarkers141 – reproducibility in large, independent cohorts; standardization of
both imaging and image analysis throughout the field; longitudinal analysis; and identification of
the most accurate and clinically useful brain regions for AD diagnosis and prognosis, particularly
as regions such as caudate nucleus or hippocampus have not differentiated between AD and
other dementias142,143.
Both task-based and resting state functional MRI (fMRI) are promising imaging biomarkers for
AD144. The difference in magnetization between oxygen-rich and oxygen-poor blood can be
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measured using fMRI to detect changes in connectivity between areas of the brain while an
individual is performing a task or resting. Some studies have shown fMRI differences between
individuals with MCI vs. controls on task-based assessments145. Of particular interest in resting
state fMRI assessments is the default mode network (DMN), a network of brain regions that is
most active when a person is not engaged in a specific cognitive task and is deactivated when an
individual is externally stimulated or is engaged in a specific task. One recent, large study of 500
individuals showed progressive decline in resting state functional connectivity across multiple
networks with disease progression146. Whether fMRI will prove useful in differential diagnosis,
prognosis, or in clinical trials awaits further studies, though it has shown promise in recent
preclinical and longitudinal studies147,148.
PET Biomarkers
PET biomarkers rely on radionuclide tracers specific to a molecule of interest within the body.
Three radioligands are used regularly in AD research and, with amyloid PET, in clinical practice
to aid in differential diagnosis of difficult or uncertain dementia cases149; 18Fluorodeoxyglucose,
or FDG PET; amyloid PET; and tau PET. FDG PET is a highly studied radioligand that acts as
an indicator of glucose metabolism and, by proxy, neuronal activity. A number of studies have
shown prognostic value for FDG PET150 in identifying individuals who will progress from MCI
to AD, but the usefulness of FDG PET as a diagnostic in differentiating cognitively normal from
AD individuals is relatively less151. Studies using smaller cohorts have also reported longitudinal
changes in FDG PET in individuals with MCI152,153(p3).
Specific to amyloid-aggregating diseases, the use of amyloid PET has increased dramatically
since the development of Pittsburgh Compound B (PiB), the first radioligand specific to fibrillar
Aβ154. There are now 3 FDA approved amyloid-imaging agents, with evidence pointing to
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efficacy in diagnosis in both research and clinical settings150, though extensive work remains to
determine the relationship between amyloid PET and prognosis. Similar to CSF analytes,
standardization of amyloid PET is a major point of concern155, including for longitudinal
study156.
Tau imaging remains in the early stages of development but there are indications it may be useful
in assessing the extent of tau pathology present in individuals with AD, as well as potentially
aiding in differential diagnosis between AD and other tauopathies such as progressive
supranuclear palsy (PSP)157,158. One very early longitudinal report indicates Tau PET may have
prognostic value in MCI and AD159, and yet another indicates it may have value in identifying
high tau aggregation levels in preclinical AD160.
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Table 1.1 Summary of Biomarker Modalities and Characteristics
Biomarker

Changes Observed

Disease Stage when

Longitudinal

in AD vs Cognitively

Reported

Data

Normal Individuals

Major Obstacles to Validation as an AD Biomarker

Available

CSF
Aβ42

Decreased

Preclinical, MCI, Dementia

Yes

Assay validation, reduction in intra- and inter-lab variability

Aβ40

Small

Preclinical, MCI, Dementia

Yes

May not be robust enough on its own

Decrease/Unclear
Aβ42/Aβ40

Decreased

Preclinical, MCI, Dementia

Yes

Validated assays, continued investigation in large, varied cohorts

Tau

Elevated

Preclinical, MCI, Dementia

Yes

Must be used in combination with other biomarkers

P-tau

Elevated

Preclinical, MCI, Dementia

Yes

Must be used in combination with other biomarkers

Tau/Aβ42

Elevated

Preclinical, MCI, Dementia

Yes

While reliable, Tau and Aβ42 may be better applied individually

VILIP-1

Elevated

Preclinical, MCI, Dementia

Yes

Continued investigation in large, varied cohorts

SNAP-25

Elevated

MCI, Dementia

No

Continued investigation in large, varied cohorts

Ng

Elevated

Preclinical, MCI, Dementia

Yes

Continued investigation in large, varied cohorts

NfL

Elevated

Preclinical, MCI, Dementia

No

Continued investigation in large, varied cohorts

YKL-40

Elevated/Unclear

Preclinical, MCI Dementia

Yes

May not be as robust as, e.g. sTREM2 due to age-associated elevation

sTREM2

Elevated

MCI, Dementia

No

Continued investigation in large, varied cohorts
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Blood-Based Biomarkers
Single

Variable

Preclinical, MCI, Dementia

Yes

Continued investigation in large, varied cohorts

Variable

Dementia

Yes

May continue to have limited viability, though multi-analyte approaches

Analyte
(Aβ(s),
Tau(s), NfL,)
MultiAnalyte

may be useful in identifying novel single analytes

Panels
Imaging Biomarkers
MRI

Increase in Atrophy

Preclinical, MCI, Dementia

Yes

Must be used in combination with other biomarkers

fMRI

Change in Connected

Preclinical, MCI, Dementia

Yes

Must be used in combination with other biomarkers

Regions
FDG PET

Elevated

Preclinical, MCI, Dementia

Yes

Must be used in combination with other biomarkers

Amyloid PET

Elevated

Preclinical, MCI, Dementia

Yes

Continued investigation in large, varied cohorts

Tau PET

Elevated

Preclinical, MCI, Dementia

Yes

Continued investigation in large, varied cohorts

Table 1.1 summarizes the biomarker modalities covered in Chapter 1.2. Changes observed refers to the most commonly seen alterations in each biomarker in AD
compared with cognitively normal individuals. Disease Stage when Reported refers to the stages of AD that a biomarker has published information available.
Longitudinal data is available for the vast majority of the reported biomarkers, but further longitudinal research is required. The Major Obstacle column refers to
only the most significant challenge for each biomarker. Continued investigation in large, varied cohorts is required to pinpoint the most useful diagnostic,
prognostic or theragnostic characteristics of most biomarkers. Aβ42 and Tau(s) – are well recognized identifiers of AD pathology in living individuals but require
further investigation as to the best application or technique for combinatorial analysis that will allow diagnosis or prognosis of AD on a within-person basis.
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1.3 Biomarkers in the Diagnosis and Prognosis of AD
Clearly, a large body of work has been created in the study of biomarkers for AD. Despite this
positive forward progress, an immense amount of work remains in defining high quality
biomarkers that could be implemented worldwide. Figures 1.1-1.4 present a brief glimpse in to
the evolution of our broad understanding of AD in terms of biomarkers.

1.3.1 Hypothetical Biomarker Models
In an ideal scenario, AD biomarkers will identify individuals during preclinical disease, well
before the neuronal death that drives cognitive impairments and within a window allowing for
secondary, or even primary, prevention of the disease. In 2009, the first of a series of
hypothetical models was published showing how markers such as CSF Aβ42 and tau(s), fMRI,
or FDG PET might change along the course of AD161. Biomarker behavior as a whole was in an
early stage of exploring preclinical AD, and most biomarkers are grouped together or shown as
changing in the very mild stage of AD.
The second group of figures (Figure 1.2 and 1.3) were published in 2010 and 2013,
respectively. The first of these figures is similar, grouping markers by Aβ, tau, brain structure,
and clinical markers162. Both Figures 1.1 and 1.2 propose a temporal ordering of biomarkers
shifting from normal to abnormal along a disease continuum, but the level of detail was
necessarily low given the state of the field at the time.
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Figure 1.1 Hypothesized Relationship Between the Timecourse of Changes in Various
Biomarkers in Relation to the Neuropathology and Clinical Changes of Alzheimer’s Disease

The first in a series of evolving proposed biomarker curves. From Craig-Schapiro et al., 2009161.

Figure 1.2 Dynamic Biomarkers of the Alzheimer’s Pathological Cascade

The second AD biomarker curve evolution. From Jack et al. 2010162: “Aβ is identified by CSF Aβ42 or
PET amyloid imaging. Tau-mediated neuronal injury and dysfunction is identified by CSF tau or
fluorodeoxyglucose-PET. Brain structure is measured by use of structural MRI. Aβ=β-amyloid.
MCI=mild cognitive impairment.”
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Figure 1.3 Revised Model of Dynamic Biomarkers of the Alzheimer’s Disease Pathological
Cascade

The third AD biomarker curve evolution. Adapted from Jack et al. 2013163: “Neurodegeneration is
measured by FDG PET and structural MRI, which are drawn concordantly (dark blue). By definition, all
curves converge at the top right-hand corner of the plot, the point of maximum abnormality. Cognitive
impairment is illustrated as a zone (light green-filled area) with low-risk and high-risk borders.” The
bottom axis reflects time rather than disease stage.

The third iteration of hypothetical curves attempted to further incorporate known difficulties in
representing a population through a single set of curves, as well as incorporated more recent
findings for the temporal ordering of biomarkers163. For instance, CSF Aβ42 and amyloid PET
reflect evidence of CSF amyloid abnormalities being detectable earlier than PET amyloid
abnormalities. The sigmoidal curve shapes are also updated to reflect potential differing rates of
change between the visualized biomarkers. Lastly, the uncertainty in individual cognitive reserve
was acknowledged by adding a high- to low-risk development of cognitive impairment. As a
reflection of this uncertainty, the x-axis was represented simply as “time” rather than “disease
state”. The premise was to define the temporal ordering of biomarkers for eventual application
on a person-by-person basis. The last, most recently updated model (Figure 1.4) was published
in 20173. This model steps back from individual biomarkers to the combined groups of (1)
amyloid, (2) cognitive performance, FDG-PET, tau PET, atrophy, and (3) clinical function,
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reflecting the uncertainty in the application of biomarkers toward very specific disease-states or
temporal orderings. The continued exploration of non-core CSF biomarkers such as VILIP-1,
SNAP-25, Ng, YKL-40, and other non-CSF biomarkers has indeed introduced a higher level of
uncertainty as to our ability to accurately pinpoint – if not diagnosis – prognosis in a single
individual.
These models are incredibly useful in allowing researchers a common visual scale with which to
compare biomarkers and biomarker modalities with respect to clinical status or time. However,
each of these sets of curves is modeled off of cross-sectional studies, with relatively little input
from within-person longitudinal studies of biomarker change – a caveat that has been clearly
acknowledged163. Having a clear picture of the general longitudinal, temporal changes in AD, as
well as their relationship with the clinical syndrome of AD, is an area of incredibly active
research. Constant thought is given as to the best translation from hypothetical models such as
those shown in Figures 1.1-1.4 to functional clinical practice. The first example of data-driven
biomarker curves was published using DIAN data, using cross-sectional data derive biomarker
curves over the span of autosomal dominant AD (ADAD) by using the time difference in
baseline biomarker measurements and each individuals parental age of AD onset as the basis for
modeling biomarker changes over time, shown in Figure 1.527. Data from the DIAN study was a
step toward indicating temporal changes in biomarkers from CSF Aβ42 to amyloid imaging
changes, to CSF Tau, hippocampal atrophy and hypometabolism, and finally to mild cognitive
decline. What remains are studies of within-person longitudinal changes that will best showcase
temporal biomarker trajectories for diagnostic, prognostic, or theragnostic utility.
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Figure 1.4 Change in Biomarkers Over Time

The latest biomarker curve evolution. Adapted from Aisen et al. 20173: “Modified graph showing that
amyloid accumulation (measured as low CSF Aβ or elevated amyloid PET standard uptake value ratio)
occurs first and functional decline occurs late in the continuum of AD (as before), bug cognitive
performance, FDG-PET, tau PET, and MRI atrophy change along a common, gradually steepening
curve”.

Figure 1.5 Comparison of Clinical, Cognitive, Structural, Metabolic, and Biochemical Changes
as a Function of Estimated Years from Expected Symptom Onset

Data derived biomarker curves from cross-sectional data using the DIAN cohort. From Bateman et al.
201227: The normalized differences between mutation carriers and noncarriers are shown versus estimated
years from expected symptom onset and plotted with a fitted curve. The order of differences suggests
decreasing Aβ42 in the CSF (CSF Aβ42), followed by fibrillar Aβ deposition, then increased tau in the
CSF (CSF tau), followed by hippocampal atrophy and hypometabolism, with cognitive and clinical
changes (as measured by the Clinical Dementia Rating–Sum of Boxes [CDR-SOB]) occurring later. Mild
dementia (CDR 1) occurred an average of 3.3 years before expected symptom onset.
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1.3.2 Translation of Research Biomarkers to Clinical Settings
As AD research moves forward, different predictions and diagnostic or prognostic models are
beginning to materialize using the wealth of biomarker information amassed in the last 10-20
years. Alongside the evolution of hypothetical models, working groups have formed, each tasked
with aggregating the numerous and varied results from biomarker studies (which the hypothetical
models do on a research-specific basis) and forming guidelines that may be applied in clinical
settings.
In 2011, the National Institute on Aging (NIA) along with the Alzheimer Association (AA) set
forth diagnostic criteria and guidelines for AD dementia in which magnetic resonance imaging
(MRI) or positron emission tomography (PET), and cerebrospinal fluid (CSF) proteins were
pinpointed as the strongest biomarkers for the disease, albeit with the caveat that extensive
biomarker validation was still needed164.
In 2013, the International Work Group (IWG) published an update on criteria developed in 2007
in which the presence of AD biomarkers indicates AD risk, while prodromal AD (MCI, by NIAAA criteria) and AD dementia can be diagnosed if an individual also has biomarkers consistent
with AD. The IWG considers low CSF Aβ plus high CSF tau or P-tau, or abnormal amyloid
imaging as molecular biomarkers of AD and MRI or FDG PET as topographic biomarkers165.
As a follow-up to the NIA-AA guidelines, in 2016 a further modification was proposed. Whereas
the 2011 guidelines set forth 3 stages of disease encompassing preclinical disease (underlying
pathology in the absence of overt cognitive changes), Mild Cognitive Impairment (MCI) due to
AD, and AD, the 2016 modifications propose a move from disease- or syndrome-centric
classifications toward unbiased indicators of pathology or damage as indicated by biomarkers166.
This evolution may be considered as the merging of the IWG and NIA-AA guidelines in to a
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single classification scheme – though these guidelines do not specify “Alzheimer Disease” as a
diagnosis, rather, they simply allow classification of whether or not an individual exhibits
biomarker changes indicative of underlying AD pathology. Dubbed “A/T/N”, this classification
scheme has three binary categories: amyloid pathology, as defined by CSF Aβ42 or amyloid
imaging; tau pathology, as defined by CSF P-tau or tau PET; and neurodegeneration, as defined
by CSF tau, FDG PET or MRI.
It may seem that these diagnostic or classification schemes are nebulous or far from
implementation on a large scale. However, each iteration of guidelines provides important
updates that either pinpoint critical issues (such as inter- and intra-lab variability in biomarkers)
in need of improvement or adjust the expectations of “ideal” AD diagnostic scenarios to those
that fit more accurately with data from AD biomarker studies. Recently, a strategic roadmap for
using biomarkers to diagnose AD at early stages was proposed that may aid in bringing the
concepts proposed by the IWG, NIA-AA, and 2016 update together167. Specific challenges in
biomarker development and implementation were clearly outlined to encourage continued
investigation in a framework of five phases of development, outlined in Table 1.1, that roughly
follow the paradigm of (1) casting a wide net for potential biomarkers; (2) developing reliable
assays to measure promising biomarkers from step 1; (3) longitudinal studies of identified
biomarkers paired with clinical changes to develop a full picture of disease; (4) application of
high-performing biomarkers in prospective cohorts to assess accuracy of biomarkers in clinical
and research settings, and (5) assess applicability of biomarkers in providing positive value in a
clinical setting.
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Table 1.2 Barriers to the Widespread Clinical Usage of Biomarkers for AD Diagnosis and Prognosis
Phase

Status

Biomarkers Involved
Non-pathologic CSF markers (eg VILIP-

Phase 1 – exploratory

1, SNAP-25, Ng, YKL-40, NfL); Imaging
Widely ongoing

studies

markers (tau PET, novel imaging analysis
techniques); Blood-based biomarkers

Phase 2 – assay

Core CSF biomarkers; Non-pathologic
Currently developing

development

CSF biomarkers; Imaging biomarkers
Ongoing in studies at large research

Phase 3 – retrospective
Limited cohorts available

centers and Alzheimer’s Disease Research

and longitudinal studies
Centers
Phase 4 – prospective
diagnostic accuracy

Promising biomarkers of all modalities
Widely ongoing

studies

have been tested in prospective cohorts
with variable efficacy
Psychiatric effects of diagnosis can be

Phase 5 – disease burden
Minimal, in progress

investigated, but not outcomes during or

reduction studies
after treatment

Information on research phase 1-5 drawn from Frisoni et al167. Information on Status and Biomarkers
involved is drawn from information covered in Chapter 1.

1.3.3 Relation of the Current Work to the Challenges Outlined by the Field
The current work was initiated to explore CSF biomarker utility in a context specific to
preclinical AD. The original hypothesis postulated that biomarkers of AD might change long
before clinical symptoms manifest, and therefore that CSF protein levels in a subset of middleaged, cognitively normal individuals would reflect such changes longitudinally; these data will
be covered in Chapter 2 and could apply to Phase 3 as outlined in Table 1.1. A secondary
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hypothesis postulated that CSF biomarkers would change longitudinally in a temporally distinct
manner as individuals progressed through different disease stages from preclinical through
symptomatic AD; these data will be covered in Chapter 3 and could apply to Phase 3. The gold
standard being sought is a biomarker or, more likely, panel of biomarkers capable of indicating
disease state and prognosis at the level of a single individual. While the current work does not
provide anywhere near such a level of detail, it is certainly a step forward for a number of the
obstacles set forth in Table 1.1 and allows for longitudinal, within-person case studies relevant to
the primary hypotheses; these data will be covered in Chapter 4 and could apply to Phase 3 and
4. Lastly, as this work began in 2011, many topics in AD biomarkers have emerged necessitating
further investigation of the analytic validation of CSF Aβ and tau which are widely considered
the gold standard in pre-mortem diagnosis alongside amyloid and FDG PET and MRI measures;
these data will be covered in Chapter 5 and could apply to Phase 2.
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Chapter 2: Longitudinal Cerebrospinal Fluid
Biomarker Changes in Preclinical Alzheimer
Disease During Middle Age
This work was published in the July 2015 issue of JAMA Neurology31.

2.1 Abstract
Importance
Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being
targeted for AD secondary prevention trials. How early during the normal life span underlying
AD pathologies begin to develop, their patterns of change over time, and their relationship with
future cognitive decline remain to be determined.
Objective
To characterize the within-person trajectories of cerebrospinal fluid (CSF) biomarkers of AD
over time and their association with changes in brain amyloid deposition and cognitive decline in
cognitively normal middle-aged individuals.
Design, Setting, and Participants
As part of a cohort study, cognitively normal (Clinical Dementia Rating [CDR] of 0) middleaged research volunteers (n=169) enrolled in the Adult Children Study at Washington
University, St Louis, Missouri, had undergone serial CSF collection and longitudinal clinical
assessment (mean, 6 years; range, 0.91-11.3 years) at 3-year intervals at the time of analysis,
between January 2003 and November 2013. A subset (n=74) had also undergone longitudinal
amyloid positron emission tomographic imaging with Pittsburgh compound B (PiB) in the same
period. Serial CSF samples were analyzed for β-amyloid 40 (Aβ40), Aβ42, total tau, tau
phosphorylated at threonine 181 (P-tau181), visinin-like protein 1 (VILIP-1), and chitinase-3-like
protein 1 (YKL-40). Within-person measures were plotted according to age and AD risk defined
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by APOE genotype (ε4 carriers vs noncarriers). Linear mixed models were used to compare
estimated biomarker slopes among middle-age bins at baseline (early, 45-54 years; mid, 55-64
years; late, 65-74 years) and between risk groups. Within-person changes in CSF biomarkers
were also compared with changes in cortical PiB binding and progression to a CDR higher than 0
at follow-up.
Main Outcomes and Measures
Changes in Aβ40, Aβ42, total tau, P-tau181, VILIP-1, and YKL-40 and, in a subset of
participants, changes in cortical PiB binding.
Results
While there were no consistent longitudinal patterns in Aβ40, (P=.001-.97), longitudinal
reductions in Aβ42 were observed in some individuals as early as early middle-age (P≤.05) and
low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques
(area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially
in mid middle-age (P<.001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1)
dramatically increased in some individuals in mid and late middle-age (P≤.02), whereas the
neuroinflammation marker YKL-40 increased consistently throughout middle age (P≤.003).
These patterns were more apparent in at-risk ε4 carriers (Aβ42 in an allele dose-dependent
manner) and appeared to be associated with future cognitive deficits as determined by CDR.
Conclusions and Relevance
Longitudinal CSF biomarker patterns consistent with AD are first detectable during early
middle-age and are associated with later amyloid positivity and cognitive decline. Such measures
may be useful for targeting middle-aged, asymptomatic individuals for therapeutic trials
designed to prevent cognitive decline.
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2.2 Introduction
Alzheimer disease (AD) is the most common cause of dementia in elderly individuals,
accounting for up to 70% of all dementia cases, and is now estimated to be the third-leading
cause of death after heart disease and cancer168. To date, clinical trials of potential diseasemodifying therapies for AD have met with little success in halting or slowing cognitive decline
in patients who already have cognitive symptoms or dementia169. However, clinicopathologic
and more recent biomarker data suggest that AD pathology begins to accrue approximately 10 to
20 years before any cognitive signs or symptoms (termed asymptomatic or preclinical
AD)9,27,64,170–175, thus providing a window of opportunity for the initiation of secondary
prevention trials that aim to prevent the development of symptoms in individuals while they are
still cognitively normal176. How early during the normal life span such pathologies begin to
develop, their patterns of change over time, and their relationship with future cognitive decline
remain to be determined.
Because, by definition, preclinical AD eludes detection by current clinical measures, diseasespecific biomarkers are necessary to identify individuals in this asymptomatic stage. To this end,
the Adult Children Study (ACS) of the Knight Alzheimer’s Disease Research Center at
Washington University, St Louis, Missouri, was initiated. The ACS is a longitudinal clinical and
biomarker research study of cognitively normal, middle-aged adults exhibiting different AD risk
profiles including age, family history of AD, and APOE genotype (APOE ε4 carriers vs
noncarrier)177. Participants undergo comprehensive, longitudinal clinical and psychometric
assessments and evaluation of biomarkers in cerebrospinal fluid (CSF) and plasma, along with
several imaging modalities. We hypothesized that biomarker patterns indicative of underlying
AD pathology would be evident in a subset of cognitively normal individuals during middle age,
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at a greater frequency in those at higher risk for AD (ie, older and/or carrying the ε4 allele of
APOE), and would increase in severity over time, ultimately culminating in cognitive decline.
The 3 CSF biomarker analytes that reflect the core neuropathologies in AD, β-amyloid 42
(Aβ42; the primary constituent of amyloid plaques), total tau (a marker of neuronal injury and/or
death), and hyperphosphorylated tau (P-tau; forms intraneuronal neurofibrillary tangles),
demonstrate excellent diagnostic and prognostic utility in research cohorts64,178,179. Other recently
identified biomarkers, including visinin-like protein 1 (VILIP-1) and chitinase-3-like protein 1
(YKL-40) (markers of neuronal death and gliosis/neuroinflammation, respectively) have also
demonstrated clinical utility in AD, especially when combined in an algorithm with CSF
Aβ4261,62,65,101,180. This first report of longitudinal biomarker changes in the ACS cohort
describes the within-person trajectories of these CSF biomarkers over time and their association
with longitudinal changes on in vivo amyloid imaging and future cognitive decline as a function
of risk conferred by APOE genotype.

2.3 Methods
Participants
Participants were cognitively normal, community-dwelling research volunteers enrolled in the
ACS at the Knight Alzheimer’s Disease Research Center at Washington University. Inclusion
criteria include the following: (1) positive family history (≥1 biological parent with age at AD
dementia onset <80 years) or negative family history (both biological parents living to age ≥70
years in the absence of AD dementia); (2) aged 45 to 74 years at study entry (1 enrollee was aged
43 years, 3 were aged 75 years, 3 were aged 76 years, and 1 was aged 81 years); (3) availability
of an informant who knows the participant well; (4) normal cognition at study entry (defined as
having a Clinical Dementia Rating [CDR]181 of 0; and (5) willingness in principle to complete all
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study procedures at baseline and longitudinally. Exclusion criteria include the following: (1)
presence of a neurological, psychiatric, or systemic illness that might affect cognition or interfere
with longitudinal follow-up; (2) a known deterministic mutation for AD; and (3) medical
contraindication to lumbar puncture for CSF collection or imaging.
Specific inclusion criteria for the present analysis included the availability of data from at least 2
serial clinical assessments and CSF collection procedures (mean [SD] interval between clinical
assessment and CSF collection, 3.3 [3.8] years) as of September 2013; thus, this cohort
represents a subset (n=169) of ACS participants to date. All procedures were approved by the
Human Research protection Office at Washington University, and written informed consent was
obtained from all participants and their informants.
Clinical and Cognitive Assessments
The presence or absence of dementia (and, when present, its severity) was operationalized with
the CDR in accordance with standard protocols and criteria182. A CDR of 0 indicates cognitive
normality, whereas CDRs of 0.5, 1, 2, and 3 are indicative of very mild, mild, moderate, and
severe dementia, respectively181.
Genotyping
Using standard procedures, DNA was extracted from peripheral blood samples. Genotyping of
APOE was performed by the Knight Alzheimer’s Disease Research Center Genetics Core as
previously described183.
CSF Collection and Processing
A sample of CSF (20-30 mL) was collected by routine lumbar puncture at 8 AM after overnight
fasting as described17. Samples were processed into 500 uL aliquots and immediately frozen at 80oC.
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CSF Biomarker Analyses
The CSF samples were analyzed for Aβ and tau proteins using single-analyte enzyme-linked
immunosorbent assays (ELISAs; research use only) from 2 different vendors. Samples were
analyzed for Aβ1-40 (Aβ40), Aβ1-42 (Aβ42), total tau, and tau phosphorylated at threonine 181
(P-tau181) using the Improved INNOTEST ELISA (Fujirebio Europe), a modified version of the
assay most widely used in the field. In parallel, Aβ40, Aβ42, and total tau were measured at the
same time (from the same sample aliquot) using a set of second-generation (precision-based and
accuracy-based) EUROIMMUN ELISAs (EUROIMMUN). The Aβ42 to Aβ40 ratio was
calculated to normalize the Aβ42 production concentrations to the total amount of Aβ (Aβ40 is
the most abundant Aβ species in CSF)184–186. The ratio of total tau (P-tau181) to Aβ42 was also
evaluated because it has been shown to be a predictor of future cognitive decline in elderly
cohorts28,61,187,188. It must be stated at the outset that the focus of this study is on the clinical
utility of the biomarker and that conclusions drawn from one assay can be confirmed or qualified
with data derived from another immunoassay. The well-studied INNOTEST ELISA was
considered a priori to be the reference assay; therefore, INNOTEST data are shown.
The VILIP-1 concentration was measured using a 2-site immunoassay (Singulex)61. The YKL-40
concentration was measured with the MicroVue ELISA (Quidel)101(p40).
Longitudinal CSF samples from a given individual were run on the same assay plate (and same
lot number) to minimize potential interpolate and interlot methodological variability. Samples
underwent a single freeze-thaw cycle prior to assay, were thawed on wet ice (approximately 3
hours) prior to analysis, and were all run in duplicate. Values had to pass quality control criteria,
including coefficients of variation of 25% or lower, kit controls within the expected range as
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defined by the manufacturer (where applicable), and measurement consistency of 2 common
pooled CSF samples that were included on each plate.
In Vivo Amyloid Imaging
A subset (n=74) of the 169 participants with longitudinal CSF analysis had also undergone
longitudinal in vivo amyloid imaging via positron emission tomography (PET) with Pittsburgh
compound B (PiB)189–191 within approximately 12 months of CSF collection (mean [SD], 84.3
[92] days). The PiB PET imaging was conducted with a Siemens 962 HR+ Emission ComputerAided Tomograph PET or Biograph 40 scanner (Siemens/CTI). Magnetic resonance imaing
using magnetization-prepared rapid-acquisition gradient-echo T1-weighted imagine (1 x 1 x 1.25
mm) was obtained for anatomical reference.
Deposition of PiB in brain regions of interest was determined using FreeSurfer version 5.1
software (Martinos Center for Biomedical Imaging)190,192,193, and a standardized uptake value
ratio (SUVR) corrected for partial volume effects194 was calculated for each region of interest.
The mean cortical SUVR was calculated from FreeSurfer regions within the prefrontal cortex,
precuneus, and temporal cortex. Cerebellar cortex served as the reference region. Based on a
study of 77 symptomatic and asymptomatic Knight Alzheimer’s Disease Research Center
participants190, PiB positivity was defined as an SUVR of 1.42, commensurate with a mean
cortical binding potential of 0.18 defined previously for PiB positivity189.
Statistical Analysis
Baseline demographic characteristics were summarized as mean (standard deviation) for
continuous variables or number (percentage) for categorical variables. Demographic variables
were compared across 3 age bins within the 2 APOE ε4 groups and between the ε4 carriers and
noncarriers within each age bin using post hoc t tests within analysis of variance for continuous
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variables or logistic regression for dichotomous variables. To quantify the within-person annual
rate of change in CSF biomarkers, general linear mixed models with random intercepts and
random time slopes at the participant level were used to regress the concentrations on time from
study entry (baseline). These models incorporated baseline age category, APOE category, and
time from study entry as fixed effects as well as all possible higher-order interactions among
these factors. This facilitated the estimation of average baseline CSF biomarker concentrations as
well as their change over time separately in each of the 6 participant groups (cross-classification
of 3 baseline age categories by 2 APOE categories). The resulting estimated average withinperson annual rates of change in CSF biomarkers were compared among the 6 groups with
model-derived approximate t tests with the approximate denominator df based on the
Satterthwaite approximation195. Baseline comparisons between CSF biomarkers among the
groups in Table 2.1 were also carried out within these general linear mixed models by testing the
estimated average concentrations when time from study entry was equal to 0. These CSF
biomarker comparisons, at baseline and on the longitudinal rate of change, were also reexamined
after adjusting for family history, sex, and education by including fixed effects for these factors
and their interactions with time from study entry. The general linear mixed model assumptions
were evaluated via analyses of residuals. Owing to the preliminary nature of hypotheses
examined in this cohort, no adjustment was made for multiplicity. For exploratory purposes, an
optimal CSF Aβ42 cutoff was determined using the Youden Index after receiver operating
characteristic analysis for discriminating between PiB-positive and PiB-negative individuals at
baseline. For each biomarker, baseline and longitudinal comparisons between PiB-positive (PiB
SUVR ≥ 1.42) and PiB-negative individuals were performed using general linear mixed models
with fixed effects included for PiB category, time from study entry, and their interaction. We
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used SAS version 9.3 statistical software (SAS Institute, Inc.) for all statistical analyses, with
statistical significance defined as P < .05.

2.4 Results
Baseline data are presented in Table 2.1 and grouped into 6 bins: the absence (n=108) or
presence (n=61) of at least 1 APOE ε4 allele (as an indicator of neutral and high AD risk,
respectively) and middle-age bin at baseline (early [45-54 years], mid [55-64 years], or late [6574 years]). Ninety-nine participants underwent 2 serial CSF collections, 65 underwent 3 serial
CSF collections, and 5 underwent 4 serial CSF collections, at intervals of approximately 3 years.
Forty-five of the 61 ε4 carriers (74%) and 49 of the 108 ε4 noncarriers (45%) reported a positive
family history.

2.4.1 Comparison of the CSF Aβ40, Aβ42, and Total Tau Assays
Data for the ACS cohort was acquired using two assays for Aβ40, Aβ42, and Tau. The data
presented in Chapter 2 are the “Improved” INNOTEST data. With the exception of
EUROIMMUN data in Table 2.1, analyses comparing the INNOTEST and EUROIMMUN
assays are located in Chapter 5.
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Table 2.1 Demographic Characteristics and Baseline Cerebrospinal Fluid Biomarkersa
Variable

APOE ε4 Noncarriers (n=108)
Early (n = 26)
Mid (n = 44)

Late (n = 38)

APOE ε4 Carriers (n=61)
Early (n = 19)
Mid (n = 17)

Late (n = 25)

50.1 (3.0)

59.4 (2.9) b

69.9 (3.5) b,c

49.6 (2.9)

59.3 (3.1) b

69.4 (3.6) b,c

Female, No. (%)

17 (65)

32 (73)

22 (58)

14 (74)

11 (65)

16 (64)

Positive family history, No. (%)

12 (46)

22 (50)

15 (39)

15 (79) d

13 (76)

17 (68) d

ε2/ε2

0

1

1

0

0

0

ε2/ε3

3

8

6

0

0

0

ε3/ε3

23

35

31

0

0

0

ε2/ε4

0

0

0

2

2

2

ε3/ε4

0

0

0

14

12

20

ε4/ε4

0

0

0

3

3

3

Education, mean (SD), y

16.1 (2.10)

16.9 (2.27)

15.6 (2.64) c

15.8 (1.95)

15.4 (3.45) d

16.3 (2.23)

Baseline MMSE score, mean (SD) e

29.5 (0.65)

29.3 (1.10)

28.8 (1.22) b

29.8 (0.38)

28.9 (1.52) b

28.9 (1.39) b

0

1

4

1

3

5

12/13/1

21/19/4

25/13/0

11/8/0

12/5/0

18/7/0

3.3 (0.76)

3.3 (0.91)

3.1 (0.77)

3.3 (0.73)

3.6 (1.4)

3.2 (0.77)

Baseline age, mean (SD), y

APOE genotype, No.

Received ≥1 CDR>0 at follow-up, No. f
Participants with 2/3/4 serial LPs, No.
LP interval, mean (SD), mo
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Baseline biomarkers, mean (IQR)
Improved INNOTEST ELISA
Aβ40, pg/mL

Aβ42, pg/mL

Aβ42 to Aβ40 ratio

Total tau, pg/mL

P-tau181, pg/mL

Tau to Aβ42 ratio

12657

14319

15382b

14555

13103

14343

(10461-14480)

(12185-16371)

(12417-17906)

(12984-16638)

(10629-15838)

(12199-16748)

1293

1340

1270

1306

936.9 b,d

969.7 b,d

(1046-1525)

(1132-1544)

(1021-1608)

(1193-1498)

(671-1116)

(733-1225)

0.1052

0.0972

0.0871b,c

0.0924

0.0719 b,d

0.0709 b,d

(0.0900-0.1225)

(0.0800-0.1100)

(0.0700-0.1000)

(0.0800-0.1000)

(0.0600-0.0850)

(0.0550-0.0900)

202.3

259.0

324.3 b,c

257.7

298.0

321.4

(146.0-243.2)

(182.6-278.7)

(205.2-389.3)

(194.4-314.6)

(210.2-391.6)

(198.6-413.2)

39.8

51.2

58.8 b

47.7

54.4

55.4

(27.7-50.3)

(37.2-55.4)

(41.7-68.5)

(38.5-55.4)

(37.9-67.8)

(38.2-69.8)

0.1541

0.1908

0.3054 b,c

0.1986

0.4207 b,d

0.3816 b

(0.1200-0.1725)

(0.1400-0.2200)

(0.1500-0.3100)

(0.1600-0.2300)

(0.1900-0.4550)

(0.2150-0.5200)

4857

5408

5569

5535

5266

5257

(3525-6101)

(4305-6220)

(4347-6224)

(4816-6433)

(3966-7043)

(4119-5942)

616.1

616.1

590.1

676.0

449.5 b,d

487.5 b,d

(438.1-683.1)

(495.90741.8)

(459.4-701.1)

(462.3-797.6)

(349.9-564.3)

(365.3-601.8)

EUROIMMUN ELISA
Aβ40, pg/mL

Aβ42, pg/mL
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Total tau, pg/mL

Tau to Aβ42 ratio

VILIP-1, pg/mL

YKL-40, ng/mL

254.7

310.3

362.5 b,c

299.1

380.5 d

395.8 b

(194.4-304.8)

(230.3-344.6)

(255.6-430.3)

(234.1-351.6)

(313.6-469.6)

(274.1-487.4)

0.4050

0.5022

0.7023 b,c

0.4563

1.073 b,d

0.9342 b,d

(0.3341-0.4851)

(0.3900-0.5192)

(0.4065-0.6874)

(0.3675-0.5390)

(0.4680-1.1100)

(0.5383-1.2250)

140.8

154.4

179.8 b,c

155.6

153.2

154.7

(102.3-169.8)

(116.7-166.4)

(133.6-218.9)

(128.8-175.4)

(105.4-193.8)

(117.0-180.2)

180.3

231.3 b

301.1 b,c

188.4

240.6 b

281.5b

(124.2-220.3)

(192.3-259.7)

(221.7-368.2)

(135.3-238.7)

(165.5-297.9)

(201.8-353.8)

Abbreviations: Aβ, β-amyloid; CDR, Clinical Dementia Rating; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; LP,
lumbar puncture; MMSE, Mini-Mental State Examination; P-tau181, tau phosphorylated at threonine 181; VILIP-1, visinin-like protein 1; YKL-40,
chitinase-3-like protein 1.
a

Age groups indicate the ages within middle-age: early, ages 45-54; mid, ages 55-64; and late, ages 65-74 years

b

Significantly different from early within the same APOE ε4 group (P < .05)

c

Significantly different from mid within the same APOE ε4 group (P < .05)

d

Significantly different from the same age group of the other APOE ε4 group (P < .05)

e

The MMSE scores can range from 0 to 30, with 30 as a perfect score

f

A CDR of 0 indicates cognitively normal; a CDR higher than 0, cognitively abnormal
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2.4.2 Baseline and Slope Analyses: CSF Biomarker Changes Occur in Middle
Age
Baseline biomarker levels (Table 2.1) and slopes of change within individuals (Table 2.2) were
evaluated in the 6 bins defined earlier. Slopes were calculated as the representative mean of all
annual individual slopes per age bin (extrapolated to 9 years for illustrative purposes) and
superimposed on the spaghetti plots of the associated individual trajectories (Figure 2.1 shows
the INNOTEST assay data for Aβ40, Aβ42, Aβ42 to Aβ40 ratio, total tau, P-tau181, and total tau
to Aβ42 ratio; Figure 2.2 shows the data for VILIP-1 and YKL-40; see Figure 5.1 Chapter 5 for
the EUROIMMUN assay data). Controlling for family history, sex, and education did not
substantially influence the comparisons between age and ε4 categories.
Aβ40, Aβ42, Aβ42 to Aβ40 Ratio
Baseline levels of CSF Aβ40 (INNOTEST) were significantly higher in the late middle-aged
group compared with the early middle-aged group in ε4 noncarriers (P = .004) (Table 2.1) but
decreased significantly within individuals in the early (P = .04) and mid (P = .01) middle-aged
groups over time (Table 2.2 and Figure 2.1A). In contrast, no significant differences were
observed in ε4 carriers at baseline or longitudinally (Table 2.1 and Table 2.2).
In contrast to Aβ40, robust decreases within individuals in all age groups were observed for
Aβ42 in both risk groups (Figure 2.1B and Table 2.2), and this pattern was detectable in many
participants as early as 45 to 54 years of age. While baseline concentrations did not differ among
the age groups in the ε4 noncarriers, levels in ε4 carriers were significantly lower in the mid (P <
.001) and late (P < .001) middle-aged groups compared with the early middle-aged group and
also significantly lower than the levels in the mid (P < .001) and late (P < .001) middle-aged ε4
noncarriers (Table 2.1).
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Similar to the patterns observed for Aβ42 alone, the ratios of Aβ42 to Aβ40 were significantly
lower in the mid (P = .02) and late (P = .005) middle-aged groups compared with the early
middle-aged group in ε4 carriers (Table 2.1), and the within-person values significantly
decreased over time in the 2 older age groups (both P < .001) (Figure 2.1C and Table 2.2).
Although baseline ratios in the ε4 noncarriers were significantly lower in the late middle-aged
group compared with the mid (P = .05) and early (P = .004) middle aged groups (Table 2.1),
they did not change significantly within these low-risk individuals at any age (Figure 2.1C and
Table 2).
Total Tau and P-tau181
Baseline total tau was higher in late middle-aged participants compared with early middle-aged
participants in both risk groups, with intermediate levels in the mid middle-aged participants,
although differences were statistically significant only in the ε4 noncarriers (P < .001 and P =
.02, respectively) (Table 2.1). Within ε4 noncarriers, total tau increased significantly over time
during late middle age (P < .001), while increases were observed earlier (mid and late middleage) in the higher-risk ε4 carriers (both p < .001) (Figure 2.1D and Table 2.2). Interestingly, the
annual mean (SE) increase in total tau in mid middle-age was significantly higher in ε4 carriers
(22.28 [4.45] pg/ml) compared with ε4 noncarriers (2.84 [2.68] pg/ml) (P < .001) (Table 2.2).
Results for P-tau181 were virtually identical to those for total tau, including more robust
elevations in the ε4 carriers during mid middle-age (Figure 2.1E and Table 2.2).

41

Table 2.2 Mean Annual Slopes of Within-Individual Longitudinal Change in Cerebrospinal Fluid Biomarkers During Middle Agea
APOE ε4 Noncarriers (n=108)
Variable

APOE ε4 Carriers (n=61)

Early (n = 26)

Mid (n = 44)

Late (n = 38)

Early (n = 19)

Mid (n = 17)

Late (n = 25)

-163.59 (80.50)

-153.82 (61.81)

-130.39 (77.20)

30.63 (102.86)

3.31 (107.75)

110.77 (97.06)

.04b

.01b

.09

.77

.98

.26

-

-

-

.14

.21

.05

-14.81 (5.83)

-19.34 (4.48)

-22.80 (5.56)

-14.99 (7.42)

-29.22 (7.79)

-26.76 (6.99)

.01b

<0.001b

<0.001b

.045b

<0.001b

<0.001b

-

-

-

.98

.27

.66

0.00027

-0.00023

-0.00068

-0.00090

-0.00202

-0.00220

(0.00042)

(0.00032)

(0.00042)

(0.00055)

(0.00057)

(0.00052)

.52

.47

.10

.10

<0.001b

<0.001b

-

-

-

.09

.007b

.02b

Aβ40
Estimated Annual Slope, mean (SE), pg/ml
Different from zero, P value
APOE ε4 carriers vs noncarriers, P value
Aβ42
Estimated Annual Slope, mean (SE), pg/ml
Different from zero, P value
APOE ε4 carriers vs noncarriers, P value
Aβ42 to Aβ40 ratio

Estimated Annual Slope, mean (SE), pg/ml

Different from zero, P value
APOE ε4 carriers vs noncarriers, P value
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Total tau
Estimated Annual Slope, mean (SE), pg/ml
Different from zero, P value
APOE ε4 carriers vs noncarriers, P value

0.96 (3.44)

2.84 (2.68)

14.58 (3.08) c,d

5.40 (4.20)

22.28 (4.45) c

18.45 (3.85) c

.78

.29

<0.001b

.20

<0.001b

<0.001b

-

-

-

.42

<0.001b

.43

0.23 (0.51)

0.32 (0.40)

1.84 (0.47) c,d

1.08 (0.63)

3.41 (0.67) c

1.92 (0.58)

.66

.43

<0.001b

.09

<0.001b

.001b

-

-

-

.30

<0.001b

.91

0.0538 c

0.0478 c

(0.0106)

(0.0088)

P-tau181
Estimated Annual Slope, mean (SE), pg/ml
Different from zero, P value
APOE ε4 carriers vs noncarriers, P value
Total tau to Aβ42 ratio
0.0268 c
Estimated Annual Slope, mean (SE), pg/ml

0.0026 (0.0084)

0.0081 (0.0066)

0.0076 (0.0100)
(0.0071)

Different from zero, P value
APOE ε4 carriers vs noncarriers, P value

.76

.22

<0.001b

.45

<0.001b

<0.001b

-

-

-

.70

<0.001b

.07

-0.18 (1.03)

-0.48 (0.80)

2.39 (1.01) d

0.79 (1.34)

5.17 (1.39) c

1.42 (1.27) d

.86

.55

.02b

.55

<0.001b

.26

-

-

-

.56

<0.001b

.55

VILIP-1
Estimated Annual Slope, mean (SE), pg/ml
Different from zero, P value
APOE ε4 carriers vs noncarriers, P value
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YKL-40
Estimated Annual Slope, mean (SE), pg/ml
Different from zero, P value
APOE ε4 carriers vs noncarriers, P value

4.80 (1.29)

4.26 (0.99)

6.91 (1.27)

6.25 (1.68)

10.83 (1.75)

4.90 (1.60) d

<0.001b

<0.001b

<0.001b

<0.001b

<0.001b

.002b

-

-

-

.50

.001b

.32

Abbreviations: Aβ, β-amyloid; P-tau181, tau phosphorylated at threonine 181; VILIP-1, visinin-like protein 1; YKL-40, chitinase-3-like protein 1;
dashes, not applicable.
Age groups indicate the ages within middle-age: early, ages 45-54; mid, ages 55-64; and late, ages 65-74 years. Results for Aβ40, Aβ42, Aβ42 to
Aβ40 ratio, total tau, P-tau181, and total tau to Aβ42 ratio are from the improved INNOTEST enzyme-linked immunosorbent assay
a

b

Statistically significant at P < .05

c

Significantly different from early within the same APOE ε4 group (P < .05)

d

Significantly different from mid within the same APOE ε4 group (P < .05)
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Ratios of Total Tau and P-tau181 to Aβ42
In ε4 noncarriers, the baseline total tau to Aβ42 ratio was significantly higher in late middle-age
compared with both early (P = .005) and mid (P = .01) middle-age (Table 2.1). In at-risk ε4
carriers, significantly higher ratios were observed even earlier (mid [P = .002] and late [P = .004]
middle-age) compared with early middle-age (Table 2.1). Longitudinal patterns for the total tau
to Aβ42 ratio were virtually identical to those of total tau, with significant within-person
increases in the late middle-aged group in ε4 noncarriers (P < .001) and even earlier (mid and
late middle-age) in the ε4 carriers (both P < .001) (Figure 2.1F and Table 2.2). Patterns for the
P-tau181 to Aβ42 ratio were virtually identical to those of the total tau to Aβ42 ratio (data not
shown).
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Figure 2.1. Longitudinal Change in Cerebrospinal Fluid Biomarkers β-Amyloid 40 (Aβ40),
Aβ42, Aβ42 to Aβ40 Ratio, Total Tau, Tau Phosphorylated at Threonine 181 (P-tau181), and
Total Tau to Aβ42 Ratio During Middle Age

Estimated group slopes and within-person changes for Aβ40 (A), Aβ42 (B), Aβ42 to Aβ40 ratio (C), total
tau (D), tau phosphorylated at threonine 181 (P-tau181) (E), and total tau/Aβ42 ratio (F) are shown in the
3 age bins for APOE ε4 noncarriers (top graph of each panel; n = 108 participants) and ε4 carriers
(bottom graph of each panel; n = 61 participants). Annual slopes have been extrapolated to 9 years, and
each slope begins at the mean baseline biomarker value from individuals in each age bin. Group

baseline values and slopes represent the estimates reported in Table 1 and Table 2, respectively,
for the different cohorts defined by baseline age in which biomarker concentrations were
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regressed on time from study entry. Data are from the INNOTEST enzyme-linked
immunosorbent assay (Fujirebio Europe).
a

Slope significantly different from 0 (P < .05).

b

Slope significantly different between APOE ε4 groups within a given age group (P < .05).

2.4.3 Other Biomarkers of Neuronal Injury and Gliosis/Neuroinflammation
VILIP-1
The concentration of VILIP-1 was positively correlated with total tau during middle age
(INNOTEST total tau: n = 401, Pearson r = 0.763 [95% CI, 0.719-0.801], P < .001;
EUROIMMUN total tau: n = 403, Pearson r = 0.743 [95% CI, 0.696-0.784], P < .001),
consistent with earlier reports in elderly cohorts. Similar to total tau, mean baseline VILIP-1
concentration increased with age, with significantly higher levels in late middle-age compared
with early (P = 0.008) and mid (P = .03) middle-age in the ε4 noncarriers (Table 2.1) and withinperson increases over time in late middle-age (P = .02) (Figure 2.2A and Table 2.2). While
baseline levels of VILIP-1 in the at-risk ε4 carriers at baseline were not significantly different
among the age groups, (Table 2.1), they significantly increased longitudinally within individuals
at an earlier age (mid middle-age [P < .001]) compared with the ε4 noncarriers (late middle-age
[P = .02]) (Figure 2.2A and Table 2.2). Also similar to total tau, the annual mean increase in
VILIP-1 concentration in mid middle-age was greater in ε4 carriers compared with ε4
noncarriers (P < .001).
YKL-40
Baseline CSF YKL-40 concentration was significantly higher in mid and late middle-age
compared with early middle-age in both ε4 groups (all P ≤ .04) as well as in late middle-age
compared with the mid middle-age in the ε4 noncarriers (P < .001) (Table 2.1). In both groups,
YKL-40 concentration significantly increased within individuals over time in all age bins (P =
.002 in late middle-age among ε4 noncarriers; all others, P < .001) (Figure 2.2B and Table 2.2).
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In mid middle-age, YKL-40 concentration increased at a significantly higher rate in the ε4
carriers compared with ε4 noncarriers (P = .001) (Table 2.2), similar to what was observed for
the injury markers.
Figure 2.2. Longitudinal Change in Cerebrospinal Fluid Biomarkers Visinin-Like Protein 1
(VILIP-1) and Chitinase-3-Like Protein 1 (YKL-40) During Middle Age

Estimated group slopes and within-person changes for VILIP-1 (A) and YKL-40 (B) are shown in the 3
age bins for APOE ε4 noncarriers (top graph of each panel; n = 108 participants) and ε4 carriers (bottom
graph of each panel; n = 61 participants). Annual slopes have been extrapolated to 9 years, and each slope
begins at the mean baseline biomarker value from individuals in each age bin. Group baseline values and
slopes represent the estimates reported in Table 1 and Table 2, respectively, for the different cohorts
defined by baseline age in which biomarker concentrations were regressed on time from study entry.
a

Slope significantly different from 0 (P < .05).
Slope significantly different between APOE ε4 groups within a given age group (P < .05).

b
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2.4.4 APOE ε4 Gene Dose Influences CSF Biomarker Patterns Consistent with
the Presence of Preclinical AD During Middle Age
Given the known APOE ε4 gene dosage effects on the risk of AD and age at dementia onset, we
evaluated biomarker trajectories as a function of ε4 allele number. The majority (82%) of ε4
noncarriers had the ε3/ε3 genotype, whereas the majority (75%) of ε4 carriers had the ε3/ε4
genotype (Table 2.1). Nine participants were ε4 homozygotes (ε4/ε4 genotype). Trajectory
patterns for Aβ40 did not differ as a function of ε4 allele dose (Figure 2.3A). In contrast,
patterns differed dramatically for Aβ42 (Figure 2.3B) and the Aβ42 to Aβ40 ratio (Figure 2.3C)
across the entire age range, with ε4 homozygotes falling among the lowest values, ε4 noncarriers
typically falling among the highest, and heterozygotes falling in the middle range (although
overlapping with many of the ε4 noncarriers). The longitudinal patterns for total tau, total tau to
Aβ42 ratio, VILIP-1, and YKL-40 in ε4 carriers appeared to overlap to a greater extent with
those for ε4 noncarriers (Figure 2.3D-F). However, the number of ε4 homozygotes is too small
to perform rigorous statistical analyses in the current cohort.

49

Figure 2.3 Longitudinal Biomarker Trajectories in Individuals with Different APOE Genotypes

Within-person trajectories of CSF A) Aβ40, B) Aβ42, C) Aβ42/Aβ40 Ratio, D) Tau, E) Tau/Aβ42 Ratio, F) VILIP-1, and G) YKL-40 are plotted
as a function of age. Aβ40, Aβ42 and tau were measured with the INNOTEST assay. Colors identify APOE genotype: no ε4 alleles (gray, ε4-/-;
ε2/ε2, ε2/ε3, ε3/ε3), one ε4 allele (purple, ε4+/-; ε2/ε4, ε3/ε4) and two ε4 alleles (orange, ε4+/+; ε4/ε4).
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2.4.5 Association of CSF Aβ42 and In Vivo Amyloid Imaging During Middle
Age
Because studies to date evaluating the concordance of CSF Aβ42 concentrations with in vivo
amyloid load have focused on elderly cohorts, it was of interest to characterize this association in
middle-age, a time during which a subset of individuals are expected to be in the very earliest
stages of preclinical AD. This analysis used data from a subset of 74 participants (n = 50 ε4
noncarriers; n = 24 ε4 carriers) within the longitudinal CSF cohort who had also undergone
longitudinal in vivo PiB PET imaging within 376 days (mean [SD], 84.3 [92] days) of CSF
collection. Twenty of these individuals were considered PiB positive (mean cortical SUVR ≥
1.42) at baseline, follow-up, or both (Figure 2.4A). Of these 20 individuals, 10 (50%) were ε4
noncarriers and 10 (50%) were ε4 carriers. Although there was no significant association
between the cross-sectional patterns (P = .12) or longitudinal trajectories (P = .65) of Aβ40 and
cortical PiB binding (Figure 2.4B), PiB positivity was associated with low baseline levels of
CSF Aβ42 (P < .001) but not longitudinal change (P = .37) (Figure 2.4C). However, 15 PiBnegative individuals (20%) had concentrations of Aβ42 that were as low as those who were PiBpositive. Because low Aβ42 values could conceivably reflect low production of all Aβ species
rather than an amyloidosis-specific decrease in Aβ42, we also evaluated the relationship between
PiB and the Aβ42 to Aβ40 ratio (Figure 2.4D). Twelve of the PiB-negative participants (16%)
had Aβ42 to Aβ40 ratios at some point that were as low as those who were PiB-positive.
Notably, all 4 ε4 homozygotes in this subcohort had a low Aβ42 concentration and a low Aβ42
to Aβ40 ratio at both baseline and follow-up (Figure 2.4C and D), including the 2 young
participants (aged <55 years at baseline) who were PiB-negative (Figure 2.4C and D, solid black
lines). The PiB-positive individuals typically had higher baseline (P < .001) and longitudinally
increasing (P < .001) levels of total tau (and P-tau181 [scatterplots not shown]) compared with
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those who were PiB-negative (Figure 2.4E). The PiB associations with baseline (P = .04) and
longitudinal (P = .004) VILIP-1 concentrations were similar to total tau but less concordant
(Figure 2.5A). Being PiB-positive was not significantly associated with YKL-40 levels at
baseline (P = .08) but was associated with greater longitudinal increases (P = .04) (Figure 2.5B).
Overall, Aβ42, Aβ42 to Aβ40 ratio, total tau, and P-tau181 appeared to be more strongly
associated with PiB positivity than were Aβ40, VILIP-1, and YKL-40.
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Figure 2.4. Association Between Longitudinal Patterns of Cerebrospinal Fluid Biomarkers βAmyloid 40 (Aβ40), Aβ42, Aβ42 to Aβ40 Ratio, and Total Tau, Cortical Pittsburgh Compound
B (PiB) Standardized Uptake Value Ratio (SUVR), and Age

A subset (n = 74) of Adult Children Study participants had undergone longitudinal amyloid imaging via
PiB positron emission tomographic imaging within 376 days (mean [SD], 84.3 [92] days) of
cerebrospinal fluid collection. Biomarker measures include cortical PiB SUVR (A), Aβ40 (B), Aβ42 (C),
Aβ42 to Aβ40 ratio (D), and total tau (E). The Aβ40, Aβ42, and total tau were analyzed by INNOTEST
enzyme-linked immunosorbent assay (Fujirebio Europe). Being PiB positive was defined as having a
mean cortical PiB SUVR higher than 1.42 and is represented by the dashed horizontal line in panel A.
Gray lines indicate PiB negative at baseline and follow-up (n = 52); solid colored lines, PiB positive at
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both baseline and follow-up (n = 14); dashed colored lines, PiB negative at baseline but positive at
follow-up (n = 6); and solid black lines, PiB negative with discordant (low) cerebrospinal fluid Aβ
measures at baseline and follow-up (n = 2). Colored solid and dashed lines are each differently colored
only to facilitate visual comparisons across all analytes for each PiB-positive individual.

Figure 2.5. Association Between Longitudinal Patterns of Cerebrospinal Fluid Biomarkers
Visinin-Like Protein 1 (VILIP-1) and Chitinase-3-Like Protein 1 (YKL-40), Cortical Amyloid,
and Age

A subset (n = 74) of Adult Children Study participants had undergone longitudinal amyloid imaging via
Pittsburgh compound B (PiB) positron emission tomographic imaging within 376 days (mean [SD], 84.3
[92] days) of cerebrospinal fluid collection. Biomarker measures include VILIP-1 (A) and YKL-40 (B).
Being PiB positive was defined as having a mean cortical PiB standardized uptake value ratio higher than
1.42 (see dashed horizontal line in Figure 3A). Gray lines indicate PiB negative at baseline and follow-up
(n = 52); solid colored lines, PiB positive at both baseline and follow-up (n = 14); dashed colored lines,
PiB negative at baseline but positive at follow-up (n = 6); and solid black lines, PiB negative with
discordant (low) cerebrospinal fluid β-amyloid measures at baseline and follow-up (n = 2). Colored solid
and dashed lines are each differently colored only to facilitate visual comparisons across all analytes for
each PiB-positive individual.

2.4.6 Aβ42 Cutoff as Estimated Using PiB at Baseline
Using only baseline CSF and PiB obtained within 376 days (mean [SD], 89.9 [95] days), a
slightly larger subcohort of 105 participants was used to calculate a cutoff for CSF Aβ42
(INNOTEST) based on PiB positivity. The optimal cutoff in this cohort is 1041 pg/mL
(sensitivity = 1; specificity = 0.82), with an area under the receiver operating characteristic curve
of 0.9352 (95% CI, 0.8895-0.9808).
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2.4.7 Case Study of Participants Who Received a CDR Higher Than 0 at
Clinical Follow-up
Biomarker studies in cognitively normal elderly cohorts have demonstrated prognostic utility of
baseline CSF measures for predicting future cognitive decline. To assess whether this
relationship exists even earlier in the preclinical stages (during middle-age), as a preliminary
analysis we compared the biomarker trajectories in participants who received a CDR higher than
0 at some point during clinical follow-up with those who retained a CDR of 0. Of the 169
participants evaluated, all of whom were cognitively normal (CDR of 0) at the time of baseline
CSF collection, 14 received a CDR of 0.5 at some point during follow-up (mean [SD], 6.55
[1.94] years; median, 6.15 years; range, 4.21-10.28 years), and 3 of these progressed further to a
CDR of 1. The remaining 155 participants had a CDR of 0 at all follow-up (mean [SD], 6.01
[1.94] years; median, 6.21 years; range 0.98-11.32 years). The duration of follow-up did not
differ significantly between the groups (P > .05). All individuals who progressed to a CDR
higher than 0 were older than 61 years at baseline. There was no apparent relationship between
baseline or longitudinal trajectories of Aβ40 and cognitive status (Figure 2.6A). In contrast, the
majority of progressors exhibited low Aβ42 (Figure 2.6B) and Aβ42 to Aβ40 ratio (Figure
2.6C) at baseline and follow-up and high total tau and total tau to Aβ42 ratio (Figure 2.6D and
E). Patterns of VILIP-1 and YKL-40 did not appear to differ between the clinical groups (Figure
2.6F and G). However, the number of clinical progressors is too small to perform rigorous
statistical analyses in the current cohort.

55

Figure 2.6 Cerebrospinal Fluid Biomarker Trajectories in Participants Receiving a Clinical Dementia Rating Higher Than 0 at Some
Point During Clinical Follow-up

Within-person trajectories of cerebrospinal fluid β-amyloid 40 (Aβ40) (A), Aβ42 (B), total tau (C), total tau to Aβ42 ratio (D), visinin-like protein
1 (VILIP-1) (E), and chitinase-3-like protein 1 (YKL-40) (F) are plotted as a function of age. The Aβ40, Aβ42, and total tau were analyzed by
INNOTEST enzyme-linked immunosorbent assay (Fujirebio Europe). Fourteen individuals received a Clinical Dementia Rating of 0.5 or 1 at
some point during follow-up (mean [SD], 6.55 [1.94] years; range, 4.21–10.28 years). Orange lines indicate individuals who received a Clinical
Dementia Rating higher than 0 at available follow-up visits; gray lines, individuals who did not receive a Clinical Dementia Rating higher than 0.
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2.5 Discussion
Our results demonstrate the following: (1) levels of CSF Aβ42 in some cognitively normal
individuals decrease over time, starting as young as early middle age (45-54 years); (2) in mid
middle-age (55-64 years), reductions in Aβ42 are associated with the development of PiBpositive amyloid plaques; (3) elevations in neuronal injury markers total tau, P-tau181, and (to a
lesser extent) VILIP-1 increase dramatically in some individuals in mid and late (65-74 years)
middle-age; (4) the gliosis/neuroinflammation marker YKL-40 increases throughout middle-age;
(5) these biomarker changes are observed in both risk groups defined by APOE genotype but are
more evident in ε4 carriers and (for amyloid-related measures) in an allele dose-dependent
manner; and (6) these AD-consistent trajectories are not clinically benign but instead are
associated with future cognitive decline. These observations were confirmed in both evaluated
immunoassays for Aβ42 and total tau.
Reductions in CSF Aβ42 concentration within certain individuals throughout middle-age suggest
an ongoing pathological process that for some people starts quite early (ages 45-54 years).
Levels may begin to decrease even earlier, but additional investigation in younger cohorts is
needed to test this hypothesis. During middle-age, the timing of this decrease is influenced by ε4
allele dosage, consistent with studies demonstrating a major influence of APOE genotype on Aβ
aggregation and clearance196,197. Baseline and follow-up Aβ42 levels are among the lowest in ε4
homozygotes compared with heterozygotes and ε4 noncarriers, with reduction evident at earlier
ages. Such effects are consistent with the ε4 dosage effects on age at dementia onset198.
Regardless of when Aβ42 levels begin to decrease during the preclinical period, these decreases
did not coincide with the presence of amyloid detectable by PiB PET until mid middle-age. The
Aβ42 level was stably low or beginning to decline in some individuals while cortical PiB binding
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was still below the threshold of positivity, and PiB binding did not begin to increase until the
CSF Aβ42 level was already relatively low. Thus, it seems likely that Aβ42 aggregation can be
detected earlier with CSF analysis than with cortical PiB PET imaging, consistent with recent
studies in autosomal dominant AD27,199. This is highlighted by 2 high-risk early middle-aged ε4
homozygotes who had stable, low Aβ42 levels (and Aβ42 to Aβ40 ratios) in longitudinal
samples but were PiB negative. This observation may reflect sequestration of Aβ42 into
oligomeric forms undetectable with the current assays or its deposition in nonfibrillar (PiBnegative) diffuse plaques. In support of the latter, low CSF Aβ42 concentration in the absence of
PiB positivity has been reported in a case in which numerous diffuse plaques, but few neuritic
plaques, were observed at autopsy200. However, the early middle-age bin of the longitudinal PiB
subcohort is quite small; subregional PiB analyses and evaluation of future longitudinal PiB scan
in ACS participants are necessary to rigorously evaluate PiB changes in early middle-age.
The calculated CSF Aβ42 cutoff in this cohort is quite high at 1041 pg/mL, higher than
previously reported using the INNOTEST kit (typically 450-650 pg/mL)17,20,201. This apparent
discrepancy may reflect the younger age of the ACS cohort. Most likely it reflects the fact that
we used a newer modified, improved INNOTEST assay. This cutoff is not suggested for clinical
use but was instead provided to evaluate amyloid positivity using CSF measures – similar to
protocols being considered for enrollment in AD prevention trials. Using this cutoff, 51 of the
169 participants (30%) would be considered amyloid positive and eligible for clinical trial
enrollment based on baseline CSF Aβ42 concentration alone. Further longitudinal follow-up is
needed to determine what percentage of these individuals will present with cognitive decline,
which will in turn enable analysis of the efficacy of CSF Aβ42 concentration at baseline for
determination of preclinical AD.
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In contrast to the early changes in Aβ42, increases in total tau, P-tau181, and VILIP-1 are
typically not apparent until later (ages ≥55 years). Notably, the rate of increase was significantly
greater in the ε4-carrying at-risk group during mid middle-age, coincident with continuing,
robust decreases in Aβ42 level. It was in this age range that many participants with the AD
biomarker pattern began to exhibit cognitive decline. Interestingly, the absolute slopes (ie, rates
of increase) of these neuronal injury markers in the ε4 carriers actually decreased from mid to
late middle-age. This pattern is consistent with a potential slowing of an earlier robust phase of
neuronal injury or perhaps reflects neuronal dysfunction that adversely affects the normal
cellular secretion or release of these proteins. It will be interesting to determine whether this
pattern is also observed in those at lower risk (ε4 noncarriers), albeit at older ages, how it
compares with proposed early markers of synaptic function currently in development, and
whether this proposed slowing continues into the symptomatic phase as has been reported in
individuals with autosomal dominant AD64 and late-onset AD dementia202. The rate accelerations
in these markers at mid middle-age observed here in the at-risk group are consistent with the
concept of an age-related transition between stage 1 (amyloid alone) and stage 2 (amyloid plus
neuronal injury) of preclinical AD proposed by the National Institute on Aging-Alzheimer’s
Association Preclinical AD Working Group203. Although these proposed stages are currently
defined by biomarker measures obtained at a single point in time, it is possible that a longitudinal
biomarker metric may have more utility. This hypothesis awaits further investigation.
The consistent pattern of increases in YKL-40 level in all age bins suggests that
neuroinflammation/gliosis (the hypothesized cause of the increase in YKL-40 level) is a process
that occurs normally with aging. However, the particularly robust increases observed in at-risk ε4
carriers during mid middle-age suggest that this age-related process may be further exacerbated
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in the presence of insults including amyloid deposition and neuronal injury. Whether this
neuroinflammatory process contributes to the concomitant increase in neuronal injury remains to
be determined.
This study is not without limitations. As by design the ACS cohort enrolls participants with and
without family history of AD for longitudinal imaging and CSF biomarker studies, participants
may not be representative of the general population. Despite the large number of participants in
this unique cohort, there are fewer in the ε4-carrying group, and most participants at the time of
analysis had only 2 longitudinal samples available. While some individuals had 10 years of
clinical follow-up, others had only 4. Although the results provide support for a scenario in
which changes in amyloid-related processes precede those of tau or other neurodegenerationrelated processes, additional analyses during a longer period are required to determine the precise
sequence of biomarker changes within a given individual. Furthermore, as expected in such a
young, asymptomatic cohort, relatively few participants in this initial report had received a CDR
greater than 0 during follow-up. Continued evaluation of longer clinical follow-up will provide
an opportunity to better elucidate the biomarker patterns in middle-age that predict future
cognitive decline.

2.5.1 Conclusions
The present groupwide analyses are supportive of a preclinical period of AD in which biomarker
patterns consistent with underlying disease pathology are first detectable during middle-age, the
timing of which is influenced by APOE genotype, with amyloid changes occurring prior to
neuronal injury. However, proposals to use biomarkers in clinical settings require demonstration
of their utility on a patient-by-patient basis. Importantly, our preliminary findings of an
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association between CSF biomarker positivity in specific individuals who go on to develop
cognitive deficits within a few years provide support for such potential use.
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Chapter 3: Longitudinal Decreases in
Multiple Cerebrospinal Fluid Biomarkers of
Neuronal Injury in symptomatic Late Onset
Alzheimer’s Disease
This work is currently under review.

3.1 Abstract
Introduction
Individuals in early stages of Alzheimer’s disease (AD) are a targeted population for secondary
prevention trials aimed at preserving normal cognition. Understanding within-person
biomarker(s) change over time is critical for trial enrollment and design.
Methods
Longitudinal cerebrospinal fluid (CSF) samples from the Alzheimer’s Disease Neuroimaging
Initiative were assayed for novel markers of neuronal/synaptic injury (VILIP-1, Ng, SNAP-25)
and neuroinflammation (YKL-40) and compared with Aβ42, Tau, and P-Tau181. General linear
mixed models were used to compare within-person rates of change in three clinical groups
(cognitively normal, mild cognitive impairment and AD) further defined by β-amyloid status.
Results
Levels of injury markers were highly positively correlated. Despite elevated baseline levels as a
function of clinical status and amyloid-positivity, within-person decreases in these measures
were observed in the early symptomatic, amyloid-positive AD group.
Discussion
Knowledge of within-person biomarker change will impact interpretation of biomarker outcomes
in clinical trials that are dependent on disease stage.
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3.2 Introduction
Clinical trials of potential disease-modifying therapies for Alzheimer’s Disease (AD) have
failed to slow cognitive decline in patients who have dementia or milder cognitive symptoms
(e.g., mild cognitive impairment, MCI)169. Since AD pathology begins to develop ~20 years
before cognitive decline (preclinical AD)27,204, it is possible that trial participants were too far
along in the disease process for such therapies to impact cognition. Therefore, individuals at
earlier stages, including the asymptomatic, preclinical stage (defined by biomarkers), are now
receiving intense focus for secondary prevention trials aimed at preserving normal cognitive
function. Understanding the patterns of biomarker(s) change over time is critical for defining
where individuals fall along the pathologic disease cascade.
Cross-sectional studies indicate that β-amyloid (Aβ)-related biomarkers become abnormal
first, followed by markers of tau-related neuronal injury, both during the preclinical period205.
Elevated injury markers in the presence of amyloid positivity then become a strong predictor of
subsequent cognitive decline44. Interestingly, while regional brain atrophy then ensues, with
abnormality increasing with symptomatic progression206, a recent study of individuals with
autosomal dominant AD (ADAD) reported longitudinal decreases in CSF levels of neuronal
injury markers including Tau, P-Tau181 and visinin-like protein 1 (VILIP-1) in symptomatic
mutation carriers64, suggesting a slowing of acute neurodegenerative processes and/or a decrease
in the number of viable neurons contributing to the pools of these markers in this later stage of
the disease. Regardless of the mechanism, if confirmed in an independent cohort of persons
developing late onset AD (LOAD), such a pattern will likely have an impact on interpretation of
biomarker outcomes in clinical trials that is dependent on the disease stage. To this end, the
present study evaluated the patterns of within-person longitudinal change in a variety of standard
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(Tau, P-Tau181) and novel (VILIP-1, neurogranin, SNAP-25) CSF neuronal injury biomarker
levels in individuals spanning the full range of AD, including normal, preclinical AD, MCI due
to AD and symptomatic AD, and a comparison of these changes with regional brain atrophy and
cognitive decline.

3.3 Methods
ADNI Study Design
CSF Aβ42, total tau (Tau) and phospho-tau181 (P-Tau), demographic, imaging and cognitive
data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(http://adniloni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by
Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging (MRI), biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early AD. ADNI participants have been recruited from more than 50 sites
across the USA and Canada. Regional ethical committees of all institutions approved of the
study, and all participants provided written informed consent. For up-to-date information, see
www.adni-info.org.
Study Participants
The ADNI cohort in the present study consisted of all cognitively normal (CN)
participants and those with MCI or AD dementia (AD) with available CSF samples from at least
two visits as of April 2012. This cohort included 152 individuals across ADNI1, ADNI GO and
ADNI2 (n=56 CN, n=73 MCI, n=17 AD). Demographic and cognitive data were downloaded in
August 2015 and were collected as described (adni.loni.usc.edu/methods/documents/). By
definition, individuals in the CN group all had a clinical dementia rating (CDR) score of 0 at the
time of lumbar puncture (LP) and a Mini-Mental State Examination (MMSE) score ≥ 24.
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Individuals with MCI also scored ≥ 24 on the MMSE but exhibited subjective memory loss (>1
standard deviation below the normal mean of the delayed recall of the Wechsler Memory Scale
Logical Memory II), received a CDR of 0.5, preserved activities of daily living and the absence
of dementia. The AD group met the definition of probable AD according to criteria established
by the National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA)207, had MMSE
scores of 20-26 and CDRs of 0.5 or 1. Groups were designated by clinical diagnosis at the time
of initial available CSF sample in the longitudinal cohort (defined herein as baseline).
ADNI Clinical, CSF and Imaging Data
Scores for MMSE and Alzheimer’s Disease Assessment Scale-cognitive 11 (ADAS11) and
ADAS13 were downloaded from the LONI site in August 2015 via ADNIMerge R Package.
Values for CSF Aβ42 (INNOBIA AlzBio3; Fujirebio, Ghent, Belgium) were downloaded at the
same time from two datasets (UPENNBIOMK4 and UPENNBIOMK6) and were used to define
amyloid-positivity based on a published, autopsy-confirmed cut-off value (<192 pg/ml)208. For
statistical analyses, values for Aβ42, total Tau (Tau) and Ptau181 (P-Tau) generated by a single
lot number of the novel, fully automated, electrochemiluminescent Elecsys® immunoassays
(Roche Diagnostics, Basel, Switzerland) were downloaded from the LONI site in March 2017
from a single dataset (UPENNBIOMK9). The Elecsys® system aims to offer a fully automated
CSF biomarker test for AD capable of achieving In Vitro Diagnostic (IVD) capability and offers
some improvements over current Research Use Only (RUO) assays including: reduction in
manual steps, improved precision and accuracy both within labs and between labs, and improved
lot-to-lot reagent performance. The Elecsys® Aβ42 immunoassay in use is not a commercially
available IVD assay. It is an assay currently under development and for investigational use only.
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The measuring range of the assay is 200 (lower technical limit) – 1700 (upper technical limit)
pg/ml. The performance of the assay beyond the upper technical limit has not been formally
established. Therefore, values above the upper technical limit have been truncated at 1700 pg/ml.
In the current study, baseline analyses excluded these data. Longitudinal statistical analyses were
run with and without these truncated values and performed nearly identically.

Magnetic resonance imaging (MRI) data for the left and right hippocampal (HP) volume (white
matter parcellation) and left and right entorhinal cortex (EC) thickness, two regions known to be
affected early in AD, were also analyzed. EC thickness and HP volume were downloaded in
November 2016 from the file UCSFFSL_02_01_16. Acquisition of 1.5 Tesla MRI and data
processing methods are as described (adni.loni.usc.edu/methods/mri-analysis/). Data were
processed with FreeSurfer v4.4, and only values that passed all quality control (QC) standards
were included in the analyses. Values for left and right HP and EC thickness were added together
to create a value for “total” HP volume and EC thickness.

Novel CSF Analytes
Samples were analyzed for YKL-40 (also known as chitinase 3-like 1, a marker of
gliosis/neuroinflammation)209, visinin-like protein 1 (VILIP-1, a neuronal calcium sensor protein
and marker of neuronal injury)210, neurogranin (Ng, a post-synaptic protein and marker of
synaptic dysfunction)106 and synaptosomal-associated protein 25 (SNAP-25, a pre-synaptic
protein and marker of synaptic dysfunction) [19]. YKL-40 was measured with a plate-based
enzyme-linked immunoassay (ELISA) (MicroVue ELISA; Quidel, San Diego, CA)31. VILIP161,62, NG63,69 and SNAP-25 were measured using microparticle-based immunoassays using the
Singulex (now part of EMD-Millipore; Alameda, CA) Erenna system, and employed antibodies
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developed in the laboratory of Dr. Jack Ladenson at Washington University. All samples (each
on the same freeze/thaw cycle) were run in triplicate on a single lot number for VILIP-1, SNAP25 and Ng and in duplicate for YKL-40. Within-person longitudinal samples were run on the
same assay plate to reduce inter- and intra-plate variability. Quality control for VILIP-1, SNAP25 and Ng included analysis of three internal standard CSF pools run on each plate and two
internal pools for YKL-40. See Appendix for assay details.
Statistical Analysis
Since the study intent was to compare baseline biomarker levels and their longitudinal change
over time in individuals who span the AD continuum (from no disease [normal], to preclinical
AD, to MCI due to AD, to AD), participants in the three diagnostic categories (CN, MCI, AD)
were further stratified into β-amyloid-positive (Aβ+) versus amyloid-negative (Aβ-) at baseline
based on the published ADNI CSF Aβ42 cut-off of <192pg/mL208. Baseline characteristics for
the five resultant groups (CN-, CN+, MCI-, MCI+, AD+) were summarized as mean (standard
deviation [SD)]) for continuous variables or number (percentage) for categorical variables.
Group differences among the various measures were assessed using one-way ANOVA and posthoc Tukey tests. Correlations between measures were assessed via Spearman correlation.
Biomarker concentrations, cognitive performance and MRI measures within individuals over
time were compared among the five groups (all AD individuals were Aβ+) by general linear
mixed models with random intercepts/slopes at the subject level to allow estimation and
comparison of within-person rates of change211. In addition to the mean intercept and slope for
each group (unadjusted models), covariates including age at baseline, APOE ε4 carriage, sex,
education, and their interactions with subject groups on the intercepts and slopes, were also
included as fixed effects (see Appendix). All general linear mixed models assumed a subject
67

level random effect on intercept and slope and were fitted using the maximum likelihood
method. Statistical tests were based on the approximate F or t- tests with denominator degrees of
freedom approximated by the Satterthwaite methods212. All analyses were performed with SAS
version 9.4 (SAS Institute Inc.), with statistical significance defined as p < 0.05.

3.4 Results
3.4.1 Demographics
Of the 152 ADNI participants who met the criteria for having longitudinal CSF samples (range
2-7 LPs over 1-7 years of follow up [mean (SD) = 4.0 (1.62)] and a mean (SD) LP interval of 16
(8.6) months), four were omitted from the dataset due to missing values for CSF Aβ42 (via
AlzBio3) required to define baseline amyloid status (Aβ+ vs Aβ-). Participants in the final
dataset of n=148 were 38% female, between 58 and 90 years of age at the time of initial LP
(mean [SD] = 75 [7.13]), and 68% were APOE ε4-positive (Table 1). As expected, baseline HP
volume and EC thickness were different among the groups (CN>MCI>AD) (p<0.0001).
Performances on MMSE, ADAS11 and ADAS13 were also as expected, with the MCI and AD
groups performing worse than the CN group (p<0.0001).
When the clinical groups were dichotomized into amyloid-positive (Aβ+) and amyloidnegative (Aβ-)208), neuronal injury/inflammation biomarker levels were higher (more AD-like)
in the Aβ+ compared to the Aβ- groups, both among and within each clinical group (Table 2).
Positive correlations were observed among the injury markers at baseline, strongest among tTau,
VILIP-1 and Ng (Spearman r= 0.798-0.853) (Appendix Table 1). SNAP-25 was moderately
correlated with the other injury markers (r= 0.619-0.720), and as expected, Tau and P-tau
exhibited the highest positive correlation (r= 0.975). Elecsys Aβ42 was positively correlated with
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AlzBio3 Aβ42 (r=0.869) and negatively correlated with Tau, P-tau and SNAP-25 (r=-0.214, 0.324 and -0.240, respectively). YKL-40 was significantly, but weakly, correlated with the injury
markers (r= 0.307-0.422) but not Aβ42.
Table 3.1 Study Demographics
CN

MCI

N

Aβ35

Aβ+
21

Aβ18

Aβ+
58

AD
Aβ+
16

Baseline age, mean (SD)

76 (5.7)

76 (3.7)

77 (7.3)

74 (6.5)

74 (6.7)

Gender, F/M (%F)
Education, mean (SD), y
APOE ε4 allele, +/- (%+)
# CDR 0/0.5/1, n
CDR-SB, mean (SD)

14/21 (40%)
16 (3.1)
3/32 (9%)
35/0/0

10/11 (48%)
16 (3.4)
9/12 (43%)
21/0/0

4/14 (22%)
17 (1.8)
0/18 (0%)
0/18/0

18/40 (31%)
16 (2.8)
40/18 (69%)
0/57/1

11/6 (65%)
15 (3.0)
13/4 (77%)
0/10/6

0.029 (0.12)C-E

0.024 (0.11)C-E

1.25 (0.55)A,B,E

1.61 (0.85)A,B,E

4.24 (1.49)A-D

MMSE, mean (SD)

29.1 (1.1)C-E

29.4 (0.9)C-E

27.6 (1.8)A,B,E

26.8 (1.8)A,B,E

23.7 (1.7)A-D

C-E

D,E

A,B,E

18.7 (6.1)A-D

ADAS 11, mean (SD)

5.3 (2.2)

ADAS 13, mean (SD)
8.4 (3.5)C-E
# LP's 2/3/4/5/6/7, n
0/15/7/8/5/0
LP interval, mean (SD),
17.01 (9.44)E
mo
LP follow-up, mean (SD,
52.9 (19.7, 23-86)E
Range), mo
Total EC thickness, mean
6.88 (0.84)C-E
(SD), mm
Total HP volume, mean
6577 (815)C-E
(SD), mm3

7.1 (3.3)

9.9 (4.1)

A,E

11.7 (5.1)

10.5 (3.9)D,E
0/8/6/4/3/0

15.5 (5.9)A,E
0/5/10/2/1/0

19.5 (7.1)A,B,E
2/26/18/5/6/1

28.9 (7.4)A-D
1/9/5/1/0/0

17.55 (10.40)E

16.92 (8.98)

15.90 (7.92)

12.73 (2.86)A,B

55.0 (17.0, 26-85)E

49.8 (17.9, 24-87)E

6.88 (0.95)C-E

6.32 (0.96)A,B,E

6.44 (0.87)A,B,E

5.26 (0.82)A-D

6553 (886)C-E

5818 (978)A,B,E

5861 (880)A,B,E

5117 (848)A-D

45.0 (18.9, 16-86)E 30.2 (10.2, 12-50)A-D

A – Significantly different from CN AβB – Significantly different from CN Aβ+
C – Significantly different from MCI AβD – Significantly different from MCI Aβ+
E – Significantly different from AD Aβ+
Abbreviations: Aβ, amyloid-β status; AD, Alzheimer disease; ADAS 11; Alzheimer’s Disease Assessment
Scale-cognitive test, version 11 (higher score is worse performance; ADAS 13, Alzheimer’s Disease
Assessment Scale-cognitive test, version 13 (higher score is worse performance); APOE, apolipoprotein E;
CDR, Clinical Dementia Rating score; CDR-SB, CDR sum of boxes; CN, cognitively normal; EC, entorhinal
cortex; HP, hippocampus; LP, lumbar puncture; MCI, mild cognitive impairment; MMSE, Mini-Mental
State Examination
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3.4.2 Patterns of Neuronal Injury and Neuroinflammatory Markers
Participant-level CSF biomarker trajectories were plotted for each of the five amyloid-defined
clinical groups (see Appendix Figure 1 for spaghetti plots). General linear mixed models (with
random intercepts/slopes at the subject level) were then used to estimate and compare baseline
biomarker levels and within-person rates of change in the five groups. Results adjusting for sex,
APOE ε4 status, education, baseline age, and total ventricular volume are provided in the
Appendix.
Elecsys® tTau
Baseline Tau levels were significantly elevated in the AD+ group compared to all other groups
(all p≤0.01) and the MCI+ compared to the MCI- and CN- (p<0.0001) and CN+ groups (p=0.02)
(Table 2). Longitudinally, Tau levels significantly increased in both CN (both p<0.05) and the
MCI+ groups (p<0.0001) (Figure 1, Table 2). Tau levels decreased longitudinally in the AD+
group, but this change did not reach statistical significance (p=0.095).
Elecsys® pTau
P-tau levels at baseline were significantly elevated in the AD+ compared to all other groups (all
p<0.01), MCI+ compared to MCI- and CN- (both p<0.0001) and CN+ groups (p=0.02), and the
CN+ compared to the MCI- and CN- groups (both p<0.03) (Table 2). Longitudinally, P-tau
levels significantly increased in the CN+ (p=0.001) and trended toward increase in the MCI+
group (p=0.055). Strikingly, P-tau levels significantly declined in the AD+ group (p≤0.0001)
(Figure 1, Table 2), with rate of change greater than the change in all other groups (p<0.001).
VILIP-1
Levels of baseline VILIP-1 were significantly higher in the MCI+ and AD+ compared to both
the MCI- and CN- groups (all p≤0.01) (Table 2). The amyloid-positive groups did not differ
from one another (all p>0.05). Longitudinally, as with P-tau, VILIP-1 levels strongly and
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significantly decreased in the AD+ group (p=0.006), whereas no significant changes were
observed in the other groups (Figure 1, Table 2).
SNAP-25
SNAP-25 values at baseline were significantly higher in the AD+ and MCI+ compared to the
CN- (both p<0.0003), CN+ (p=0.001 and p=0.01, respectively), and MCI- groups (both
p<0.0001) (Table 2). Longitudinally, SNAP-25 levels declined significantly in the AD+ group
(p=0.05), whereas no significant changes were observed in the other groups (Figure 1, Table 2).
Ng
Baseline levels of Ng were significantly higher in the AD+ group than the CN- (p=0.003), CN+
(p=0.02), and MCI- (p=0.0006) groups, although not between the MCI+ and AD+ groups
(p=0.10) (Table 2). Levels were also higher in the MCI+ compared to the CN- (p=0.004) and
MCI- (p=0.02) groups. Longitudinally, Ng markedly and significantly decreased in the AD+
group (p<0.0001), whereas no significant changes were observed in the other groups (Figure 1,
Table 2).
YKL-40
In contrast to the markers of neuronal injury, baseline levels and longitudinal patterns of change
in the neuroinflammatory marker, YKL-40, exhibited a large degree of within-group variability.
Baseline YKL-40 was significantly higher in the AD+ compared to the MCI- (p=0.04) but not
the other groups (Table 2). Longitudinally, all groups showed an increase in mean levels over
time, but this increase was statistically significant only in the MCI+ group (p=0.03) (Figure 1,
Table 2), perhaps due to less variability (smaller SD) within that group.
Elecsys® Aβ42
Although CSF Aβ42 (as measured in ADNI by AlzBio3) was used a priori to define amyloid
status in the clinical groups, we were also interested in evaluating the patterns of this biomarker
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using the novel Elecsys® platform. As expected, baseline Aβ42 levels (via Elecsys®) were
significantly lower in all Aβ+ compared to Aβ42- groups (all p<0.0001) (Table 2).
Longitudinally, levels decreased in all groups (and at similar rates), although only the AD+ and
CN- groups reached statistical significance (p=0.04 and p=0.0004, respectively) (Figure 1,
Table 2).
Table 3.2 Baseline CSF biomarker levels and estimated within-person annual change over time
MCI

CN
Aβ+
21

Aβ18

Aβ+
58

AD
Aβ+
16

687 (274)A,C

1404 (318)B,D,E

590 (187)A,C

578 (214)A,C

272 (84.9)D,E

215 (68.2)D,E

331 (117.5)A-C,E

407 (167.5)A-D

18.1 (5.83)B,D,E 33.7 (13.62)A-C,E

42.8 (19.90)A-D

AβN
35
Baseline CSF Biomarkers
Elecsys Aβ42, mean (SD), pg/ml 1413 (284)B,D,E
Elecsys tTau, mean (SD), pg/ml 230 (70.8)D,E
Elecsys pTau, mean (SD), pg/ml 20.3 (6.30)B,D,E
VILIP-1, mean (SD), pg/ml
143.3 (44.9)D,E

27.4 (9.56)A,C-E
152.6 (49.8)

140.5 (50.2)

D,E

176.7 (61.0)

A,C

185.6 (70.1)A,C

SNAP-25, mean (SD), pg/ml

4.45 (1.5)D,E

4.66 (1.4)D,E

3.72 (1.3)D,E

6.01 (2.2)A-C

6.84 (3.3)A-C

Ng, mean (SD), pg/ml

2302 (1066)D,E
384.1 (20.08)

2339 (953)E
399.6 (19.4)

1962 (945)D,E

3383 (1576)A-C

361.6 (19.4)E

2836 (1426)A,C
401.3 (17.87)

CSF Biomarker Estimated Annual Slope
Elecsys Aβ42, pg/ml (SE)
-20.91 (5.6)
p value
0.0004 F

-7.96 (7.27)
0.28

-2.38 (8.4)
0.78

-7.82 (5.17)
0.13

-29.48 (14.2)

4.29 (2.1)E

6.75 (2.7)E

1.10 (3.1)

7.55 (1.8)E

0.048 F

0.015 F

0.72

<0.0001 F

-7.11 (4.2)A,B,D
0.095

0.39 (0.2)E
0.069

0.88 (0.3)C,E

0.028 (0.3)B,E
0.93

0.35 (0.2)E
0.055

YKL-40, mean (SD), ng/ml

Elecsys tTau, pg/ml (SE)
p value
Elecsys pTau, pg/ml (SE)
p value

0.0013

F

-0.23 (1.0)E
0.89 (1.2)E
-0.21 (1.4)E
-0.96 (0.9)E
p value
0.81
0.48
0.88
0.27
SNAP-25, pg/ml (SE)
-0.0453 (0.042) 0.00279 (0.053) 0.00715 (0.060) -0.0387 (0.037)
p value
0.28
0.96
0.91
0.29
VILIP-1, pg/ml (SE)

Ng, pg/ml (SE)
p value
YKL-40, ng/ml (SE)
p value

-2.74 (26.1)E
0.92
4.51 (3.5)
0.20

19.88 (33.6)E
0.56
6.29 (4.3)
0.15

A – Significantly different from CN AβB – Significantly different from CN Aβ+
C – Significantly different from MCI AβD – Significantly different from MCI Aβ+
E – Significantly different from AD Aβ+
F – Statistically significant slope
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471.9 (41.86)C

0.039 F

-1.65 (0.4)A-D
<0.0001 F
-6.31 (2.3)A-D
0.006 F
-0.172 (0.088)
0.05 F

15.5521 (38.2)E -38.6334 (23.6)E -232.43 (58.9)A-D
0.68
0.10
<.0001 F
5.54 (4.9)
6.37 (3.0)
1.68 (7.1)
F
0.81
0.26
0.035

Bold – Slope that is statistically different from zero
All significance at least p<0.05
Abbreviations: Aβ, amyloid-β status; AD, Alzheimer disease; CN, cognitively normal; MCI, mild cognitive
impairment; Ng, neurogranin; P-tau, phospho-tau181; SNAP-25, synaptosomal associated protein-25;
Tau, total tau; VILIP-1, visinin-like protein 1
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Figure 3.1 Baseline Biomarker Values and Estimated Within-person annual Change in CSF
Biomarkers
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Baseline biomarker values (top panel) and estimated group slopes for Aβ42 (A), tTau (B), pTau (C),
VILIP-1 (D), SNAP-25 (E), Ng (F), and YKL-40 (G). Baseline is shown for each individual, estimated
group slopes are shown as average annual change in 5 bins defined by diagnostic group and amyloid
status, extrapolated to show 5 years of change.
A

Different from CN- group

B

Different from CN+ group

C

Different from MCI+ group

D

Different from AD+ group

E

Different from MCI group

* Different from 0.

3.4.3 Cognitive Measures
Cognitive Measures
As expected, cognitive performance differed with clinical diagnosis, particularly in the Aβ+
symptomatic groups. Furthermore, Aβ+ individuals exhibited longitudinal changes in MMSE
and ADAS11/13 that are consistent with a worsening of cognitive performance and often at a
faster rate than the Aβ- groups. See Appendix Figure 2 for spaghetti plots.
MMSE
Baseline MMSE was lower (indicative of worse performance) in the AD+ group than any other
group (all p<0.0001), lower in the MCI+ compared to the MCI- (p=0.03) and both CN groups
(both p<0.0001), and in the MCI- compared to both CN groups (both p<0.03) (Table 3). In the
AD+ and MCI+ groups, MMSE was decreasing significantly (both p<0.0001) and at a faster rate
in the AD+ compared to the MCI+ group (p<0.0001) (Table 3).
ADAS11 and ADAS13
At baseline, ADAS11 was significantly elevated (indicating worse performance) in the AD+
compared to both CN groups (both p<0.0001), both MCI groups compared to both CN groups
(both p<0.02), and in the AD+ compared to both MCI groups (both p<0.0001) (Table 3).
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Longitudinally, ADAS11 score significantly increased in the AD+ and MCI+ groups (both
p<0.0001) and at a significantly faster rate in the AD+ versus the MCI+ group (p<0.0001)
(Table 3).
Baseline ADAS13 performance was similar to ADAS11 except that the MCI+ group was also
significantly elevated (worse performance) compared to the MCI- group (p=0.05) (Table 3).
Longitudinally, ADAS13 was significantly increasing in all three Aβ+ groups (all p<0.004), at a
faster rate in the AD+ compared to the MCI+ (p=0.0005) and CN+ (p<0.0001) groups, and at a
faster rate in the MCI+ than the CN+ group (p=0.02) (Table 3).

3.4.4 Volumetric MRI Measures
As expected, HP volume and EC thickness were smaller at baseline in the AD+ compared to the
other groups. However, all but the CN- group exhibited significant atrophy over time, albeit at
different rates. See Appendix Figure 3 for spaghetti plots.
Hippocampal Volume
HP volume at baseline was significantly smaller in the AD+ compared to all other groups
(p<0.001 for both CN groups; p=0.03 for both MCI groups) and in both MCI groups compared
to the CN groups (MCI- vs CN- [p=0.003] and CN+ [p=0.01]; MCI+ vs CN- and CN+ [both
p≤0.0007]) (Table 3). Longitudinally, all groups exhibited significant HP shrinkage over time
(all p≤0.0001) (Table 3). Volume in the AD+ and MCI+ groups decreased at a significantly
faster rate than in both CN groups (p≤0.003 and p≤0.001, respectively) and the MCI- group
(p=0.04 and p=0.003, respectively). The rate of atrophy in the MCI- group was faster than the
CN- group (p=0.0009) and in the CN+ compared to the CN- group (p=0.03).
Entorhinal Cortex Thickness
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At baseline, EC thickness was significantly smaller in the AD+ compared to all other groups
(p≤0.0003), in the MCI+ compared to the CN groups (p=0.0004 for CN- and p=0.01 for CN+)
(Table 3). MCI-was also significantly thinner than the CN- group (p=0.03) and at the
significance level compared to the CN+ group (p=0.05). Longitudinally, EC thickness was
declining in all but the CN- group (all p≤0.0003) and at a faster rate in the AD+ compared to the
CN+ (p=0.005) and MCI- (p=0.007) groups (Table 3). The EC in the MCI+ group was also
shrinking more quickly than the CN+ and MCI- groups (both p≤0.0001).
Table 3.3 Baseline cognitive performance and imaging measures and estimated within-person
annual change over time
CN

MCI

AβN
35
Baseline Cognitive and Imaging Biomarkers
MMSE, mean (SD)
29.1 (1.1)C-E

Aβ+
21

Aβ18

Aβ+
58

AD
Aβ+
16

29.4 (0.9)C-E

27.6 (1.8)A,B,D,E

26.8 (1.8)A-C,E

23.7 (1.7)A-D

ADAS 11, mean (SD)

5.3 (2.2)C-E

7.1 (3.3)C-E

9.9 (4.1)A,B,E

11.7 (5.1)A,B,E

18.7 (6.1)A-D

ADAS 13, mean (SD)

C-E

A-C,E

28.9 (7.4)A-D

Total EC thickness, mean (SD),
mm
Total HP volume, mean (SD),
mm3

8.4 (3.5)

10.5 (3.9)

C-E

15.5 (5.9)

A,B,D,E

19.5 (7.1)

6.88 (0.84)C-E

6.88 (0.95)C-E

6.32 (0.96)A,B,E

6.44 (0.87)A,B,E

5.26 (0.82)A-D

6577 (815)C-E

6553 (886)C-E

5818 (978)A,B,E

5861 (880)A,B,E

5117 (848)A-D

-0.22 (0.2)D,E
0.30

-0.039 (0.2)D,E
0.87

-1.26 (0.1)A-C,E

-2.49 (0.3)A-D

0.20 (0.3)D,E
0.52

0.75 (0.4)D,E
0.06

0.30 (0.4)D,E
0.50

2.06 (0.3)A-C,E

4.74 (0.6)A-D

<0.0001 F

<0.0001 F

D,E

D,E

D,E

A-C,E

Cognitive and Imaging Estimated Annual Slope
-0.051 (0.2)D,E
p value
0.76

MMSE, points (SE)

ADAS 11, points (SE)
p value
ADAS 13, points (SE)
p value

0.37 (0.3)
0.27

1.25 (0.4)

0.0042 F

0.53 (0.5)
0.27

<0.0001

2.43 (0.3)

F

<0.0001 F

<0.0001 F

4.98 (0.7)A-D
<0.0001 F

-0.0401 (0.022)B-E-0.118 (0.023)A,D,E-0.118 (0.031)A,D,E -0.261 (0.018)A-C -0.295 (0.057)A-C
p value
0.069
<0.0001 F
0.0003 F
<0.0001 F
<0.0001 F

Total EC thickness, mm (SE)

-59.4 (14.5)B-E -111.2 (18.2)A,D,E -145.9 (20.5)A,D,E -216.3 (11.9)A-C -230.8 (36.0)A-C
Total HP volume, mm3 (SE)
p value
<0.0001 F
<0.0001 F
<0.0001 F
0.0001 F
<0.0001 F

A – Significantly different from CN AβB – Significantly different from CN Aβ+
C – Significantly different from MCI AβD – Significantly different from MCI Aβ+
E – Significantly different from AD Aβ+
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F – Statistically significant slope
Bold – Slope that is statistically different from zero
All significance at least p<0.05
Abbreviations: Aβ, amyloid-β status; AD, Alzheimer disease; ADAS 11; Alzheimer’s Disease Assessment
Scale-cognitive test, version 11 (higher score is worse performance); ADAS 13, Alzheimer’s Disease
Assessment Scale-cognitive test, version 13 (higher score is worse performance); CN, cognitively normal;
EC, entorhinal cortex; HP, hippocampal; MCI, mild cognitive impairment; MMSE, Mini-Mental State
Examination (0-30, with 30 as perfect score)

3.5 Discussion
Our primary finding is the decrease over time in the concentration of several different CSF
markers of neuronal injury (Tau, P-tau, VILIP-1, SNAP-25, Ng) in individuals once they have
developed symptomatic AD. In contrast, elevations in Tau, but not the other injury markers, were
observed at earlier stages (amyloid-positive MCI and CN groups). These findings replicate
similar longitudinal patterns (for Tau, P-tau and VILIP-1) reported in a cohort of autosomaldominant AD64, thus supporting a commonality in neuropathologic processes in sporadic and
genetic forms of the disease. Knowledge of such within-person patterns of change has important
implications for clinical trials in MCI and early stage AD in terms of the use of biomarker
concentrations as pathologic endpoints in determining treatment efficacy for neuronal integrity.
While all the injury markers decreased over time in the AD+ group, the reduction in Ng was
especially robust. Neurogranin is a calmodulin-binding postsynaptic neuronal protein213,214
thought to be involved in activity-dependent synaptic plasticity and long-term potentiation215.
Levels are reduced in AD brain216,217 and elevated in AD CSF73,106 , with high levels predictive
of progression from mild cognitive impairment (MCI) to AD dementia68,69,72,218. Since elevations
in CSF Ng are associated with brain atrophy69,218 and reduced brain glucose uptake218, it is
considered a marker of synaptic dysfunction/loss.
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Although less is known about SNAP-25 (a pre-synaptic t-SNARE molecule that plays a crucial
role in calcium-dependent exocytosis of synaptic vesicles) in AD, like Ng, levels are reduced in
brain219 and elevated in CSF80 compared to controls. Although both synaptic markers were
decreasing longitudinally in the AD+ group, Ng was dropping at more than twice the rate as
SNAP-25 (annual decreases of 6.9% vs 2.5%, respectively) and the other markers (1.8% Tau,
3.9% P-tau, and 3.4% VILIP). Interestingly, Aβ42 was also significantly decreasing annually by
5% in the early AD+ group but less so in the other groups. Although levels of Aβ42 are known
to drop early in the disease and then plateau as amyloid continues to accumulate204, 63% (10/16)
of individuals in the current AD group were at very early symptomatic stages (CDR 0.5).
Baseline levels of YKL-40, an astrocyte-derived protein with presumed neuroinflammatory
properties220, also increased with clinical severity as reported previously221, but we observed a
high level of within-group variability in longitudinal patterns. It is likely that YKL-40 reflects
neuroinflammatory components not specifically due to AD. Interestingly, levels appeared to
increase with age in the AD+ group (Appendix Figure 1) as has also been observed in
cognitively normal middle-aged individuals31. Further studies regarding the role of YKL-40 in
neurodegenerative diseases are warranted222,223.
Despite the fact that there were strong positive correlations among levels of the various injury
markers, consistent with previous reports69,70, discordance in patterns of longitudinal change over
time for tTau was observed in the amyloid-positive MCI group (robust increases in Tau but no
statistical change in the other markers, including P-tau). CSF Tau levels are known increase in
response to acute neuronal death as occurs in response to stroke, traumatic brain injury and
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Creutzfeld-Jakob disease (CJD)224, thus suggesting a robust phase of neuronal death and/or
alterations in the normal metabolism of tau at the very early (MCI) symptomatic stage of AD, the
time during which the first signs of cognitive impairment are evident. The reason(s) for a lack of
within-person increase in these other injury markers remains unclear but may have something to
do with the relatively short follow-up time in the current cohort (mean 4.0 ± 1.61 years) and/or
the lack of information regarding how long a given individual had been in their designated
clinical group at the time of baseline LP (i.e., where in the natural progression of the disease).
Alternatively, such discordance may indicate that these markers reflect different processes
associated with synaptic dysfunction and/or neuronal injury70. A full understanding of biomarker
trajectories will require serial samples being collected from a larger number of individuals over a
long period of time as they progress from one clinical stage to the next.
The biological reason(s) for reductions in CSF injury markers over time in early AD is unclear.
In fact, very little is known about the normal metabolism of these markers that would lead to
their appearance in the CSF in both normal and pathological settings. While it is conceivable that
such reductions simply reflect a general dilution of CSF proteins that would come with
increasing ventricular volume associated with overall brain atrophy, reductions were still
observed after controlling for ventricular volume. It is possible that longitudinal reductions from
an elevated baseline during early AD reflect a slowing of acute neurodegenerative processes with
symptomatic disease progression and/or neuronal death leading to a smaller number of neurons
that remain and contribute to the pool in CSF. Unlike structural MRI and amyloid (and tau) PET
imaging measures that reflect cumulative change over the course of the disease, CSF measures
reflect a snapshot in time, thus measuring different things. Indeed, hippocampal and EC atrophy
continued over the course of the disease even in the face of decreasing levels of injury markers in
80

the CSF. It is therefore not unexpected that there exists some discordance when defining
biomarker positivity (and notably for neuronal injury), as a function of imaging versus CSF225.
This issue is important to consider when selecting biomarker modalities (CSF and/or imaging)
for use in screening and/or outcome measures in clinical trials.
This study is not without limitations. The cohort with longitudinal CSF samples available for
analysis was relatively small which, when divided into five groups, may limit statistical power to
detect longitudinal changes, especially in the preclinical and early symptomatic AD groups.
Although serial LP follow-up was longer than in previous longitudinal ADNI CSF studies226,227,
it was still relatively short (3-5 years). Also, despite the groups being dichotomized as amyloidpositive versus -negative in order to ascertain plaque status in the clinical groups, there was
considerable overlap in clinical and biomarker patterns between individuals, especially in the
MCI and AD groups. Finally, due to the small numbers of individuals in the clinical/biomarker
groups, statistical models were not adjusted for multiple comparisons.

3.5.1 Conclusions
The present results underscore the importance of evaluation of true longitudinal, serial measures
of CSF biomarkers from individuals as they progress through the normal course of the disease as
opposed to the more traditional approach of inferring longitudinal change by comparing crosssectional data from groups of individuals at different disease stages. Indeed, concentrations of
each of the markers have been reported to be elevated in AD compared to MCI and cognitively
normal controls221. While we also observed such elevations in baseline levels of these injury
markers among the different clinical/amyloid groups, the within-person patterns of change over
time were different. For clinical trial purposes, given the stage-specific differences in the
direction of true longitudinal change in these biomarkers, a “positive” biomarker outcome would
81

be different depending on the characteristics of the trial cohort. For example, a slowing of the
course of neuronal injury may be indicated by a slowing of the rate of increase in CSF Tau in
individuals who are early in the disease process (MCI), but perhaps a stabilization or even a
slowing or reversal of the downward trajectory later in the disease (mild AD), potentially
reflected as a longitudinal increase or as no decrease in this marker. Such possibilities warrant
consideration in clinical trial design.

82

Chapter 4: ACS and ADNI Case Studies
In the previous chapters, data was discussed that covered CSF and imaging biomarkers across
two very different cohorts. Because biomarker investigation is not yet at the level of singleperson analysis, the data presented thus far has involved the grouping of individuals within each
cohort by similar risk factors – APOE genotype and age for the ACS in Chapter 2 and CSF
amyloid positivity and cognitive status for the ADNI study in Chapter 3 – and outlining baseline
and longitudinal characteristics within each risk factor grouping. Elucidating biomarker patterns
in this way is only one step forward; for a biomarker or panel of biomarkers to be useful, they
must be able to identify disease within an individual. The current chapter is dedicated to
exploring biomarker profiles in specific individuals chosen from both the ACS and ADNI
Cohorts.

4.1 Case Studies from the ACS Cohort
The ACS was a particularly interesting cohort to study longitudinally because of the relatively
young age at baseline (45-74 years) of study participants. It also represented a significant
challenge in that few participants showed cognitive decline during their participation in the study
(14 of 169, 8%), even as of the writing of this document in October 2017, forcing reliance on
biomarker behavior as the primary indicator of AD.

4.1.1 Methods
To best visualize longitudinal change, the case study cohort was restricted from the ACS cohort
defined in Chapter 2 to only individuals with 3 or 4 serial LP’s, then defined by amyloid status
according to CSF Aβ42 levels, see Table 4.1 for details. Ten individuals were Aβ- at baseline
but converted to Aβ+ at a future LP, defined as having levels above and below 1,041 pg/ml CSF
Aβ42, respectively, according to the cutoff defined in Chapter 2; this group is identified as the
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converter group (Aβ42 Converter). Thirteen individuals had baseline levels of CSF Aβ42 below
the cutoff at baseline and all follow-up LP’s, hereafter identified as stable amyloid positive
(Stable Aβ42+). Thirteen individuals had CSF Aβ42 levels >1,041 pg/ml at baseline and all
follow up LP’s, identified as stable amyloid negative (Stable Aβ42-).
Multiple graphing paradigms were considered for showing CSF Aβ42, Aβ40, Tau, P-tau181,
YKL-40, VILIP-1, and the Aβ42/Aβ40 and Tau/Aβ42 ratios on a single graph. It was determined
after finalizing each paradigm that the Aβ42/Aβ40 ratio, VILIP-1, and YKL-40 were too variable
to be of use on an individual basis in this cohort. The only CSF biomarkers graphed in Figures
4.1-4.6, therefore, were CSF Aβ42, Tau, P-tau181, and the Tau/Aβ42 ratio. Each figure shows
graphs for individuals within 5-year age bins by baseline LP: 45-49 years old, 50-54 years old,
55-59 years old, 60-64 years old, 65-69 years old, and 70-74 years old at baseline.
In determining which graphing paradigm to best illustrate the longitudinal changes of multiple
biomarkers, a number of options were considered. Transforming each biomarker to a z-score,
while putting all biomarkers on the same scale, gave a skewed picture of the case study data
because the ACS dataset biomarkers are quite homogenous and therefore z-scores largely
centered close to the mean for each of the 36 individuals in the case study cohort. Percent change
from BL was also considered, but this only gave an indication of whether biomarkers were
changing within an individual and in what direction – a critical piece of data was lost because
percent change does not take in to account the original biomarker level, which is particularly
important when considering biomarker cutoffs or positivity. The last considered paradigm is
common in AD CSF biomarker research and involves splitting a cohort in to tertiles for analysis.
However, because the ACS case study cohort was small, increased granularity was required to
see differences within and between individuals, so quintiles were calculated for each CSF
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biomarker based on the overall ACS cohort. For each of the 36 individuals in the case study
cohort, the baseline level of each biomarker was graphed as a quintile (1-5), allowing a
straightforward visualization of the baseline biomarker levels within each individual in the
context of the ACS cohort as a whole.
Most individuals, though, remained within a given quintile for each followup LP which gave the
impression of no longitudinal change when followup was also graphed as a quintile. As an
example, the quintiles for Aβ42 are: Q1, 310-768 pg/ml; Q2, 769-1226 pg/ml; Q3, 1227-1683
pg/ml; Q4, 1684-2141 pg/ml; and Q5 2142-2599 pg/ml. A given individual could have a baseline
Aβ42 level of 1224 pg/ml and a follow up of 770 pg/ml, a substantial drop in concentration, and
still be graphed within the second quintile for both time points, resulting in the visual of a
straight line between the baseline and first followup LP. The final paradigm considered was
unorthodox, but for visualization purposes allowed the comparison of all CSF biomarkers by
graphing baseline in quintiles, while each followup LP was graphed as absolute percent change.
Again, as an example, if an individual had a baseline CSF Aβ42 value of 1224 pg/ml, time 0 (T0)
would be visualized at quintile 2. For a followup value of 770 pg/ml, the percent change from T0
to T1 is -63%. In the following figures, this translated to T0 = “2” and T1 = “1.26”. The absolute
percent change is the same, whether discussing the original biomarker level or the quintile proxy,
and graphing in this manner allowed the visualization of baseline status and the magnitude and
direction of change for each of the 5 biomarkers on a single, within-person graph.
A second set of graphs was designed to show biomarker changes within the overall context of
age because the non-core biomarkers VILIP-1, YKL-40, and the Aβ42/Aβ40 Ratio were difficult
to interpret on a within-person level – potentially due to age-related influences on these CSF
biomarker values. In this graphing paradigm all individuals in the stable Aβ42- (n=13), Aβ42
85

converters (n=10), and stable Aβ42+ (n=13) were graphed by group Aβ42 status. Instead of
baseline biomarker being represented as a quintile at T0, baseline quintile is graphed at the age
of each individual baseline LP; all follow up LP’s are graphed as absolute percent change at the
corresponding age at LP. Each Aβ42 status group is represented by two graphs, for a total of six
graphs in Figure 4.7: the core biomarkers and Aβ40 are contained in one graph and the non-core
biomarkers VILIP-1, YKL-40, and Aβ42/Aβ40 Ratio are on a second graph. Baseline quintile
and absolute percent change for the core biomarkers and Aβ40 are identical to the data graphed
in Figures 4.1-4.6.

4.1.2 Results
The case study cohort was split in to six groups based on baseline age matching – Group 1, 4549 years; Group 2, 50-54 years; Group 3, 55-59 years; Group 4, 60-64 years; Group 5, 65-69
years; Group 6, 70-74 years. Table 4.1 contains demographic information on each participant.
Of the 36 individuals comprising the case study cohort: 23 were female (64%), 11 had at least
one APOE ε4 allele (31%), 6 had one ε2 and one ε3 allele (17%), and 19 had two ε3 alleles
(53%) (percentages add up to 101 due to rounding). After baseline LP, each of the 36 individuals
had between 4 and 9 years of follow up LP data with LP’s performed approximately every 3
years, and between 7 and 13 years of clinical follow up. Only 4 of 36 individuals were assigned a
CDR >0 at any point during clinical follow up (11%), and these were exclusively in the stable
Aβ42+ group. Statistical analyses were not performed on this cohort for two reasons: (1)
individuals were selected from a volunteer population already considered to be different from the
general population due to recruitment based on a family history of AD (as outlined in Chapter 2)
and high levels of education and (2) only 36 individuals are represented in this cohort.
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Table 4.1. Demographic Information on the 36 ACS Case Study Cohort Individuals.

n

Stable Aβ42-

Aβ42 Converter

Stable Aβ42+

13

10

13

45-49 Years at BL LP

A

B

D

E

C

Avg. LP Interval (Yr)

4.0

3.0

2.9

3.2

2.9

8

6

6

6

6

12

12

9

9

10

--

Year 3

Year 3

Year 7

--

--

9

6

2

--

CN

CN

CN

CN

CN

Stable

Stable

--

-Negative

Negative

LP Followup (Yr)
Clinical Followup
(Yr)
Aβ42 Conversion
Clinical Followup
After Conversion (Yr)
Clinical Status

Stable
PiB Status

Negative

Sex

M

M

F

F

F

APOE ε Alleles

3/3

3/3

3/3

3/3

3/3
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Table 4.1 Cont.
50-54 Years at BL LP
Avg. LP Interval (Yr)
LP Followup (Yr)

F

I

K

G

J

H

2.9

3.1

3.2

3.0

3.1

3.2

6

9

6

6

6

7

9

12

12

12

9

12

--

--

--

Year 3

Year 6

--

--

--

--

9

3

--

CN

CN

CN

CN

CN

CN

--

--

--

Year 6

--

F

M

M

F

M

M

3/4

3/3

2/3

4/4

3/4

2/3

Clinical Followup
(Yr)
Aβ42 Conversion
Clinical Followup
After Conversion (Yr)
Clinical Status

Stable
PiB Status
Sex
APOE ε Alleles

Negative
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Table 4.1 Cont.
55-59 Years at BL LP

L

O

M

P

N

Q

R

Avg. LP Interval (Yr)

3.1

2.9

3.4

3.1

3.0

3.3

3.1

9

6

7

9

6

7

6

12

13

10

13

11

9

9

--

--

Year 7

Year 9

--

--

--

--

--

3

4

--

--

--

CN

CN

CN

CN

CN

CN

LP Followup (Yr)
Clinical Followup
(Yr)
Aβ42 Conversion
Clinical Followup
After Conversion (Yr)

CDR 0.5
Clinical Status

at year 9

--

--

--

PiB Status
Sex
APOE ε Alleles

Stable

PiB+ at

Stable

Negative

year 3

Positive

Year 9

F

F

F

M

M

F

F

3/3

2/3

3/3

3/3

3/3

3/3

4/4
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Table 4.1 Cont.
60-64 Years at BL LP
Avg. LP Interval (Yr)
LP Followup (Yr)

S

V

X

T

U

W

2.1

3.1

3.3

2.7

3.1

3.0

6

6

7

5

6

9

10

10

9

8

12

--

--

--

--

--

--

--

--

--

--

CN

CN

CN

CN

CN

Stable

Stable

Stable

Stable

Stable

Positive

Positive

Clinical Followup
(Yr)
Aβ42 Conversion

Year 3

Clinical Followup
After Conversion (Yr)
Clinical Status

-PiB Status
Sex
APOE ε Alleles

Negative

Negative

Negative

F

M

F

F

F

F

3/3

3/3

3/3

3/4

3/4

3/3
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Table 4.1 Cont.
65-69 Years at BL LP

Y

BB

DD

Z

AA

CC

EE

Avg. LP Interval (Yr)

2.1

2.5

2.6

3.0

3.0

3.1

3.1

4

5

5

6

6

6

6

8

9

10

9

9

10

--

--

--

Year 6

--

--

--

--

--

--

4

--

--

--

LP Followup
Clinical Followup
(Yr)
Aβ42 Conversion
Clinical Followup
After Conversion (Yr)

CDR 0.5,
CN

CN

CN

CN

Clinical Status
Stable

Stable

--

Sex
APOE ε Alleles

CN

1, Yr 9
Stable

PiB Status

Yr 4; CDR

Negative

Stable

Stable

Positive

Negative

Year 6
Negative

Negative

F

F

M

M

F

M

M

2/3

2/3

2/3

3/4

3/4

3/4

3/3
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Table 4.1 Cont.
70-75 Years at BL LP

FF

GG

HH

II

JJ

Avg. LP Interval (Yr)

3.0

3.1

2.8

2.5

3.0

6

6

6

5

6

10

7

10

9

--

Year 3

--

--

--

--

4

--

--

--

LP Followup (Yr)
Clinical Followup
(Yr)
Aβ42 Conversion
Clinical Followup
After Conversion (Yr)

CDR 0.5,
CN

CN

CN

Clinical Status

1, Yr 9

--

APOE ε Alleles

Stable

Stable

Stable

Positive

Positive

Positive

--

PiB Status
Sex

Yr 6; CDR

F

F

F

F

F

3/3

3/3

3/4

3/3

3/4

The cohort was split in to 6 bins by baseline age: 45-49 years, 50-54 years, 55-59 years, 60-64 years, 65-69 years, and 70-74 years. Within each
age group, individuals were further separated by amyloid status: stable Aβ42- (BL and Followup CSF Aβ42 values all above 1,041 pg/ml), Aβ42
Converter (declining from CSF Aβ42 >1,041 pg/ml at BL to <1,041 pg/ml during Followup), and stable Aβ42+ (BL and Followup CSF Aβ42
values all below 1,041 pg/ml).
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Average LP interval and LP followup indicate the frequency and duration of LP followup from LP baseline.
Clinical Followup in years accounts for years from LP baseline to the most recent clinical examination.
Aβ42 Conversion indicates number of years after baseline LP conversion occurred, while Clinical Followup After Conversion indicates the
number of years after exhibiting Aβ42 positivity converters had clinical followup information available.
Clinical Status accounts for the latest clinical examination in the case of cognitively normal (CN) individuals while, for those who progress from
CN to a CDR 0.5 or 1, the year of conversion is indicated.
The letters A-JJ identify each individual allowing comparison between Table 4.1 and Figures 4.1-4.6.
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Figure 4.1 Core CSF Biomarkers and CSF Aβ40 for Individuals from 45-49 Years Old at Baseline Lumbar Puncture
A

C

B

6

6

6

5

5

5

4

4

4

3

3

3

2

2

2

1

1

1

0

0

0
0

2

4

6

8

1 0

0

2

4

6

8

1 0

0

2

4

6

8

1 0

T im e (Y r )

A b s o lu te %

C h a n g e fr o m

B L

Q u in tile

A b s o lu te %

C h a n g e fr o m

B L

Q u in tile

T im e (Y r )

D
6

5

4

3

2

1

0
0

2

4

6

8

1 0

2

4

6

8

1 0

E
6

5

4

3

2

1

0
0

T im e (Y r )

Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42;
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate
the time of Aβ42 transition from negative to positive during study follow up.
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Figures 4.1 through 4.6 illustrate core and Aβ40 biomarkers on a within-person basis. The
alphabetical labels in Table 4.1 correspond to each individual graph in Figures 4.1-4.6. The core
biomarkers (CSF Aβ42, Tau, and P-tau181) and CSF Aβ40 are graphed on a single graph for each
individual. Each figure encompasses a five-year age bin at baseline LP (Figure 4.1, 45-49 years
old; Figure 4.2, 50-54 years old; Figure 4.3, 55-59 years old; Figure 4.4, 60-64 years old;
Figure 4.5, 65-69 years old; and Figure 4.6, 70-74 years old), and within each figure the left
column are stable Aβ42- individuals, the middle column are Aβ42 converters, and the right
column are stable Aβ42+ individuals. There is a distinctly different biomarker profile for each
Aβ42 classification, with stable Aβ42- individuals having lower Tau(s) at baseline, Quintile 1 or
2 with the exception of individual “O”, and Tau/Aβ42 Ratios in the first quintile at BL exhibiting
little change throughout follow up. Similarly, Aβ42 converters had low Tau(s) in Quintile 1 or 2
at baseline but were more likely to increase over time than stable Aβ42- individuals throughout
follow up. In contrast, many of the stable Aβ42+ individuals exhibited levels of Tau(s) and
Tau/Aβ42 in Quintile 1-3 at baseline, though over time levels of Tau(s) and, to a greater extent,
Tau/Aβ42 increased more than in either the stable Aβ42- or Aβ42 converters. CSF Aβ40 in most
individuals was in the same quintile as Aβ42 and followed similar longitudinal trajectories, but
was less consistent than the core biomarkers.
Individuals in the center, Aβ42 converter columns of Figures 4.1-4.6 were marked with a black
arrow indicating the LP at which their CSF Aβ42 status changed from – to +. None of these
individuals or the Aβ42- individuals exhibited a CDR >0.5 at any time from baseline LP through
the most recent clinical assessment; for the stable Aβ42- group, clinical follow up lasted between
8 and 13 years from baseline LP and for the Aβ42 converter group, clinical follow up lasted
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Figure 4.2 Core CSF Biomarkers and CSF Aβ40 for Individuals from 50-54 Years Old at Baseline Lumbar Puncture
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Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42;
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate
time of Aβ42 transition from negative to positive.
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between 7 and 13 years from baseline LP. In contrast, 4 of 13 individuals in the Aβ42+ group
(31%) were assigned a CDR of 0.5 or 1 at some point during clinical follow up from baseline LP,
which lasted between 8 and 12 years. Individual R (Figure 4.3) received a CDR 0.5 10 years
after baseline LP; CSF Aβ42 was considered positive even at baseline and remained stable, while
Tau and P-tau181 were in the second quintile but increasing over time. The Tau/Aβ42 Ratio began
in the third quintile and increased substantially throughout follow up. Individual CC (Figure 4.5)
received a CDR 0.5 at 4 years after baseline LP, which further progressed to a CDR 1 9 years
after baseline LP. The CSF Aβ42 level was in the second quintile, and decreasing slightly while
the Tau(s) and Tau/Aβ42 Ratio were increasing over time. Individual HH (Figure 4.6) received
a CDR 0.5 at 9 years after baseline LP, though this returned to a CDR 0 at 10 years. The Tau(s)
and Tau/Aβ42 Ratio patterns show an increase followed by a decrease between years 4 and 6
after baseline LP while Aβ40 in individual HH is the only instance exhibiting a longitudinal
increase in Aβ40 in the ACS Case Study cohort. Individual II (Figure 4.6) received a CDR 0.5 at
7 years after baseline LP and a CDR 1 at 9 years after baseline. While the Tau(s) were only in
the first Quintile at baseline and increasing slightly over time, the Tau/Aβ42 Ratio was in
Quintile 2 at baseline and exhibited large increases longitudinally.
Graphing individuals by baseline age bin, while informative, does not give a visual sense of how
longitudinal biomarker changes may perform across a large age range within Aβ42-, Aβ42
converter, and Aβ42+ groups. To better visualize this, Figure 4.7 was created to show biomarker
changes across the entire middle-age range of the ACS cohort (45-74 years of age). While
difficult to pinpoint biomarker behavior on a single-individual basis, this did better represent
biomarker changes across nearly a 30-year span during middle-age.
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Figure 4.3 Core CSF Biomarkers and CSF Aβ40 for Individuals from 55-59 Years Old at Baseline Lumbar Puncture
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Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42;
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate
time of Aβ42 transition from negative to positive, red arrows indicate a Clinical Dementia Rating Score of 0.5.
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Figure 4.4 Core CSF Biomarkers and CSF Aβ40 for Individuals from 60-64 Years Old at Baseline Lumbar Puncture
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Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42;
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate
time of Aβ42 transition from negative to positive.
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Figure 4.5 Core CSF Biomarkers and CSF Aβ40 for Individuals from 65-69 Years Old at Baseline Lumbar Puncture
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Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42;
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate
time of Aβ42 transition from negative to positive, red arrows indicate a Clinical Dementia Rating (CDR) Score of 0.5, dark red indicate a CDR>1.
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Figure 4.6 Core CSF Biomarkers and CSF Aβ40 for Individuals from 70-74 Years Old at Baseline Lumbar Puncture
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Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42;
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate
time of Aβ42 transition from negative to positive, red arrows indicate a Clinical Dementia Rating (CDR) Score of 0.5, dark red indicate a CDR>1.
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Figure 4.7 Longitudinal Biomarker Change by Aβ42 classification, Core and Non-Core
Biomarkers in the ACS Case Study Cohort

Longitudinal biomarker changes starting at baseline age. Left column, core biomarkers and Aβ40 (Red,
Aβ42; Orange, Aβ40; Blue, Tau; Light blue, P-Tau181; Purple dash, Tau/Aβ42 Ratio), right column, noncore biomarkers (Green, VILIP-1; Teal, YKL-40; Gold dash, Aβ42/Aβ40 Ratio).
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4.1.3 Discussion
When visualizing the ACS case study cohort using the graphing paradigm shown, it becomes
clear that there are indeed differences on a within-person level that indicate the very earliest
stages of AD pathology. Figures 4.1-4.6 show that levels of Aβ42, as expected, are
comparatively higher (Quintile 2-5 at BL) in the Stable Aβ42- individuals than the Stable Aβ42+
individuals (Quintile 1-3 at BL), with Converters at intermediate levels (Quintile 2-3 at BL).
Across the full age range of 45-74 years, Tau and Ptau181 in Stable Aβ42- individuals remained
low and unchanging (Quintile 1), except the oldest member of the cohort who had Tau(s) levels
in Quintile 2 at BL which remained unchanged at followup for 9 years. In the Converter group,
levels of Tau and Ptau181, as well as the Tau/Aβ42 ratio, were in Quintile 1-2 at baseline and all
but the two youngest showed increases over time. All individuals whose Tau/Aβ42 Ratio reached
the third quintile, with the exception of individual Q, exhibited signs of cognitive decline.
Analysis on an individual level in the ACS cohort indicates that, at least for the core CSF
biomarkers, there is a clear difference over time in individuals who exhibit eventual clinical
decline compared to those who do not. The greatest strength and the greatest weakness of the
ACS cohort, as a whole, is the preclinical nature of the cohort – middle-aged, cognitively normal
individuals recruited to the study because of their family history of AD. On one hand, this
relatively young cohort is unique because individuals with an AD CSF profile are in the
preclinical stage until cognitive status begins to change which provides a perspective on very
early CSF biomarker changes in AD; on the other hand, because this is such a young cohort very
few individuals have exhibited cognitive decline even after 6 or more years of clinical follow up.
Assessing longitudinal biomarker change in these individuals is interesting, but ultimately does
not provide additional information on the relationship between CSF biomarkers and disease
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status until an individual begins to show signs of dementia. However, this case study is an
interesting and, ultimately, a net gain in the identification of AD on a within-person basis. The
biggest barrier to clinical translation is that the quintile data would not be informative without
longitudinal data – these case study analyses do not provide a single-timepoint identification
with the available data.
Despite this, it remains clear that AD can be pinpointed even in individuals who remain
cognitively normal for a number of years post-amyloid-biomarker positivity. Future work should
focus on the biomarker trajectories of individuals who begin studies in the preclinical phase of
disease and eventually progress to show cognitive decline. The combination of clinical follow up
and CSF biomarkers alone will likely not be sufficient to account for environmental factors such
as cognitive reserve, but investigation on a within-person basis on a large scale may elucidate
trends in biomarker behavior that correspond to these environmental factors, thus rendering them
easier to account for in studies of preclinical AD.

4.2 Case Studies from the ADNI Cohort
The ADNI cohort provided a unique perspective on within-person changes in CSF biomarkers
due to the heterogeneous nature of the cohort. Individuals in the ADNI study may be cognitively
normal, exhibit MCI, or have a diagnosis of AD at study entry. The longitudinal ADNI cohort in
Chapter 3 also covered an extensive older age range, from 58 to 90 years old at baseline,
compared with the ACS cohort.

4.2.1 Methods
The majority of the ADNI cohort had data from 3 or more LP’s, therefore the case study cohort
was defined by the number of Aβ42 converters. As with the original analyses in Chapter 3, Aβ42
status was defined by xMAP values. In the ADNI cohort, the cutoff value for Aβ42 has been
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reported widely as 192 pg/ml, therefore individuals who transitioned from CSF Aβ42 >192
pg/ml to <192 pg/ml were classified as Aβ42 converters; 9 total individuals met these criteria.
The availability of both xMAP and Elecsys data aided in selecting 9 stable Aβ42- and 9 stable
Aβ42+ individuals. The Elecsys assay provided a much larger working range (1,472 pg/ml)
compared with the xMAP assay (300 pg/ml) of Aβ42 values in the ADNI cohort. The 9
individuals with the highest Elecsys Aβ42 and lowest Elecsys Aβ42 values were chosen to
represent stable Aβ42- and +, respectively, and compared with xMAP values to ensure that Aβ42
status was consistent between the two assays.
The graphing paradigm used for the ADNI cohort was identical to that used for the ACS cohort.
Age matching was not possible because 9 of 27 individuals were either 77 or 78 years old at
baseline, therefore the ADNI case studies are grouped by Aβ42 status in 3 groups. Additionally,
the ADNI cohort did not have Aβ40 data available, so Figures 4.7-4.9 represent only the core
CSF biomarkers Aβ42, Tau, P-tau181 and the Tau/Aβ42 ratio. Figure 4.10 represents the core
CSF biomarkers and the non-core biomarkers VILIP-1, SNAP-25, Ng, and YKL-40.

4.2.2 Results
The case study cohort visualized in 3 groups representing Aβ42 status as the age distribution was
not even enough to bin by baseline age. Table 4.2 contains demographic information on each
participant. Of the 27 individuals comprising the case study cohort: 13 were female (48%), 5 had
one APOE ε4 allele (19%%), 2 had two ε4 alleles (7%). After baseline LP, each of the 27
individuals had between 2 and 9 years of follow up LP data with LP’s performed approximately
every year, and between 2 and 9 years of clinical follow up. Of 27 individuals, 9 were diagnosed
as having MCI at baseline (33%), and 2 were diagnosed with AD at baseline (7%).
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Across the Aβ42 status groups, the Aβ42 converter group had 8 of 9 individuals diagnosed as
cognitively normal at baseline, but 5 of those 8 exhibited cognitive decline which justified a
diagnosis of MCI at some point during clinical followup (6-9 years). The individual diagnosed as
having MCI at baseline showed no change over 8 years. The stable Aβ42- group had 3 MCI
individuals. Of those, one showed no cognitive change over 8 years, one was diagnosed at a
CDR 1 but reverted to CDR 0.5, and one reverted from CDR 0.5 to CDR 0. One CN individual
was diagnosed at CDR 0.5 at followup but then reverted to CDR 0. The stable Aβ42+ group had
five individuals diagnosed with MCI at baseline and 2 diagnosed with AD, of which 6 converted
to CDR 1 or 2 during followup (2-6 years), and one MCI individual showed no change over 3
years. Two individuals were cognitively normal at baseline, one progressed to CDR 0.5 and
CDR 2 during 8 years of followup and one converted to CDR 0.5 at year 3 but reverted to CDR 0
at year 4. Statistical analyses were not performed on this cohort for similar reasons as the ACS
case study cohort, except that the ADNI study does not recruit based on family history of AD
and has a much more varied cohort in terms of demographic variables such as education.

107

Table 4.2 Demographic Information on the 27 ADNI Case Study Cohort Individuals.
n

9

Stable Aβ42-

A

B

C

D

E

F

G

H

I

2.4 (1.2)

1.6 (1.0)

1.0 (0.1)

1.5 (0.5)

1.5 (0.6)

1.7 (0.6)

1.6 (0.6)

1.4 (0.6)

1.6 (0.6)

LP Followup (Yr)

7

5

3

5

6

5

8

7

8

Clinical Followup (Yr)

7

8

7

6

7

8

8

7

8

CN

CN

CN

CN

CN

MCI

MCI

CN

MCI

CDR 1

CDR 0.5

Avg. LP Interval, Yr
(SD)

Diagnosis at BL

No

No

CDR 0.5

No

No

No

Yr 2,

Yr 3,

Revert

Change

Change

Yr 6

Change

Change

Change

Revert

Revert

Yr 3

Yr 4

Yr 7

Clinical Followup
Age at BL (Yr)

70

79

76

62

90

74

83

72

86

Sex

M

M

F

F

F

F

F

F

M

APOE ε4 Alleles (#)

1

0

0

0

0

0

0

0

0
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Table 4.2 Cont.
n

9

Aβ42 Converters

J

K

L

M

N

O

P

Q

R

1.6 (0.8)

1.5 (0.5)

3.0 (3.1)

1.3 (0.5)

1.2 (0.5)

1.5 (0.7)

1.5 (0.7)

1.3 (0.5)

1.4 (0.8)

LP Followup (Yr)

8

9

6

5

5

3

6

8

7

Clinical Followup (Yr)

8

9

6

6

8

9

7

8

8

Aβ42 Conversion

Yr 5

Yr 1

Yr 6

Yr 3

Yr 4

Yr 3

Yr 6

Yr 3

Yr 3

Diagnosis at BL

CN

CN

CN

CN

MCI

CN

CN

CN

CN

No

CDR 0.5

No

CDR 0.5

No

CDR 0.5

CDR 0.5

No

CDR 0.5

Change

Yr 6

Change

Yr 3

Change

Yr 9

Yr 7

Change

Yr 8

Age at BL (Yr)

78

77

72

78

79

82

77

78

77

Sex

F

F

F

M

M

F

M

F

F

APOE ε4 Alleles (#)

0

0

0

0

0

0

0

0

o

Avg. LP Interval, Yr
(SD)

Clinical Followup

109

Table 4.2 Cont.
n

9

Stable Aβ42+

S

T

U

V

W

X

Y

Z

AA

1.2 (0.6)

1.3 (0.5)

1.0 (0.0)

1.3 (0.6)

1.0 (0.0)

1.0 (0.1)

1.3 (0.6)

1.0 (0.1)

1.0 (0.1)

LP Followup (Yr)

5

4

2

4

2

3

4

3

3

Clinical Followup (Yr)

6

4

2

4

2

3

8

5

6

MCI

MCI

AD

CN

AD

MCI

CN

MCI

MCI

CDR 1

CDR 0.5

CDR 0.5

CDR 1

Avg. LP Interval, Yr
(SD)

Diagnosis at BL

CDR 1

Clinical Followup

Yr 3,

CDR 2

Yr 1,

Yr 3,

CDR 1

No

Yr 7,

Yr 1,

CDR 2

CDR 2

Yr 4

CDR 2

Revert

Yr 1

Change

CDR 2

CDR 2

Yr 6

Yr 2

Yr 4

Yr 8

Yr 4

Yr 4

Age at BL (Yr)

70

71

69

76

68

73

77

77

78

Sex

M

M

M

M

F

M

M

M

M

APOE ε4 Alleles (#)

2

2

0

0

1

1

1

1

1

The cohort was split in to 3 bins by baseline amyloid status: stable Aβ42- (BL and Followup CSF Aβ42 values all above 192 pg/ml [xMAP] or
1,200 pg/ml [Elecsys]), Aβ42 Converter (declining from CSF Aβ42 >192 pg/ml at BL to <192 pg/ml during Followup), and stable Aβ42+ (BL and
Followup CSF Aβ42 values all below 192 pg/ml [xMAP] or 1,200 pg/ml [Elecsys]).
Average LP interval and LP followup indicate the frequency and duration of LP followup from LP baseline.

110

Clinical Followup in years accounts for years from LP baseline to the most recent clinical examination.
Aβ42 Conversion indicates number of years after baseline LP conversion occurred, while Diagnosis at BL and Clinical Followup indicate the
cognitive status (CN, MCI, or AD) and change in cognitive status for each individual during followup.
The letters A-AA identify each individual allowing comparison between Table 4.2 and Figures 4.7-4.9.
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Figure 4.8 Core CSF Biomarkers for Stable Aβ42- ADNI Participants
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Each graph represents a single individual from the ADNI Case Study cohort, with each color representing a different biomarker (Red, Aβ42; Dark
Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with T0 indicating
baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change from the
baseline biomarker level. A tan background indicates individuals diagnosed with MCI at baseline. Pink arrows indicate a Clinical Dementia Rating
(CDR) Score of 0.5, red arrows indicate a CDR 1, dashed arrows indicate a CDR that reverted to a lower score at a later clinical followup.
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Figures 4.7 through 4.9 illustrate ADNI core CSF biomarkers on a within-person basis. The
alphabetical labels in Table 4.2 correspond to each individual graph in Figures 4.7-4.9. The core
biomarkers (CSF Aβ42, Tau, and P-tau181) and the Tau/Aβ42 ratio are graphed on a single graph
for each individual. Each figure represents 9 individuals with differing Aβ42 statuses: Figure
4.7, stable Aβ42-; Figure 4.8, Aβ42 Converters; Figure 4.9, stable Aβ42+. Biomarkers are more
homogenous between Aβ42 classification groups than was seen in the ACS cohort. Stable Aβ42individuals had lower Tau(s) at baseline, Quintile 1 or 2, and Tau/Aβ42 Ratios in the first
quintile at BL, all exhibiting little change throughout follow up. Similarly, Aβ42 converters had
low Tau(s) in Quintile 1 or 2 at baseline but were more likely to increase over time than stable
Aβ42- individuals throughout follow up. Many of the stable Aβ42+ individuals exhibited levels
of Tau(s) and Tau/Aβ42 in Quintile 1-2 at baseline and, unlike the ACS cohort, the levels of Tau,
P-tau181 and the Tau/Aβ42 ratio changed less over time.
The differential diagnoses of CN, MCI, and AD at baseline were coded by filling the
corresponding graph background with tan (MCI) or pink (AD) to visually indicate individuals
with evidence of cognitive decline at baseline. The stable Aβ42+ group had the largest number
of impaired individuals at baseline. The stable Aβ42- group was next, but the majority of
individuals that showed impairment or progression also reverted back to their baseline cognitive
status over the course of the study. Interestingly, the Aβ42 converter group had the smallest
number of both individuals with an MCI or AD diagnosis at BL, but did show a high rate of
conversion from CN to a CDR 0.5.
The Aβ42 converter group showed the most change in core biomarkers over time. Whereas the
stable Aβ42- group remained stable throughout followup for all core biomarkers, the converter
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Figure 4.9 Core CSF Biomarkers for Aβ42 Converter ADNI Participants
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Each graph represents a single individual from the ADNI Case Study cohort, with each color representing a different biomarker (Red, Aβ42; Dark
Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with T0 indicating
baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change from the
baseline biomarker level. A tan background indicates individuals diagnosed with MCI at baseline. Pink arrows indicate a Clinical Dementia Rating
(CDR) Score of 0.5 clinical followup.

116

Figure 4.10 Core CSF Biomarkers for stable Aβ42+ ADNI Participants
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Each graph represents a single individual from the ADNI Case Study cohort, with each color representing a different biomarker (Red, Aβ42; Dark
Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with T0 indicating
baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change from the
baseline biomarker level. A tan background indicates individuals diagnosed with MCI at baseline, a pink background indicates individuals
diagnosed with AD at baseline. Pink arrows indicate a Clinical Dementia Rating (CDR) Score of 0.5 clinical followup, red arrows indicate a CDR
1 diagnosis, and dark red arrows indicate a CDR 2 diagnosis. Dashed pink arrows indicate a reversion from CDR 0.5 to CDR 0.
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group showed concomitant longitudinal changes in Aβ42, Tau, P-tau181 and the Tau/Aβ42 ratio.
The stable Aβ42+ group did not show elevated levels of Tau, P-tau181 or the Tau/Aβ42 ratio – in
fact, in many individuals such as T, U, or W exhibited longitudinal decreases in these
biomarkers.
As with the ACS case study cohort, it is difficult to visualize biomarker changes in relation to
age. Figure 4.10 shows biomarker levels by baseline quintile and followup percent change
across the entire age range of the ADNI case study cohort. The age range for the stable Aβ42group covered the full age range from approximately 60-90 years of age at baseline for included
individuals. The Aβ42 converter group was more compact, approximately 70-90 years and the
stable Aβ42+ group was approximately 65-85 years at baseline. The stable Aβ42- exhibits
relatively stable levels of all core biomarkers; the Aβ42 converter group exhibits decreasing CSF
Aβ42 levels and increasing Tau, P-Tau181, and Tau/Aβ42 levels. The stable Aβ42+ group
exhibits low Aβ42 levels and a mix of behavior for the Tau(s) biomarkers, including increasing
over time, remaining relatively stable, and decreasing.

4.2.3 Discussion
The ADNI case study cohort is particularly interesting because many individuals included
exhibited some form of cognitive impairment either at baseline or during clinical followup. This
clinical data makes it a more conducive dataset for following changes through all stages of
disease whereas the ACS cohort has greatest strength in the preclinical stage. A particular
within-person characteristic that fits well with the longitudinal data presented in Chapter 3 –
where significant decreases in markers of neuronal injury/death were seen in the AD group – are
the relatively low and, in some cases, decreasing concentrations of the Tau(s) and Tau/Aβ42
ratio in the stable Aβ42+ group. Unfortunately, as the preclinical stage of AD lasts between
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Figure 4.11 Longitudinal Biomarker Change by Aβ42 classification, Core and Non-Core
Biomarkers in the ADNI Case Study Cohort
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10-20 years, there is an important cross-section of disease that is under-represented in the ADNI
case study cohort: Aβ42 converters that go on to show signs of cognitive decline. A particular
confounding factor is the use of both xMAP and Elecsys Aβ42 data – Chapter 5 briefly explores
the analyte differences between the two platforms, particularly with respect to when an
individual would be considered a “converter”, and the two assays do not agree in most of the 9
Aβ42 converter cases in the ADNI dataset. This detail complicates the identification of the Aβ42
conversion time point and, therefore, the downstream biomarkers of Tau(s) and the Tau/Aβ42
ratio. The ADNI longitudinal cohort dataset was defined and analyzed before the Elecsys data
became available, thus necessitating the retention of xMAP Aβ42 data because the study had
been defined with it, regardless of the fact that the data was not truly longitudinally assayed. On
the other hand, the Elecsys is a new platform for measuring AD biomarkers and does not have
the same wealth of legacy data. Both concerns have been recognized in research facilities around
the world, so the most thorough option seemed to be using both xMAP and Elecsys Aβ42 data
when looking at case studies.
Despite analytical differences, individuals J, K, O, Q, and R all exhibit strikingly similar core
biomarker profiles to the ACS case study Aβ42 converter group. Individuals L and P appear to
be in even earlier stages of preclinical disease, but further longitudinal followup is necessary to
confirm these observations. Individuals M and N are notable due to unstable Aβ42 values –
decreasing, then increasing – despite “N” having a baseline diagnosis of MCI. More individuals
like these, with longer longitudinal followup, are necessary to get a clearer picture of disease
progress in unstable Aβ42 cases.
Perhaps the most striking visualization in the ADNI case study cohort comes from the stable
Aβ42- group who, across a period of nearly 40 collective years, exhibit remarkably stable and
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consistent core biomarker profiles that indicate the absence of AD. The Aβ42 converter and
stable Aβ42+ groups covered a much smaller age range (70-90 years old and 65-85 years old,
respectively) and show much more change over time than the stable Aβ42- group. In general, the
core biomarkers of neuronal death/injury are increasing in the converter group while the stable
Aβ42+ group exhibits higher levels of these markers at baseline, but variable longitudinal
behavior. The non-core biomarkers of neuronal injury and inflammation were inconclusive
across all three groups, similar to the ACS cohort. There is potential that these non-core
biomarkers of neuronal injury or inflammation may be more useful after better understanding the
mechanistic or risk-factor-based causes that result in the longitudinal change seen in AD.
As with the ACS case study cohort, the ADNI case study cohort is too small to perform rigorous
statistical analyses.

4.3 Conclusions
Visualizing multiple markers on a single graph, while not statistically rigorous, again points to
the consistency of core biomarker changes that have been seen in both longitudinal and crosssectional CSF biomarker studies – low Aβ42, high Tau(s) and high Tau/Aβ42 ratio are indicators
of future cognitive decline. However, longitudinal studies such as the DIAN27 and the ADNI
longitudinal cohort tell a slightly different story in that markers of neuronal injury/death may
begin to decline after a certain point in disease. The ACS and ADNI case study cohorts are of
great interest because they provide a window in to the behavior of AD biomarkers as they relate
to one another on an individual basis. Noting the distinct similarities between the Aβ42 converter
groups, if nothing else, shows that despite obstacles with analytical aspects of these assays
(Aβ42 assays in particular), biomarkers behave similarly enough to eventually combine data
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from diverse and varied cohorts with CSF data to better understand and track disease progress on
a within-person level as well as a group level.
A number of considerations also spring from the apparent lack of association - or weak
association in the case of the ACS case study cohort - between non-core biomarkers of neuronal
injury/death and inflammation. Though it is important to note that group-level changes in these
biomarkers were seen in both the ACS and ADNI cohorts, associated with either disease risk and
amyloid status or diagnosis and amyloid status. As CSF biomarkers were the only biomarker
modality considered in this chapter, the addition of imaging biomarkers (e.g. longitudinal
hippocampal volume) may pinpoint other aspects of disease that are more closely related to, for
instance, the synaptic markers SNAP-25 or Ng. The current longitudinal datasets available are
not large enough to allow such intricate analyses across all stages of disease. As stated earlier,
preclinical longitudinal datasets have the drawback of tracking little cognitive change and
datasets such as ADNI typically have very small AD groups due to the difficulty of retaining
impaired individuals as part of a volunteer study. However, future work in assay development,
continued longitudinal followup in these and similar studies, and more data from group-wise
analyses should result in the sensitive and specific tracking of AD across all disease states.
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Chapter 5: Assay Platform and Cohort
Comparison
Portions of this chapter were published in the July 2015 issue of JAMA Neurology31.
Some important pitfalls in AD biomarker investigation became apparent during the timeframe of
the work covered in the current document. Analytical variability, particularly with the Aβ42
peptide, has become a focus of investigation as the field attempts to solve 3 major problems
hindering the translation of CSF biomarkers from research use to widespread clinical use: (1)
high inter- and intra-lab variability, (2), analytical challenges within and between assay platforms
and (3) lack of a certified reference material. While not the main focus of the current work, a
number of assay comparisons were performed to assess agreement between different assay
platforms on samples treated in an identical manner from collection, through processing, storage,
and finally, analysis.

5.1 Reasoning for Assay Comparison
Studies like those covered in Chapter 2 and Chapter 3 are of paramount importance because
groups such as the Alzheimer’s Association Quality Control (AAQC) Program, along with
independent research labs, have discovered consistent undesirable characteristics when assessing
CSF biomarkers – particularly Aβ42 – that may hinder diagnosis or prognosis in a transition to
consistent clinical application.
In 2013, the AAQC program reported consistency between participating laboratories in AD
diagnosis, using cutoffs established prior to the formation of the program, but noted this was in
spite of high measurement variability228. Some of the variability is due to inter-lab differences in
assay technique and sample handling, but another setback was in assay variability. An important
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guidance issued in the AAQC program report was that assay kit manufacturers, in particular
those of enzyme-linked immunosorbent assays (ELISASs) and Multi-Analyte Profiling (xMAP)
should consider it “critically important” to improve product quality and minimize lot-to-lot
variability228 which, in an additional study, was considered a hindrance to applying biomarkers
in a clinical setting229. Performing assay comparisons can help identify when an assay is not
performing well, and can also serve as trials for new but promising assays.
A more recent study that stemmed from the longitudinal ACS cohort found that one of the most
commonly used assays worldwide (INNOTEST ELISA) exhibited significant upward drift in
CSF Aβ42 over more than a decade of production230, and such assay drift has multiple
implications for past and future data analysis. For example, individuals in the ACS cohort
covered in Chapter 2 and Chapter 4 return for LP’s once every 3 years, if assays are run shortly
after each LP, the upward drift may obscure biologically important changes in CSF Aβ42 levels,
particularly if protein levels are close to the cutoff for amyloid positivity. A second implication is
a moving cutoff for amyloid positivity over time; Aβ42 cutoffs have risen in conjunction with
both assay drift and an improved INNOTEST ELISA, which improved variability but raised the
absolute average value of Aβ42 substantially230. In this case, performing a single-lot analysis on
samples that had been collected and analyzed over a period of ten years on different lots was
what led to the investigation on assay drift.

5.2 ACS Assay Comparisons
5.2.1 INNOTEST Versus EUROIMMUN ELISA in the ACS Cohort
As part of the design of the ACS longitudinal study (Chapter 2), the analysis of Aβ42, Aβ40, and
Tau were performed simultaneously on the same set of samples. An experienced scientist
performed “Improved” INNOTEST ELISA’s for Aβ42, Aβ40, Tau and P-Tau181 and
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immediately after, the author performed EUROIMMUN ELISA’s for Aβ42, Aβ40, and Tau, as
described in Chapter 2. All analyses were performed on the same set of samples, in parallel, to
reduce variability in sample handling. Assay performance characteristics are reported in Table
5.1. Compared to the previous version of the INNOTEST assays, the improved assays each
contain a set of ready-to-use calibrator series, run validation control samples (calibrator in
buffer), and harmonized buffer reagents. The EUROIMMUN assays are considered second
generation assays because they do not have matrix interference problems (i.e., they exhibit good
dilutional linearity). The amount of CSF required for testing is lower in the EUROIMMUN
assays, thereby reducing the issues with matrix interference179,231. So, in principle, the
EUROIMMUN assay measures another fraction of the free, non-protein bound analyte in a
sample, unlike many other Aβ42 ELISA’s which show poor dilutional linearity. All ELISA kits
passed in-house quality control measures including: 1) standard curve values having a CV <25%
and no more than two standards either oversaturating or undersaturating using a Synergy 2
Multi-Mode Reader (Bio-Tek Instruments, Inc.), 2) no more than one provided kit control and
one internal pooled CSF control failing due to reading outside the provided range or having a CV
>25% with the exception of one assay in which both internal CSF controls failed due to high CV
– in this case, both kit controls passed, and 3) individual samples failed if there was a CV >25%.
The Singulex kits passed in-house quality control measures including: 1) standard curves were
assessed according to software provided by Singulex, 2) no more than 2 of 3 internal pooled CSF
controls falling outside the range determined by all previous runs using the same lot number of
kits and 3) samples failed if there was a CV >25%.
Comparisons of CSF Aβ40, Aβ42, and total tau obtained with the 2 assays were positively
correlated (Aβ40, n=412, Pearson r = 0.772 [95% CI, 0.730-0.808], P < .001; Aβ42, n=394,
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Pearson r = 0.879 [95% CI, 0.855-0.900], P < .001; total tau, n = 410, Pearson r = 0.958 [95%
CI, 0.949-0.965], P < .001). Although the absolute values for Aβ40 and Aβ42 differed between
the assays (roughly 2- to 3-fold higher with EUROIMMUN compared with INNOTEST),
absolute values for total tau were similar. Patterns of within-person biomarker changes over time
were virtually identical between the 2 assays for Aβ42, total tau, and the total tau to Aβ42 ratio.
However, baseline comparisons and longitudinal patterns for Aβ40 were slightly different
between the assays and thus are difficult to interpret. Clinical observations were confirmed in
both immunoassays for Aβ42 and total tau.
More recent work has highlighted the same disparity in absolute concentration for Aβ42, as well
as good correlation between multiple assays, for the INNOTEST and EUROIMMUN assays232.
Head-to-head comparisons such as these are of paramount importance for studying Aβ42 (and, to
a lesser extent Tau(s)) and allow for a focus on assay performance as many of the pre-analytical
and analytical variables are controlled for, e.g. limited or no changes in kit lots, uniformity in
assay conditions, or uniformity in sample handling across a single study233.
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Table 5.1 Assay Performance Specifications as Provided by the Vendors
EUROIMMUN

Fujirebio (formerly Innogenetics)

Vendor
Analyte

QUIDEL

SINGULEX

Aß1-40

Aß1-42

Total tau

Ptau181

Aß1-40

Aß1-42

Total tau

YKL-40

VILIP-1

ELISA
Colorimetric

ELISA
Colorimetric

ELISA
Colorimetric

ELISA
Colorimetric

ELISA
Colorimetric

ELISA
Colorimetric

ELISA
Colorimetric

ELISA
Colorimetric

Single Molecule
Counting (SMCTM)

CSF
2G3
35-40
3D6
1-5

CSF
21F12
37-42
3D6
1-5

CSF
AT120
218-224
HT7/BT2
159-163/193-198

CSF
HT7
159-163
AT270
176-182

CSF
2G3
Aßx-40
3D6
Aβ1-x

CSF
21F12
Aßx-42
3D6
Aß1-x

CSF
ADx 201
Proline-rich region
ADx 215
N-terminus

CSF
Not Available
Not Available
Not Available
Not Available

CSF
3A8.1
Not Available
Sheep 22
Multiple

Calibrator Concentration Range,
pg/mL (lot specific, for this study)

7.8 - 1000
(n=8)

62.5 - 4000
(n=6)

50 - 2500
(n=6)

15.6 - 1000
(n=6)

54 - 711
(n=6)

83 - 1236
(n=6)

30 - 1050
(n=6)

20 - 300
(n=6)

3.9 - 3000
(n=10)

Limit of Detection (LOD), pg/mL,
(range), number of runs

3.3
(0.7 - 4.2)
4 runs

65
(52-87)
7 runs

34
(25-47)
8 runs

13.4
(11.4 - 14.9)
4 runs

70
(58 - 85)
6 runs

7.5
(6.3 - 9.0)
6 runs

44.2
(41.1 - 46.8)
4 runs

5.4
Not available
Not available

1.4
(0.077-6.9)
16 runs

1:100
75
100
2

No
25
100
2

No
25
100
2

No
75
100
2

1:21
15
115
2

No
15
115
2

No
25
125
2

1:03
20
120
2

No
15
200
2

14-18
2-8°C

1
23-27°C

14-18
23-27°C

14-18
2-8°C

3
23-27°C

3
23-27°C

3
23-27°C

1
23-27°C

2
23-27°C

Reported Intra-Assay Variability ,
% CV, (range), number of runs

2.8
(0.3 - 7.8)
5 runs

4.6
(0.8 - 11.0)
3 runs

3.2
(0.0 - 13.2)
2 runs

1.7
(0.0 - 8.9)
4 runs

2.7
(2.4 - 3.1)
3 runs

3.9
(2.3 - 6.2)
3 runs

5.0
(3.9 - 6.5)
4 runs

6
(5.6 - 6.6)
Not available

4.4
(3.1 - 7.0)
10 runs

Reported Inter-Assay Variability1,
%CV, (range), number of runs

4.4
(3.2 - 5.8)
4 runs

7.8
( 1.4 - 18.0)
3 runs

11.5
(3.8 - 42.8)
2 runs

11.4
(6.6 - 19.2)
4 runs

8.3
(7.3 - 9.3)
5 runs

5.6
(4.4 - 7.6)
7 runs

7.4
(6.1 - 9.3)
5 runs

6.7
(6.0 - 7.0)
Not available

6.2
(5.0 - 7.0)
1 run

2.7
(0.4 - 12.7)
12 runs

4.4
(0.2 - 13.7)
12 runs

2.0
(0.0 - 11.4)
12 runs

1.0
(0.1 - 4.6)
12 runs

2.3
(0.1 - 6.0)
12 runs

3.0
(0.1 - 9.7)
12 runs

5.42
(0.8 - 22.9)
12 runs

1.9
(0.1 -6.4)
12 runs

4.5
(0.0 - 20.8)
16 runs

3.8
(0.0 - 24.6)
12 runs

4.3
(0.0 - 20.6)
12 runs

2.1
(0.0 - 14.8)
12 runs

2.2
(0.0 - 17.5)
12 runs

14
(0.1 - 13.7)
12 runs

4.1
(0.0 - 16.7)
12 runs

4.1
(0.0 - 24.2)
12 runs

3.7
(0.0 - 21.6)
12 runs

4.3
(0.0 - 24.8)
12 runs

Technology
Fluid Sample
Capture Antibody
Capture Antibody Epitope
Detection Antibody
Detection Antibody Epitope

Sample Specifications
Sample Pre-dilution
Volume Sample Per Well (µL)
Total Well Volume
Number of Replicate Wells
Sample Incubation
Time, hrs
Temperature
1

2

Study Intra-Assay Variability ,
% CV, (range), number of runs
2

Study Inter-Assay Variability ,
%CV, (range), number of runs

Samples were analyzed for Aβ1-40, Aβ1-42, Tau, and P-tau181 using the “Improved” INNOTESTTM ELISA (Fujirebio Europe [formerly
Innogenetics], Gent, Belgium). For comparison purposes, concentrations of Aβ1-40, Aβ1-42 and total tau were also measured using
EUROIMMUN ELISAs (EUROIMMUN, Luebeck, Germany). For Aβ species, both assays utilize the same monoclonal antibodies, but they are
obtained from a different process of culture, production, and purification. YKL-40 (also known as chitinase-3 like 1), an astrocyte-derived marker
of gliosis/neuroinflammation, was measured with the MicroVue ELISA (Quidel, San Diego, CA). Visinin-like protein 1 (VILIP-1), a marker of
neuronal injury, was measured using a two-site immunoassay implemented via a microparticle-based Erenna immunoassay system (Singulex,
Alameda, CA). 1 performance characteristics as provided by the vendor. 2 actual performance characteristics in the current study.
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Figure 5.1 Group Longitudinal Change Over Spaghetti Plots of EUROIMMUN CSF Biomarkers During Middle-age.
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Estimated slopes and within-person patterns for A) Aβ40, B) Aβ42, C) the Aβ42/Aβ40 ratio, D) tau, and E) tau/Aβ42 are shown in three age bins
for APOE ε4-negative (top graph of each panel, n=108participants) and ε4-positive (bottom graph of each panel, n=61 participants) groups.
Annual slopes have been extrapolated to 9 years, and each slope begins at the mean baseline biomarker value of each age bin. Blue, EARLY
middle-age (45-54 years at baseline); Black, MID middle-age (55-64 years at baseline); Red, LATE middle-age (65-74 years at baseline). * slopes
significantly different from 0 (p<0.05). +, slopes significantly different between APOE ε4 groups within a given age group (p<0.05). Trend,
p=0.051-0.06.
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While no judgements were made as to the quality of either the INNOTEST or EUROIMMUN
ELISAs, this comparison was informative in that consistent results were found with both assays.
The exception was Aβ40: the slopes in the APOE ε4 non carrier group were declining in the
early- and mid-middle age groups. However, the EUROIMMUN data shows a significant decline
in Aβ40 slope across all 6 groups. The INNOTEST data shows no change and perhaps even a
slight increase in Aβ40 over time in the three APOE ε4 carrier groups, though not significant.
Because assay comparison has largely focused on the problematic Aβ42 peptide, it is difficult to
speculate the reasons behind this difference. However, recent data from Vanderstichele and
colleagues may offer a potential explanation: despite both INNOTEST and EUROIMMUN using
the same capture antibodies (21F12 for Aβ42 and 2G3 for Aβ40), and the same detection
antibody (CD6) across all four assays, INNOTEST displays a dose-dependent difference in Aβ42
levels that corresponds to Aβ40232. They speculate that this is due to Aβ40 interfering in the
Aβ42 assay through CD6 binding, where higher levels of Aβ40 in the CSF result in a lower
Aβ42 value. Because CD6 is a component of both the Aβ40 and Aβ42 assays there is some
potential for interference in the Aβ40 assay, though Aβ40 is roughly ten times as abundant in
CSF as Aβ42. It is additionally difficult to say how this interference is happening as the ELISA
format goes through multiple washing steps before applying the detection antibody. Unless there
is substantial binding of Aβ40 to the 21F12 antibody or oligomerization of Aβ40 on to Aβ42 that
has bound to 21F12, there should be little to no interference as it is reported by Vanderstichele
and colleagues. Interestingly, this interference is not seen with the EUROIMMUN assay. These
questions are further support for the continued comparison of different assays and assay
platforms as those used most frequently are not ready to transition in to clinical use at this time.
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5.2.2 xMAP Versus Elecsys Comparison in the ADNI Cohort
Unlike the ACS cohort, assays for Aβ42, Tau, and P-Tau181 were not performed in-house in the
ADNI cohort. Data for these analyses were downloaded from the ADNI, thus there is no way to
compare specific performance characteristics of each assay. ADNI researchers analyze CSF
samples on a rolling basis, though some longitudinal analyses have been completed. The ADNI
study reported in Chapter 3 relied on two sets of xMAP data generated by re-analyzing
longitudinal samples from an individual at the same time, rather than relying on data that was
generated on the rolling basis. Unfortunately, not all samples were assayed in one longitudinal
run and there is no way to determine which lot number of xMAP assay was used. Further,
without access to the raw data, it is not possible to perform comparisons between the two sets of
xMAP data to ensure continuity between assay lots. Fortunately, assay validation and assay
comparisons are a major focus of numerous large studies, ADNI included, and data from the new
Elecsys platform was released for Aβ42, Tau and P-Tau181 in early 2017. Correlations between
xMAP and Elecsys data for Aβ42 and Tau were as expected – Tau was highly correlated
(Pearson r = 0.948, p<0.001) and Aβ42 showed more variability but still correlated well between
the two assay platforms (Pearson r = 0.884, p<0.001). Originally, P-tau181 was excluded from
analysis due to clear variability between the two xMAP datasets. Typically, both Tau and Ptau181 show very close correlation, as with the INNOTEST and EUROIMMUN comparisons
above, but in this case xMAP and Elecsys P-tau181 did not correlate as well as would be expected
(Pearson r = 0.743, p<0.001).
Despite these close correlations, there were clear differences in diagnostic ability in individuals
who converted from Aβ- at baseline LP to Aβ+ at a later LP. Figure 5.2 illustrates all nine
individuals in the ADNI longitudinal cohort who converted from Aβ42- to Aβ42 positive as
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defined by the cutoff of 192 pg/ml for the xMAP assay. This paradigm was used to classify
individuals as amyloid + or – for the analyses in Chapter 3. A poster presentation in July 2017
outlined potential cutoffs for amyloid positivity as defined by Elecsys values234. Three cutoffs
were presented: 1,065 pg/ml when compared to xMAP Aβ42, 1,017 or 1,172 pg/ml when
modeled by unweighted and weighted densities respectively, and 1,198 pg/ml when compared to
amyloid imaging. The xMAP and Elecsys Aβ42 values showed good concordance, but better
concordance was found when comparing to amyloid imaging. Mixture modeling identifies subpopulations in a given sample and weighting takes in to account the distribution of each subpopulation in the overall population. The rich history of amyloid imaging and CSF biomarker
analysis means that (1) concordance between amyloid imaging and CSF Aβ42 is high in most
studies and (2) a general estimate for amyloid positivity in cognitively normal individuals can be
established, therefore a cutoff of 1,200 pg/ml was chosen to indicate amyloid positivity using the
Elecsys assay for the purposes of the current study.
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Figure 5.2 ADNI Aβ42 Converter xMAP Versus Elecsys Positivity Comparison
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Core CSF biomarkers, Tau/Aβ42 Ratio and MMSE score in the nine individuals in the ADNI longitudinal cohort that converted from Aβ42- to
Aβ42+ at any LP after that baseline LP, as defined by xMAP Aβ42. Each graph represents a single individual, with T0 representing the baseline
LP and representative baseline quintile for each biomarker. Follow up LP’s or MMSE tests are marked by open circles. Each colored line
represents a different biomarker (Red, Elecsys Aβ42; Blue, Elecsys Tau; Light blue, Elecsys P-Tau181; Purple dash, Aβ42/Tau Ratio; Black,
MMSE score). At the top of each graph, pink arrows indicate the time when an individuals’ CDR score changed from 0 to 0.5; black arrows
indicate the time point that an individual would be considered Aβ42+ according to xMAP data; grey dashed arrows indicate the time point an
individual would be considered Aβ42+ according to Elecsys data; grey dashed arrows with a star indicate an Elecsys value very close to the Aβ42
cutoff of 1200 pg/ml.
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Only one individual exhibited agreement between xMAP and Elecsys amyloid positivity –
individual 61. Individual 210 was considered amyloid positive 6 years after baseline with the
xMAP assay; with the Elecsys assay the CSF Aβ42 value was 1,271 pg/ml, very close to the
1200 pg/ml cutoff. Individual 454, though showing decline in Aβ42 over time, did not exhibit
amyloid positivity when using the Elecsys cutoff, even though xMAP Aβ42 values converted to
positivity 3 years after baseline LP and a CDR score of 0.5 was given 9 years after baseline LP.
The remaining 6 individuals would be classified as Aβ42+ one to five years earlier using Elecsys
data than they would using xMAP data. Visually, the earlier positive classifications using
Elecsys data fit better with the hypothesis of a long period of amyloid accumulation before
cognitive symptoms appear and also match data from the ACS longitudinal cohort showing that
amyloid changes are detected earlier than tau and cognitive changes.

5.2.3 Conclusions
Reductions in CSF Aβ42 over the time-course of AD are now a well-established phenomenon,
but recent discoveries regarding the variability in measurement over time for this important
biomarker have added an element in longitudinal analysis that is difficult to control for, much
less anticipate. The increase in assay comparison studies, alongside the emergence of new assay
platforms such as the Elecsys assays for Aβ42, Tau and P-tau181, is a barometer for the next
important phase in AD research: the search for or development of reliable assays that can be used
worldwide for the consistent measurement of Aβ42 from bodily fluids such as CSF.
The ADNI dataset provides an interesting opportunity to compare a widely used assay – xMAP –
and a new assay platform – Elecsys – in the same set of samples. The biggest caveat to the ADNI
observations above is that they cannot, at this time, be statistically validated due to the very small
group of only nine individuals. However, these data do again showcase the necessity for
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biomarker comparison across multiple assays and assay platforms in the effort to find an assay
(or assays) that perform most sensitively and most specifically in identifying AD on a withinindividual basis.
There is a delicate balance between adequate assay testing and the depletion of precious stores of
CSF from cohorts such as the ACS and ADNI, which necessitates careful consideration of
appropriate assay platforms and study design. The development and adoption of stable
measurement techniques for Aβ42 and other AD biomarkers will likely contribute greatly to
defining the within-person changes that will allow biomarker-based diagnosis and prognosis on
an individual basis.
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Chapter 6: Conclusions and Discussion
The development in CSF biomarkers of AD has progressed rapidly over the last decade. From
the development of core biomarkers of disease through the identification and study of important
non-core biomarkers, the field as a whole is learning important lessons about AD progression
and about the difficulties involved in measuring biomarkers in a slow-developing disease where
the organ of interest is not easily accessible. The current work is a step toward developing CSF
biomarker profiles that may eventually provide, over the full course of the disease, diagnostic
and prognostic applicability in conjunction with neuroimaging and psychometric analysis. The
results reported in this document, alongside other work in the field, indicate that the diagnostic
and prognostic paradigm for AD will likely require multi-factorial, longitudinal, assessment in
order to pinpoint disease on a within-person basis. They also provide support for viewing AD as
a continuum as outlined by Aisen et al3.
The aim of the works presented here were primarily to define the behavior or CSF biomarkers in
large, independent cohorts during the preclinical and early symptomatic stages of AD. In
agreement with data from the DIAN cohort, changes in core CSF biomarkers of AD begin to
differentiate individuals at higher risk of developing the disease than those at lower risk, as
defined by APOE ε4 allele carriage in the ACS cohort, as early as 45 years of age. In many
cases, these changes occurred earlier in ε4 carriers than non-carriers, though the rates of change
did not differ between the two groups. In mid middle-age, core markers of neuronal injury and
death, as well as non-core markers of neuronal injury and neuroinflammation in the ε4 carrier
group increased at a faster rate than mid middle-age non-carriers, but this rate of change was not
different between late or mid middle-aged carriers or late middle-aged non-carriers, indicating
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that regardless of the age of disease onset, it progresses at roughly the same rate across
individuals, when defined by biomarker status.
Further investigation in the ACS cohort – though of an n too small to perform statistical analyses
– indicated that PiB positivity developed only after CSF Aβ42 levels were reduced. This perhaps
was most plainly indicated by two individuals with stable low CSF Aβ42 who were PiB
negative. Interestingly, CSF Tau, VILIP-1, and YKL-40 were increasing slightly or at mid-tohigh concentrations compared to other individuals at similar ages, which suggests these
individuals were in the beginning stages of amyloid deposition in the brain. Further follow-up
with these individuals would be particularly interesting to confirm that indeed, this may be
evidence of the very earliest stages of preclinical disease.
These visual associations with PiB imaging, alongside an association with cognitive changes in
late middle-age are an indication that the utilization of multiple modalities may lead to a more
accurate representation of the full continuum of disease. The ACS cohort provides an incredibly
important glimpse of CSF changes during preclinical AD, from very early longitudinal decreases
in CSF Aβ42, followed by longitudinal increases in CSF markers of neuronal injury or death
alongside the development of PiB positivity in mid middle-age, followed lastly by evidence of
cognitive changes in the oldest age group studied. A larger n, paired with continued follow-up of
this group of study participants has the potential to allow analysis of biomarker trajectories
throughout the continuum of early disease.
In contrast, the ADNI cohort provided the ability to study CSF biomarkers across the spectrum
of cognitive impairment that physicians currently use to define AD in research and clinical
settings. Only the core CSF biomarkers Aβ42, Tau, and P-tau showed longitudinal change in the
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preclinical, cognitively normal amyloid negative and/or amyloid positive groups, mirroring
changes seen in the ACS cohort. The non-core markers VILIP-1 and YKL-40 did not exhibit
changes during this period, unlike the changes seen in the ACS cohort. However, the core
biomarkers and non-core markers indicative of neuronal dysfunction (either neuronal injury,
death, or synaptic injury) showed longitudinal decreases during the early symptomatic stages of
disease with the exception of CSF Tau. Again based on data from the DIAN cohort, longitudinal
decreases in CSF biomarkers of neuronal dysfunction were not unexpected64. However, the work
published here supports these findings in a large, independent cohort of individuals with sporadic
AD, providing further evidence that the pathologic disease processes of AD are indeed the same
in both ADAD and sporadic AD, regardless of differing etiology.
These data have important implications for clinical trials looking to enroll individuals during
preclinical AD. For instance, a trial aiming to capture individuals across the spectrum of changes
that occur during preclinical AD may enroll participants with only low CSF Aβ42, with low CSF
Aβ42 and who are amyloid imaging positive, or who are CSF or amyloid imaging with evidence
of high or increasing markers of neuronal dysfunction. Such separation may provide
opportunities to test anti-amyloid therapeutics at varying states of disease prior to cognitive
impairment to best pinpoint when during preclinical disease these agents are most efficacious. It
may also provide a platform for testing alternative therapeutic agents such as anti-tau or secretase
inhibiting drugs to determine if/when they are efficacious at preventing amyloid or tau
accumulation or neuronal death. Further reasoning for determining in-depth biomarker
trajectories over the full course of AD is apparent in the ADNI data. In many cases, reduction in
a biomarker that is elevated during disease would be seen as an indicator of therapeutic efficacy
in a clinical trial. However, if the core and non-core biomarkers are indeed decreasing
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longitudinally during the early symptomatic stages of AD (individuals with a CDR score of 0.5
to 1), a reduction in, for instance, Tau or VILIP-1 might be indicative of the natural course of
disease rather than therapeutic target engagement or treatment efficacy. This is particularly
important in clinical trials enrolling individuals with mild cognitive impairments, where a
reduction in markers of neuronal injury might well be considered an indicator of treatment
downstream treatment efficacy, even with anti-amyloid therapeutics.
As mentioned in Chapter 1, the hypothetical models of biomarker change that have thus far been
proposed were invariably represented as sigmoidal curves. Much work remains to allow crossstudy comparisons of biomarkers in a way that would render modeling changes in the ACS and
ADNI groups together a possibility. However, the pictures of core AD CSF biomarkers
developed in the ACS, ADNI, DIAN and other studies are largely in agreement in terms of
direction of change (increasing or decreasing) over the course of the disease. If the non-core CSF
biomarkers are considered similarly, the ACS and ADNI data may also indicate how these
biomarkers change, as a whole, over the course of disease. Figure 6.1 outlines what the
biomarker trajectories of CSF Aβ42, Tau, Ptau, VILIP-1, SNAP-25, Ng, and YKL-40 might look
like as further data from longitudinal studies is added to our knowledge base. Current constraints
do not allow for the ACS and ADNI data to be formally compared to one another, but for the
purposes of visualizing biomarker change based on disease state, the ACS and ADNI data are
considered on the same curve for each individual biomarker. The ACS data likely shows a more
complete picture of preclinical AD as the CN Aβ- and Aβ+ groups were small. However, without
enough longitudinal follow-up to show individuals progressing from cognitively normal and
biomarker positive through clinically recognizable cognitive impairments, it is currently only
possible to speculate which individuals might be in the very earliest stages of disease
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(hypothesized to exhibit only CSF amyloid changes). Therefore the hypothetical curves do not
extend through the full range of “preclinical AD” as labeled in Figure 6.1. Further, as SNAP-25
and Ng were only assessed in the ADNI cohort, the hypothetical curve (shown in lavender)
begins later in the “preclinical AD” range than the other CSF biomarkers. The inflection points
where markers of neuronal dysfunction hit a peak and then fall between the “MCI” and “AD”
labels are hypothesized to occur in the ADNI group designated as MCI Aβ+, individuals who
most likely are exhibiting impairment due to AD. Data from Chapter 3 indicates that these
markers do not significantly change during MCI, potentially due to either a plateau once
biomarker concentrations are at their maximum, followed by the decline seen in the AD group,
or due to the slope of biomarker change being in effect washed out by individuals on one side of
the inflection increasing longitudinal and individuals on the other side decreasing. Further
research will be needed to develop these curves more fully.
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Figure 6.1 Hypothetical Model of Combined ACS and ADNI CSF Biomarker Trajectories

Hypothetical trajectories of CSF biomarkers based on data from both the ACS and ADNI datasets
combined. The x-axis indicates disease state as it progresses from Preclinical AD, through MCI, through
AD; vertical dashed lines indicate, roughly, the transition from one disease state to the next. The y-axis
indicates direction of longitudinal change, which can be interpreted as upward change corresponding to
significant increases in biomarkers over time, downward change corresponding to significant decreases
over time, and plateaus or inflection points corresponding to no significant change over time in the
respective diagnostic groups. Each line indicates a single CSF biomarker trajectory: Red, Aβ42; Dark
Blue, Tau; Light Blue, Ptau; Purple, VILIP-1; and Orange, YKL-40; Lavender represents both SNAP-25
and Ng as both biomarkers performed similarly in the ADNI cohort.
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Biomarker research in AD is still only just beginning. The data generated by this project will be
used moving forward for a number of projects: 1) analyzing VILIP-1 and YKL-40 across both
the ACS and ADNI datasets to assess whether the two cohorts might be viably combined, thus
increasing the n for at least two non-core biomarkers to 317 individuals; 2) assessing further
promising non-core biomarkers in these populations such as NfL; 3) exploring further statistical
analyses based on the addition of neuroimaging biomarkers or different classification schemes.
The wealth of data offered by these studies allows for a multitude of avenues of investigation. In
particular, the data presented lends itself well to investigation using groups defined by the
proposed A/T/N classification from the NIA-AA. Grouping by APOE allele risk factor or by
amyloid positivity only as defined by CSF Aβ42 may obscure longitudinal changes occurring in
the later preclinical or MCI stages of AD. For instance, grouping individuals by CSF Aβ42 status
only may not accurately capture differences in the rates of longitudinal change in biomarkers of
neuronal dysfunction that could occur in an individual who is amyloid positive only, compared
with an individual who is amyloid positive and tau positive. There is much left to learn from
these studies.
By far, one of the biggest limitations of the current studies is the low n; despite both the ACS and
ADNI being the largest longitudinal studies of AD reported to date, they are still quite small in
terms of statistical power. However, these studies may be used to perform power calculations in
further cohorts, allowing judicial allocation of precious CSF for testing at a time when enough
samples have been collected. Another limitation was brought to the forefront in Chapter 5: assay
variability. Particularly with CSF Aβ42, the reproducibility and comparability of Aβ42 when
measured in labs around the world is not at a level that receives confidence from regulatory
agencies as a validated diagnostic, prognostic, or theragnostic tool – though in Europe the
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measurement of core CSF biomarkers is more widely approved and more common than in the
United States. Additionally, non-core biomarkers may be especially valuable in tracking
downstream indicators of therapeutic efficacy in clinical trials. However, further longitudinal
validation is needed on each of the biomarkers reported here, as well as development of other
promising biomarkers, to bring the level of confidence in such markers on par with the core
biomarkers.
Large longitudinal studies such as the ACS and ADNI require rigorous planning, protocol
adherence, abundant funding, and, most importantly, dedicated populations of volunteers willing
to undergo a gamut of testing modalities on a regular basis. Despite being active for nearly two
decades, the ACS is only now at a point to assess longitudinal CSF data from enough
participants to allow rigorous statistical analysis. The ADNI study is just over a decade old
though, as a study designed with the validation of AD biomarkers in mind, much more data has
been collected and on a shorter time-scale than the ACS. Data gained through both crosssectional and longitudinal data on these and other large, diverse cohorts is essential to the
forward movement in understanding the full course of AD. Hopefully, these data will allow
development of statistically validated trajectories of biomarkers throughout the course of disease,
allowing clinical trials to accurately assess biomarker changes in relation to therapeutic agents
and eventually allowing physicians to reliably diagnose individuals with AD at any stage and
offer a prognosis or, someday, the appropriate treatment at the best possible junction.
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Appendix
A.1 Appendix Data and Figures for Chapter 3
A.1.1 Assay Details
VILIP-1
Mouse anti-human VILIP-1 and sheep anti-human VILIP-1 were used to develop a sandwich
ELISA using an Erenna instrument (Singulex). Assay reagents include biotinylated mouse antihuman VILIP-1, clone 3A8.1 “capture” antibody, bound to streptavidin-coated magnetic micro
particles and Invitrogen Alexa Fluor 647 dye labeling of sheep anti-human VILIP1. Additional
materials purchased from Singulex include 10X Wash Buffer (02-0001-01), Elution Buffer (020297-xx) and elution step neutralization Buffer C (02-0298-00).
Prior to the assay all samples were centrifuged (11,000 g x 3 minutes) to remove particulates. All
assay steps were performed at room temperature unless otherwise indicated. A calibration curve
was prepared using dilutions of recombinant human VILIP-1 ranging from 3.9 to 3000pg/mL in
assay buffer (prepared daily for the assay and filtered before use contained per liter) containing
10 mm TRIS, 150 mm NaCl, pH = 8.1, supplemented with 0.1% each of Triton X (Sigma T9284), and Sodium Azide, also with 1 gram BSA (Sigma A-7030), as well as 2 gram EquitechBio mouse IgG (SLM66) (2 mg/mL) and 2 mM CaCl2 (Sigma 21115), with each concentration
assayed in triplicate. 15 μL standards or CSF sample were combined with 135ul assay buffer and
50μL antibody coated micro particles. The assay plate was incubated for two hours on a plate
shaker set to 525 revolutions per minute. Micro particles were then magnetically separated and
washed one time using an Agilent (Santa Clara, CA) Bravo Automated Liquid Handling
Platform using Singulex Wash Buffer. Fluorescent dye labeled detection antibody (20μL per
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well) was added and incubated for one hour. After washing the magnetic micro-particles five
times, 20μL per well of Singulex Elution Buffer was added for 10 minutes to separate detection
antibody from the micro-particles. Eluted antibodies were then transferred with the Bravo
instrument to a clean 384 well plate for reading in the Erenna® immunoassay system.
SNAP-25
Mouse anti-human SNAP-25 antibodies were used for development of a sandwich ELISA using
an Erenna instrument (Singulex). Assay reagents included a preparation of the monoclonal
capture antibody 6H07-2C12 for binding to Invitrogen (Carlsbad, CA) MyOne magnetic microparticles and Invitrogen Alexa fluor dye labeling of monoclonal antibody 9E11, using Singulex
labeling kits (capture antibody labeling kit 03-0077-xx and detection antibody labeling kit 030076-02). Additional materials purchased from Singulex include 10X Wash Buffer (02-000101), Elution Buffer (02-0297-xx) and elution step neutralization Buffer C (02-0298-00).
Prior to the assay all samples were centrifuged (11,000 g x 3 minutes) to remove particulates. All
assay steps were performed at room temperature unless otherwise indicated. A calibration curve
was prepared using dilutions of recombinant human SNAP25 (CSI15602) from Cell Science, Inc
(Seattle, WA) ranging from 0.078 to 90pg/mL in Thermo Scientific, Inc (Rockford IL) Blocker
Casein in TBS plus 0.1% Tween-20 from Sigma-Aldrich, Inc (St Louis MO) and with each
concentration assayed in triplicate. 100μL standards or CSF diluted 4-fold were combined with
100μL antibody coated micro particles diluted in Blocker Casein in TBS plus 1% Tween-20. The
assay plate was incubated for two hours on a plate shaker set to 525 revolutions per minute.
Micro-particles were then magnetically separated and washed one time using an Agilent (Santa
Clara, CA) Bravo Automated Liquid Handling Platform using Singulex wash buffer. Fluorescent
dye labeled detection antibody diluted in Blocker Casein in TBS plus 1% Tween-20 (20μL per
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well) was added and incubated for one hour. After washing the magnetic micro-particles five
times, 20μL per well of Singulex Elution Buffer was added for 10 minutes to separate detection
antibody from the micro particles. Eluted antibodies were then transferred with the Bravo
instrument to a clean 384 well plate for reading in the Erenna® immunoassay system.
Ng
Two epitope-specific rabbit anti-human NGRN antibodies were used for development of an
ELISA using an Erenna instrument (Singulex). Assay reagents included a preparation of a Cterminal specific antibody (P-4793) for binding to Invitrogen (Carlsbad, CA) MyOne magnetic
micro-particles and Invitrogen Alexa fluor dye labeling of N-terminal specific antibody (P-4794)
using Singulex labeling kits (capture antibody labeling kit 03-0077-xx and detection antibody
labeling kit 03-0076-02). Additional materials purchased from Singulex include 10X Wash
Buffer (02-0001-01), and custom Elution Buffer (02-0002-01).
Prior to the assay all samples were centrifuged (11,000 g x 3 minutes) to remove particulates. All
assay steps were performed at room temperature unless otherwise indicated. A calibration curve
was prepared using dilutions of synthetic full-length NGRN purchased from AAPPTec, (Louisville
KY), ranging from 1.75 to 3000pg/mL in standard diluent (TBS, 2 mg/ml rabbit IgG from
Equitech-Bio [Kerrville, TX] plus 0.1% Tween-20), with each concentration assayed in
triplicate. 50μL standards or CSF diluted 10-fold were combined with 100μL antibody coated
micro-particles diluted in assay buffer (TBS, rabbit IgG plus 1% Tween-20). The assay plate was
incubated for two hours on a plate shaker set to 525 revolutions per minute. Micro-particles were
then magnetically separated and washed one time using an Agilent (Santa Clara, CA) Bravo
Automated Liquid Handling Platform using Singulex Wash Buffer. Fluorescent dye labeled
detection antibody diluted in assay buffer (20μL per well) was added and incubated for one hour.
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After washing the magnetic micro-particles 5 times, 20μL per well of Singulex custom Elution
Buffer (PN 02-0002-03) was added for 30 minutes to separate detection antibody from the
micro-particles. Eluted antibodies were then transferred with the Bravo instrument to a clean 384
well plate for reading in the Erenna® immunoassay system.
YKL-40
YKL-40 was measured using the MicroVue YKL-40 ELISA assay (Quidel, San Diego, CA).
Prior to the assay, all samples were lightly vortexed for 5 seconds. All assay steps were
performed at room temperature unless otherwise noted. The complete standard curve of YKL-40
purified from osteosarcoma MG-63 cells is provided with the assay kit, and each standard and
sample was assayed in duplicate. All CSF samples were diluted 1:2 in Standard A (0 ng/ml) on
an ice cold pre-plate before transferring 20μl to the coated ELISA plate. After adding 100μl
capture solution, the plate was incubated for 60 minutes followed by washing 4 times with 250μl
wash buffer. Enzyme conjugate (100μl) was prepared prior to beginning the assay and added to
the assay plate, followed by a 60 minute incubation. The substrate solution was prepared during
this step to ensure dissolution of the substrate tablet. After another wash (four times with 250μl
wash buffer), 100μl substrate was added to the assay plate followed by a 60 minute incubation.
Finally, 100μl stop solution was added to the assay plate, and samples were read at an optical
density of 405nm and analyzed with a linear regression curve-fit.

A.1.2 Assay Quality Control
All samples (each from the same freeze/thaw cycle) were run in triplicate for VILIP-1, SNAP-25
and Ng and in duplicate for YKL-40, all using a single assay lot number. Importantly, withinperson longitudinal samples were run on the same assay plate to reduce inter- and intra-plate
variability. Quality control (QC) for VILIP-1, SNAP-25 and Ng included analysis of three
internal standard CSF pools run on each assay plate. For YKL-40, two internal standard CSF
169

pools were run on each plate. QC mean and tolerance limits for VILIP-1, SNAP-25 and Ng were
established by computing the average of at least 15 values collected over at least four runs prior
to running ADNI samples. Tolerance limits were defined at ± two standard deviations (2SD) and
± three standard deviations (3SD) from the mean. QC mean and tolerance limits for YKL-40
were determined by the kit manufacturer. For VILIP-1, SNAP-25 and Ng plates with two or
more QC sample values greater than 2SD from the mean were reanalyzed. For YKL-40, plates
with two or more internal pooled controls and/or kit-provided controls falling outside the 2SD
limit were reanalyzed. In addition, any individual sample with a coefficient of variation (% CV)
greater than 25% was reanalyzed. Samples that failed QC were refrozen and stored at -80°C for
at least 48 hours before being reanalyzed. When samples were reanalyzed due to QC failure, all
within-person longitudinal samples were reanalyzed as well, on the same freeze/thaw cycle. Due
to the availability of only a single 500uL aliquot of ADNI CSF, workflows defined that VILIP-1,
SNAP-25 and Ng were to be run on the first freeze/thaw cycle, while YKL-40 (and any required
reruns for VILIP-1) was run on the second freeze/thaw cycle. Internal QC experiments
previously revealed <10% loss of YKL-40 over four freeze/thaw cycles (unpublished
observations). Any samples that required repeat SNAP-25 or Ng measurements were performed
on the third freeze/thaw cycle samples. Due to protein loss from multiple freeze/thaw cycles,
SNAP-25 reruns did not pass QC; therefore, any samples that failed QC from the first
freeze/thaw were removed from the SNAP-25 dataset. In total, 21 of 587 (3.4%) samples failed
initial QC for VILIP-1, 1 of 587 (0.2%) for SNAP-25, 126 of 587 (21.5%) for Ng, and 73 of 587
(12.4%) for YKL-40.

A.1.3 Statistical results adjusting for sex, APOE ε4 status, education and
baseline age
Elecsys® tTau
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When adjusting for sex, females had significantly higher levels of tTau at baseline (p=0.008), but
such adjustment had no effect on longitudinal change. Adjusting for sex resulted in the loss of
significant increase in the CN groups and a gain of significance of a longitudinal decrease in the
AD+ group (p=0.02). Between-group comparisons were identical to the unadjusted model at
baseline and longitudinally. Adjusting for education had no significant effects on baseline or
longitudinal tTau or between-group comparisons, but the between group differences no longer
reached statistical significance, likely due to inadequate statistical power. Adjusting for baseline
age significantly affected the MCI+ group at baseline, lower in older individuals (p=0.04), but
had no effect on longitudinal or between-group comparisons. The MCI+ group remained
significantly higher at baseline than the CN- group (p=0.04). Adjusting for total ventricular
volume significantly affected tTau in the MCI+ group at baseline (p=0.007), but did not
influence longitudinal change or between-group comparisons. Adjusting for APOE ε4 status had
no effect on baseline or longitudinal tTau patterns.
Elecsys® pTau
Adjusting for education and baseline age had no significant effect on baseline or longitudinal
pTau values or between-group comparisons. However, the between-group differences seen in the
unadjusted model no longer achieved statistical significance, nor did the longitudinal changes in
the CN+ and AD+ groups, likely due to inadequate statistical power. Adjusting for sex showed
that females had significantly elevated baseline pTau (p=0.01), but it did not change any
longitudinal or between-group comparison findings compared to the unadjusted model.
Adjusting for APOE ε4 status negated the significantly elevated baseline in the CN+ compared to
the CN- group (p=0.07), but otherwise the results were the same as in the unadjusted model.
Adjusting for total ventricular volume significantly affected pTau in the MCI+ group at baseline
(p<0.001), but did not influence longitudinal change or between-group comparisons.
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VILIP-1
Adjusting for education had no significant effect on baseline or longitudinal VILIP-1 or
between-group differences, but the between-group differences observed in the unadjusted model
no longer achieved statistical significance, likely due to inadequate statistical power. Adjusting
for baseline age had a significant effect in the MCI+ group at baseline (higher levels with older
age, p<0.01) but did not change the group differences between MCI+ and the MCI- and CNgroups. Adjusting for APOE ε4 status or sex had a significant effect on baseline VILIP-1 (ε4+
and female individuals were higher at baseline (both p<0.03)). The significant between-group
comparisons at baseline were lost in the ε4 model. In the sex model, all aspects remained
identical to the unadjusted model except that the MCI+ was now significantly higher than the
CN+ group at baseline (p=0.03). Adjusting for total ventricular volume had a significant effect
on baseline in the MCI+ group (p<0.0001), but not longitudinally. Between-group comparisons
at baseline were lost in the AD+ compared with both CN- and MCI- groups as well as
longitudinal comparisons in the AD+ compared with the CN-, CN+, and MCI- groups.
SNAP-25
Adjusting for APOE ε4 status had a significant effect on baseline SNAP-25 (higher in ε4+
individuals, p<0.0001) In addition, baseline differences between the MCI+ and the CN groups is
lost, as is the significant longitudinal decrease in the AD+ group. Adjusting for baseline age and
education had no significant effect on baseline or longitudinal SNAP-25 or between-group
comparisons, but the between-group differences seen in the unadjusted model no longer reached
significance, likely due to inadequate statistical power. Adjusting for sex had no effect on
baseline or longitudinal SNAP-25 patterns. Adjusting for total ventricular volume significantly
affected baseline SNAP-25 (p=0.02), but not longitudinal patterns. The baseline difference
between the AD+ and CN+ groups was lost.
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Ng
Adjusting for APOE ε4 status had no effect on baseline or longitudinal Ng; however, the MCI+
group at baseline was no longer higher than the MCI- and CN- groups (p=0.1 and p=0.057).
Adjusting for sex had a significant effect on baseline Ng (higher in females, p=0.03), but did not
have a significant effect on longitudinal Ng. Between group comparisons were identical to the
unadjusted model except the MCI+ group now also showed significant decreases over time
(p=0.04). Adjusting for baseline age and education had no significant effect on baseline or
longitudinal Ng or between-group comparisons, but the between-group differences observed in
the unadjusted model no longer reached significance, likely due to inadequate statistical power.
Adjusting for total ventricular volume significantly affected baseline Ng (<0.0001), but not
longitudinal patterns. The baseline difference between the AD+ and CN+ groups was lost as
were longitudinal differences between the AD+ and CN-, CN+, and MCI- groups.
YKL-40
Adjusting for sex impacted many of the baseline and longitudinal patterns of YKL-40 among the
groups. In general females showed higher levels of baseline YKL-40 compared to males
(p=0.003). Baseline levels of YKL-40 were still significantly higher in the AD+ compared to the
MCI- group (p=0.04), but was now also higher in the AD+ compared to the CN- group (p=0.03),
as well as the MCI+ compared to the MCI- (p=0.005) and both CN groups (p=0.03 for CN+,
p=0.001 for CN-). Longitudinally, YKL-40 levels no longer increased significantly in the MCI+
group, but instead now decreased in the AD+ group (p=0.003). Adjusting for baseline age and
education had minimal effect on baseline or longitudinal patterns of YKL-40, but the betweengroup differences seen in the unadjusted model no longer reached significance, potentially due to
high variability and inadequate statistical power. Adjusting for APOE ε4 status had no significant
effect on baseline or longitudinal YKL-40, but the difference at baseline between the AD+ and
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MCI- groups was no longer significant (p=0.08). Adjusting for total ventricular volume had a
significant effect on longitudinal YKL-40 (p<0.001), but not on baseline levels, and the
difference at baseline between the AD+ and MCI- groups was no longer significant (p=0.22).
Elecsys® Aβ42
Adjusting for APOE ε4 status affected baseline Aβ42 levels right at the statistical significance
level (i.e., ε4+ had lower Aβ42, p=0.05), but did not influence longitudinal change or betweengroup comparisons. Adjusting for sex only impacted the longitudinal decline in the AD+ group
(i.e., losing significance, now p=0.08). Adjusting for baseline age eliminated the statistical
significance of decline in both the AD+ and CN- groups. In addition, most between-group
comparisons at baseline lost significance, except that the AD+ group was still lower than the CNgroup at the statistical significance level (p=0.05). Adjusting for total ventricular volume affected
baseline levels and longitudinal change in the MCI- group (p=0.05 and p=0.01, respectively) but
not between-group comparisons.
Adjusting for education had a significant effect on baseline Aβ42 in the CN+ group (p=0.006),
with more education associated with a higher baseline Aβ42. Longitudinally, more education had
a significant impact in the MCI- group which showed significant yearly increases in Aβ42. The
significant longitudinal decline in the AD+ and CN- groups seen in the unadjusted model was
lost. The significant difference at baseline between the MCI+ and MCI- groups was also lost, but
the MCI+ group now had significantly lower Aβ42 than the CN+ group (p=0.03), possibly
driven by the significant effect of education on the CN+ group.
MMSE
Adjusting for education had no effect on baseline or longitudinal MMSE, though all betweengroup comparisons at baseline lost significance. In this model, longitudinal MMSE in the AD+
174

and MCI+ groups still decreased at a significant rate (both p<0.04), but were not significantly
different from each other.
Adjusting for baseline age had no effect on baseline MMSE, but did significantly affect
longitudinal change in the AD+ group (slowed the decline) (p=0.05); however, the AD+ and
MCI+ groups still decreased at a significant rate (both p<0.03). Adjusting for APOE ε4 status
and sex had no effect on baseline or longitudinal MMSE or between-group comparisons, and the
significant results were identical to those in the unadjusted model.
ADAS11 and ADAS13
Adjusting for education had no effect on baseline or longitudinal ADAS11; however, it did affect
the between-group comparisons, with only the difference between the MCI+ and CN+ groups
remaining significant (p=0.05). In this model, the AD+ group was still significantly increasing
longitudinally (p=0.0035). Adjusting for baseline age had a significant effect on the slope in the
AD+ and MCI+ groups (slowed the rate of increase) (both p<.02), but both groups retained the
significant longitudinal increases observed in the unadjusted model (both p<0.003). The between
group effects seen at baseline in the unadjusted model were absent, though the AD+ group still
increased longitudinally at a faster rate than the MCI+ group (p=0.05). Adjusting for APOE ε4
status and sex had no effect on baseline or longitudinal ADAS11 and yielded results identical to
the unadjusted model.
Adjusting for education had no effect on baseline or longitudinal ADAS13, but affected
between-group comparisons similarly to ADAS11, with the MCI+ group being elevated
compared to both CN groups (both p<0.04). In this model, the AD+ group was not significantly
increasing longitudinally (p=0.07). Adjusting for baseline age showed similar results to those
seen in ADAS11; however, the AD+ group was no longer increasing at a faster rate than the
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MCI+ group (now p=0.13). Adjusting for APOE ε4 status did not affect baseline or longitudinal
ADAS13, except that no significant difference was observed between the MCI+ and MCIgroups (p=0.09). Adjusting for sex significantly affected the longitudinal change in ADAS13,
with females showing a faster increase (decline in performance)(p=0.03). Between-group
comparisons at baseline remained identical to the unadjusted model. The longitudinal increase in
the CN+ group was no longer significant (p=0.06), but between-group differences remained
identical to the unadjusted model.
HP Volume
Adjusting for baseline age had no significant effect on baseline or longitudinal HP volume or
between-group comparisons, but the slopes and between-group differences observed in the
unadjusted model no longer reached significance, likely due to inadequate statistical power. The
model adjusted for sex showed a significant effect on baseline HP volume, with females having a
smaller volume (p=0.006). The significant differences at baseline between the AD+ and both
MCI groups were lost (p=0.08 for MCI-, p=0.06 for MCI+), and longitudinally the AD+ group
was no longer decreasing at a faster rate than the MCI- group (p=0.06). Adjusting for APOE ε4
status had no effect on baseline or longitudinal HP volume, but the longitudinal between-group
differences were lost for the AD+ and MCI- groups, the CN+ and CN- groups, and the MCI+ and
MCI- groups (all p=0.2).
EC Thickness
Adjusting for baseline age affected EC thickness the same way it did HP volume. Adjusting for
sex had no effect on baseline or longitudinal EC thickness, and between-group comparisons
remained identical to the unadjusted model. Adjusting for APOE ε4 status had a significant effect
on longitudinal change, with ε4+ individuals thinning more rapidly (p=0.03), and the CN- group
now also significantly declining (p=0.005). Longitudinally the AD+ group was thinning
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significantly faster than the CN- group (p=0.0007), but the MCI- versus CN+ between-group
difference was no longer significant when adjusting for APOE ε4 status, nor were the
longitudinal between-group differences for the AD+ and MCI- groups or the MCI+ and MCIgroups.
Figure A.1 Spaghetti plots of longitudinal change in CSF biomarkers.
A

CN

MCI

AD

1000

1000

800

800

800

600

600

600

400

400

400

200

200

200

t T a u ( p g /m l )

1000

0

0
60

70

80

90

100

0
60

70

A g e (Y e a rs )

p T a u ( p g /m l )

B

120

100

100

80

80

60

60

40

40

20

20

100

70

80

60

90

80

90

100

60

70

MCI

400

400

400

300

300

300

200

200

200

100

100

100

0
100

90

100

AD
500

90

80
A g e (Y e a rs )

500

80

100

0
70

CN

A g e (Y e a rs )

90

50

500

70

100

AD

A g e (Y e a rs )

0

90

100

60

100

80

150

A g e (Y e a rs )

60

70

A g e (Y e a rs )

0
60

V I L IP - 1 ( p g /m l )

90

MCI

CN
120

0

C

80
A g e (Y e a rs )

0
60

70

80
A g e (Y e a rs )

177

90

100

60

70

80
A g e (Y e a rs )

Supplemental Figure 1 (continued)
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Figure A.2 Spaghetti plots of longitudinal change in cognition
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Figure A.3 Spaghetti plots of longitudinal change in MRI measures.
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Table A.1 Spearman R Correlation Matrix for CSF Biomarkers
Aβ42
Aβ42
VILIP-1
SNAP-25
Ng
YKL-40
E-Aβ42
E-tTau
E-pTau

VILIP-1 SNAP-25

-0.235
-0.413
-0.22

Ng

YKL-40

0.72
0.849

0.619

a

0.311

0.307

0.422

0.868
-0.416
-0.512

a

-0.240
0.688
0.668

-0.154a
0.853
0.803

-0.121

-0.131
0.798
0.744

0.007a
0.389
0.346

E-Aβ42

-0.214
-0.324

E-tTau

0.975

Bold, significant correlations (at least p<0.008)
a
not significantly correlated
Abbreviations: Aβ42, AlzBio3 Aβ42; VILIP-1, visinin-like protein 1; SNAP-25, synaptosomal associated
protein-25;Ng, neurogranin; E-Aβ42, Elecsys Aβ42; E-tTau, Elecsys tTau; E-pTau, Elecsys pTau181
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